
<html lang="en"     class="pb-page"  data-request-id="9ac311c5-59fd-404c-8c05-747476908bce"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm401418s;website:website:acspubs;issue:issue:10.1021/jmcmar.2013.56.issue-22;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Bifunctional PEGylated Exenatide-Amylinomimetic Hybrids to Treat Metabolic Disorders: An Example of Long-Acting Dual Hormonal Therapeutics" /></meta><meta name="dc.Creator" content="Chengzao  Sun" /></meta><meta name="dc.Creator" content="James L.  Trevaskis" /></meta><meta name="dc.Creator" content="Carolyn M.  Jodka" /></meta><meta name="dc.Creator" content="Swetha  Neravetla" /></meta><meta name="dc.Creator" content="Pete  Griffin" /></meta><meta name="dc.Creator" content="Kui  Xu" /></meta><meta name="dc.Creator" content="Yan  Wang" /></meta><meta name="dc.Creator" content="David G.  Parkes" /></meta><meta name="dc.Creator" content="Bruce  Forood" /></meta><meta name="dc.Creator" content="Soumitra S.  Ghosh" /></meta><meta name="dc.Description" content="Peptide hybrids (phybrids) comprising covalently linked peptide hormones can leverage independent biological pathways for additive or synergistic metabolic benefits. PEGylation of biologics offers ..." /></meta><meta name="Description" content="Peptide hybrids (phybrids) comprising covalently linked peptide hormones can leverage independent biological pathways for additive or synergistic metabolic benefits. PEGylation of biologics offers ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 6, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401418s" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401418s" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401418s" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401418s" /></link>
        
    
    

<title>Bifunctional PEGylated Exenatide-Amylinomimetic Hybrids to Treat Metabolic Disorders: An Example of Long-Acting Dual Hormonal Therapeutics | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401418s" /></meta><meta property="og:title" content="Bifunctional PEGylated Exenatide-Amylinomimetic Hybrids to Treat Metabolic Disorders: An Example of Long-Acting Dual Hormonal Therapeutics" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0010.jpeg" /></meta><meta property="og:description" content="Peptide hybrids (phybrids) comprising covalently linked peptide hormones can leverage independent biological pathways for additive or synergistic metabolic benefits. PEGylation of biologics offers enhanced stability, duration, and reduced immunogenicity. These two modalities can be combined to produce long-acting therapeutics with dual pharmacology and enhanced efficacy. Compound 10 is composed of an exenatide (AC2993) analogue, AC3174, and an amylinomimetic, davalintide (AC2307), with an intervening 40 kD PEG moiety. It displayed dose-dependent and prolonged efficacy for glucose control and body weight reduction in rodents with superior in vitro and in vivo activities compared to those of a side-chain PEGylated phybrid 6. In diet-induced obese (DIO) rats, the weight-loss efficacy of 10 was similar to that of a combination of PEG-parents 3 and 4. A single dose of 10 elicited sustained body weight reduction in DIO rats for at least 21 days. Compound 10’s terminal half-life of ∼27 h should translate favorably to weekly dosing in humans." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401418s"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401418s">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401418s&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401418s&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401418s&amp;href=/doi/10.1021/jm401418s" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 9328-9341</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401399c" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm4014357" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Bifunctional PEGylated Exenatide-Amylinomimetic Hybrids to Treat Metabolic Disorders: An Example of Long-Acting Dual Hormonal Therapeutics</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chengzao++Sun">Chengzao Sun</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+L.++Trevaskis">James L. Trevaskis</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carolyn+M.++Jodka">Carolyn M. Jodka</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Swetha++Neravetla">Swetha Neravetla</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pete++Griffin">Pete Griffin</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kui++Xu">Kui Xu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Wang">Yan Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+G.++Parkes">David G. Parkes</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce++Forood">Bruce Forood</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Soumitra+S.++Ghosh">Soumitra S. Ghosh</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Amylin Pharmaceuticals, LLC, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Tel: 858-405-2904. E-mail: <a href="/cdn-cgi/l/email-protection#f5b69d909b928f949ab59298949c99db969a98"><span class="__cf_email__" data-cfemail="115279747f766b707e51767c70787d3f727e7c">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401418s&amp;href=/doi/10.1021%2Fjm401418s" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 9328–9341</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 21, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 September 2013</li><li><span class="item_label"><b>Published</b> online</span>6 November 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 November 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401418s" title="DOI URL">https://doi.org/10.1021/jm401418s</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9328%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChengzao%2BSun%252C%2BJames%2BL.%2BTrevaskis%252C%2BCarolyn%2BM.%2BJodka%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D22%26contentID%3Djm401418s%26title%3DBifunctional%2BPEGylated%2BExenatide-Amylinomimetic%2BHybrids%2Bto%2BTreat%2BMetabolic%2BDisorders%253A%2BAn%2BExample%2Bof%2BLong-Acting%2BDual%2BHormonal%2BTherapeutics%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9341%26publicationDate%3DNovember%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401418s"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">841</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401418s" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Bifunctional PEGylated Exenatide-Amylinomimetic Hybrids to Treat Metabolic Disorders: An Example of Long-Acting Dual Hormonal Therapeutics&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chengzao&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;L. Trevaskis&quot;},{&quot;first_name&quot;:&quot;Carolyn&quot;,&quot;last_name&quot;:&quot;M. Jodka&quot;},{&quot;first_name&quot;:&quot;Swetha&quot;,&quot;last_name&quot;:&quot;Neravetla&quot;},{&quot;first_name&quot;:&quot;Pete&quot;,&quot;last_name&quot;:&quot;Griffin&quot;},{&quot;first_name&quot;:&quot;Kui&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;G. Parkes&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;Forood&quot;},{&quot;first_name&quot;:&quot;Soumitra&quot;,&quot;last_name&quot;:&quot;S. Ghosh&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;9328-9341&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401418s&quot;},&quot;abstract&quot;:&quot;Peptide hybrids (phybrids) comprising covalently linked peptide hormones can leverage independent biological pathways for additive or synergistic metabolic benefits. PEGylation of biologics offers enhanced stability, duration, and reduced immunogenicity. These two modalities can be combined to produce long-acting therapeutics with dual pharmacology and enhanced efficacy. Compound 10 is composed of an exenatide (AC2993) analogue, AC3174, and an amylinomimetic, davalintide (AC2307), with an intervening 40 kD PEG moiety. It displayed dose-dependent and prolonged efficacy for glucose control and body weight reduction in rodents with superior in vitro and in vivo activities compared to those of a side-chain PEGylated phybrid 6. In diet-induced obese (DIO) rats, the weight-loss efficacy of 10 was similar to that of a combination of PEG-parents 3 and 4. A single dose of 10 elicited sustained body weight reduction in DIO rats for at least 21 days. Compound 10’s terminal half-life of ∼27 h should translate favorably t&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401418s&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401418s" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401418s&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401418s" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401418s&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401418s" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401418s&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401418s&amp;href=/doi/10.1021/jm401418s" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401418s" /></input><a href="/doi/pdf/10.1021/jm401418s" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401418s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401418s%26sid%3Dliteratum%253Aachs%26pmid%3D24144329%26genre%3Darticle%26aulast%3DSun%26date%3D2013%26atitle%3DBifunctional%2BPEGylated%2BExenatide-Amylinomimetic%2BHybrids%2Bto%2BTreat%2BMetabolic%2BDisorders%253A%2BAn%2BExample%2Bof%2BLong-Acting%2BDual%2BHormonal%2BTherapeutics%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D22%26spage%3D9328%26epage%3D9341%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291414" title="Pegylation">Pegylation</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jmcmar.2013.56.issue-22/production/jmcmar.2013.56.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Peptide hybrids (phybrids) comprising covalently linked peptide hormones can leverage independent biological pathways for additive or synergistic metabolic benefits. PEGylation of biologics offers enhanced stability, duration, and reduced immunogenicity. These two modalities can be combined to produce long-acting therapeutics with dual pharmacology and enhanced efficacy. Compound <b>10</b> is composed of an exenatide (AC2993) analogue, AC3174, and an amylinomimetic, davalintide (AC2307), with an intervening 40 kD PEG moiety. It displayed dose-dependent and prolonged efficacy for glucose control and body weight reduction in rodents with superior <i>in vitro</i> and <i>in vivo</i> activities compared to those of a side-chain PEGylated phybrid <b>6</b>. In diet-induced obese (DIO) rats, the weight-loss efficacy of <b>10</b> was similar to that of a combination of PEG-parents <b>3</b> and <b>4</b>. A single dose of <b>10</b> elicited sustained body weight reduction in DIO rats for at least 21 days. Compound <b>10</b>’s terminal half-life of ∼27 h should translate favorably to weekly dosing in humans.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chronic, highly prevalent metabolic disorders such as diabetes, obesity, and metabolic syndrome are predominantly polygenic, and therefore, it is unlikely that a monotherapy approach would suffice for effective treatment. Additive or synergistic clinical benefits can be potentially realized by simultaneously activating independent biological pathways. These are being actively explored via combination therapies or molecular engineering technologies to create single molecule entities that exhibit multiple pharmacologies. While the design of a small molecule drug directed to multiple independent molecular targets poses a significant challenge, it is feasible to design peptide/protein therapeutics with dual or even triple pharmacologies, hence enhancing their clinical effectiveness. Preclinical studies with dual-pharmacology molecules such as chimeric peptides<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6 ref7">(1-7)</a> derived from parent molecules with significant sequence similarities and bispecific proteins<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> especially antibodies<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15">(9-15)</a> have demonstrated robust proof-of-concept in animal models, with some successfully advancing into clinic trials.</div><div class="NLM_p">Peptide hormone therapeutics such as glucagon-like peptide-1<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> (GLP-1) and amylin<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> receptor agonists have highlighted the benefits of neurohormonal therapies for treating diabetes. Meanwhile, there are intense efforts to combine two or even three peptide hormones targeting multiple biological pathways for additive or synergistic effects.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34">(20-34)</a> While preclinical studies on these combinations have generated remarkably efficacious results, few have advanced for clinical evaluation. This may be due in part to the more complex development path required for peptide combination drugs as compared to monotherapy-based clinical studies. An elegant solution is engineering two or more peptides into a single molecule, possessing multiple pharmacologies and efficacies matching or even surpassing those of the combinations. Peptide hormones such as GLP-1, cholecystokinin (CCK), peptide YY (PYY), and amylin are structurally unrelated, hence a chimeric approach for combining such peptides into a single molecule is not feasible. Consequently, we chose to pursue a peptide hybrid (termed phybrid hereafter) strategy that covalently links these peptide hormones into a single molecular entity.</div><div class="NLM_p">GLP-1 and amylin receptor agonists are attractive to consider as components for a phybrid approach because of the extensive clinical evidence with these agents for mediating robust glucose lowering with the added benefit of weight loss in patients with type 2 diabetes. GLP-1 is an incretin whose potent antidiabetic effects are mediated by stimulation of glucose-dependent insulin secretion, suppression of inappropriately elevated postprandial glucagon secretion, suppression of food intake, and slowing of gastric emptying. Amylin is cosecreted with insulin from pancreatic β cells in response to meals. It works in concert with insulin to regulate postprandial glucose via actions to slow gastric emptying, suppress glucagon release, and promote satiety/reduce food intake.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The glucoregulatory and satiety effects of amylin and GLP-1 occur through discrete receptor pathways (amylin and GLP-1 receptors, respectively). Hence, while they exhibit several overlapping physiological mechanisms of action, the potential for additive or synergistic metabolic benefits when these peptides are used in combination, is quite feasible. The anorexigenic actions may also be complementary. The area postrema (AP) is considered an important target for circulating peptides that can regulate food intake. AP neurons are coactivated by amylin and GLP-1 under <i>ex vivo</i> conditions, indicating a plausible interaction site for convergence of amylin and GLP-1 signaling at the level of the brainstem.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> A recent study combining the GLP-1 receptor (GLP-1R) agonist exenatide with the amylin receptor agonist salmon calcitonin, produced at least additive reductions in food intake in nonhuman primates.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> These reports suggested that by creating phybrid molecules comprising GLP-1 and amylin receptor agonists, one could generate single peptide therapeutics with equal or better glucose control compared to that of exenatide, together with enhanced body weight loss.</div><div class="NLM_p">Although the hallmarks of peptide hormones are their high potency, efficacy, specificity, and relatively few off-target effects, certain limitations for their development as therapeutics include a short <i>in vivo</i> half-life due to poor metabolic stability and renal clearance and the need for parenteral administration. Therefore, our objective toward a successful phybrid therapeutic included the incorporation of a molecular scaffold within these phybrid molecules that would improve stability, prolong <i>in vivo</i> half-life, and provide a once-weekly drug presentation.</div><div class="NLM_p last">Here, we report on a technology platform combining the advantages of the phybrid approach with PEGylation. It utilizes large heterobifunctional polyethyleneglycol (PEG) to link two peptide hormones with distinct pharmacological actions while preserving their receptor functional activities and prolonging their duration of action <i>in vivo.</i> The large 40 kD PEG serves as a linker to join the two peptides and form a single molecule. In doing so, it helps mitigate undesirable steric or charge interactions and also functions as a long-duration molecular scaffold for prolonging <i>in vivo</i> half-life. We applied this approach to a peptide combination comprising an exenatide analogue AC3174<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37-39)</a> and an amylin analogue davalintide (AC2307).<a onclick="showRef(event, 'ref1 ref7'); return false;" href="javascript:void(0);" class="ref ref1 ref7">(1, 7)</a> The prototype construct, compound <b>10</b>, is a highly potent molecule that leverages the pharmacological properties of the parent peptides to drive enhanced glycemic control and weight loss in rodent models, along with a prolonged <i>in vivo</i> half-life that is predicted to translate into once-weekly dosing in humans.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Design, Synthesis, and Structure/<i>in Vitro</i>–Activity Relationships of Side-Chain and Heterobifunctional PEGylated Phybrids</h3><div class="NLM_p">AC3174 and davalintide were selected as the peptide pair in the phybrid for our PEGylation studies. AC3174 is a close analogue of exenatide with a single substitution of methionine to leucine at position 14, which eliminates the potential for oxidation at this amino acid site to potentially improve shelf life stability.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> It has similar <i>in vitro</i> potency compared to that of exenatide for receptor binding and activation. In rodent studies, AC3174 is comparable to exenatide for its glucoregulatory effects and inhibition of food intake, and in decreasing gastric emptying.<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37-39)</a> The N-termini of exenatide and AC3174 are crucial for receptor activation,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> whereas truncation or extension at the C-terminus does not adversely affect biological activity. AC3082 (exenatide (1–28)), a truncated analogue of exenatide, which is similar to exenatide in its <i>in vitro</i> and <i>in vivo</i> activities, was also included in our studies. Davalintide is an amylinomimetic that is devoid of the amyloidogenic residues 20–29 in human amylin<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and shares ∼49% amino acid sequence homology with rat amylin or pramlintide. It is a potent agonist at amylin and calcitonin receptors (calcitoninR) and displays enhanced pharmacological effects compared to those of rat amylin for feeding suppression and reduction of body weight.<a onclick="showRef(event, 'ref1 ref7'); return false;" href="javascript:void(0);" class="ref ref1 ref7">(1, 7)</a> Limited modifications of davalintide are tolerated at the N-terminus but not at the C-terminus (e.g., extensions) for receptor engagement, indicating that the latter region has to be maintained for the bioactivity of amylin and its anologues<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> (unpublished results).</div><div class="NLM_p">We elected to link the N-terminus of davalintide to the C-terminus of AC3082 or AC3174, based on our prior knowledge on modification of both peptides that preserve receptor agonist activity. Compounds <b>1</b> and <b>2</b> are two phybrids prepared in such an orientation and contain a triple glycine sequence (GGG) as an intervening spacer. Comparable receptor activities were noted for AC3082 and AC3174 containing phybrids (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Compared to the parent peptides, <b>1</b> and <b>2</b> show dual pharmacology, with a ∼5 fold decrease in activity in a GLP-1R functional assay and a 15–60-fold decrease in potency in human amylin receptor (amylinR) or calcitonin receptor (calcitoninR) binding and functional assays. The <i>in vivo</i> half-lives (<i>t</i><sub>1/2</sub>) for both peptides were determined to be ∼70 min by subcutaneous injection in male Sprague–Dawley rats using the WinNonlin Professional (version 5.2) software application (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>), which are about twice that of AC3174 (42–43 min)<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and davalintide (26 min).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Compound Description and <i>in Vitro</i> Activity at the GLP-1 Receptor, Rat Calcitonin Receptor, and Human Amylin Receptor<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd number</th><th class="colsep0 rowsep0" align="center">description</th><th class="colsep0 rowsep0" align="center">PEGylation method</th><th class="colsep0 rowsep0" align="center">GLP-1R cyclase<a class="ref internalNav" href="#t1fn1" aria-label="b">b</a> EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">calcitoninR cyclase<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a> EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">calcitoninR binding IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">exenatide (AC2993)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.004 ± 0.001 (53)</td><td class="colsep0 rowsep0" align="left">>1000 (1)</td><td class="colsep0 rowsep0" align="left">>1000 (1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">L14-exenatide (AC3174)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.010 ± 0.008 (6)</td><td class="colsep0 rowsep0" align="left">>100 (1)<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>1000 (1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">exenatide (1–28) (AC3082)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.010 ± 0.003 (8)</td><td class="colsep0 rowsep0" align="left">>1000 (1)</td><td class="colsep0 rowsep0" align="left">>1000 (1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">davalintide (AC2307)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>1000 (3)</td><td class="colsep0 rowsep0" align="left">0.060 ± 0.008 (68)</td><td class="colsep0 rowsep0" align="left">0.050 ± 0.023 (20)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">AC3082-GGG-AC2307</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.060 ± 0.019 (3)</td><td class="colsep0 rowsep0" align="left">1.3 ± 1.1 (2)</td><td class="colsep0 rowsep0" align="left">0.77 ± 0.02 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">AC3174-GGG-AC2307</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.043 ± 0.016 (7)</td><td class="colsep0 rowsep0" align="left">3.7 ± 0.6 (5)</td><td class="colsep0 rowsep0" align="left">1.9 ± 0.4 (3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">mPEG40K-desLys1-AC2307</td><td class="colsep0 rowsep0" align="left">N-terminal</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.9 ± 2.7 (9)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">AC3174-mPEG40K</td><td class="colsep0 rowsep0" align="left">C-terminal</td><td class="colsep0 rowsep0" align="left">0.29 ± 0.16 (20)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">AC3082-GC(mPEG40K)G-AC2307</td><td class="colsep0 rowsep0" align="left">phybrid side-chain</td><td class="colsep0 rowsep0" align="left">6.2 (1)</td><td class="colsep0 rowsep0" align="left">96 (1)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">AC3174-GC(mPEG40K)G-AC2307</td><td class="colsep0 rowsep0" align="left">phybrid side-chain</td><td class="colsep0 rowsep0" align="left">0.50 ± 0.034 (2)</td><td class="colsep0 rowsep0" align="left">13 ± 0.24 (2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">AC3082-PEG12K-desLys1-AC2307<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">bifunctional</td><td class="colsep0 rowsep0" align="left">4.1 ± 3.4 (2)</td><td class="colsep0 rowsep0" align="left">4.0 ± 3.2 (2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">AC3174-PEG12K-desLys1-AC2307<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">bifunctional</td><td class="colsep0 rowsep0" align="left">0.40 ± 0.29 (12)</td><td class="colsep0 rowsep0" align="left">7.2 ± 4.5 (2)</td><td class="colsep0 rowsep0" align="left">5.7 (1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">AC3174-PEG30K-desLys1-AC2307<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">bifunctional</td><td class="colsep0 rowsep0" align="left">0.17 (1)</td><td class="colsep0 rowsep0" align="left">6.0 ± 1.5 (2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">AC3174-PEG40K-desLys1-AC2307<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">bifunctional</td><td class="colsep0 rowsep0" align="left">0.18 ± 0.12 (6)</td><td class="colsep0 rowsep0" align="left">1.4 ± 1.1 (9)</td><td class="colsep0 rowsep0" align="left">5.3 (1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">AC3174-PEG40K-desLys1-AC2307<a class="ref internalNav" href="#t1fn5" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">bifunctional</td><td class="colsep0 rowsep0" align="left">0.082 ± 0.007 (2)</td><td class="colsep0 rowsep0" align="left">1.5 ± 0.1 (2)</td><td class="colsep0 rowsep0" align="left">3.5 (1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">AC3174-PEG60K-desLys1-AC2307<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">bifunctional</td><td class="colsep0 rowsep0" align="left">0.17 (1)</td><td class="colsep0 rowsep0" align="left">5.3 ± 2.0 (2)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">AC3174-PEG80K-desLys1-AC2307<a class="ref internalNav" href="#t1fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">bifunctional</td><td class="colsep0 rowsep0" align="left">0.42 (1)</td><td class="colsep0 rowsep0" align="left">6.7 ± 3.2 (2)</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup>a</sup><p class="last">Values are the mean ± SD; the number of experiments is shown in parentheses.</p></div><div class="footnote" id="t1fn1"><sup>b</sup><p class="last">GLP-1R cyclase assay data are normalized against the control peptide: AC2993 EC<sub>50</sub> = 4 pM; AC2592 EC<sub>50</sub> = 10 pM.</p></div><div class="footnote" id="t1fn2"><sup>c</sup><p class="last">CalcitoninR cyclase assay data are normalized against the control peptide: AC2307 EC<sub>50</sub> = 60 pM.</p></div><div class="footnote" id="t1fn3"><sup>d</sup><p class="last">AC3174 was tested only up to 100 nM in the calcitonin cyclase assay, and it was inactive at 100 nM.</p></div><div class="footnote" id="t1fn4"><sup>e</sup><p class="last">PEG was linked to AC3174 through the maleimide–thiol bond to the Cys side-chain in a Lys(Cys(−)) residue at the C-terminus of AC3174.</p></div><div class="footnote" id="t1fn5"><sup>f</sup><p class="last">PEG was linked to AC3174 through the maleimide–thiol bond to the Cys side-chain in a Lys-Cys(−)-Gly extension sequence at the C-terminus of AC3174.</p></div></div></div><div class="NLM_p">Next, we explored scaffolding methods to engineer the phybrid for enhanced <i>in vivo</i> duration of action for potential once-weekly administration. Fatty acid acylation, along with polyethylene glycol (PEG), albumin, and antibody Fc conjugations, exemplify key approaches for half-life extension of peptides and proteins. Several desirable attributes of PEGs contributed to the selection of PEGylation for phybrid modification, namely, their excellent water solubility, low toxicity and immunogenicity, and large hydrodynamic radius. PEG agents are available in different molecular weights, and with various reactive functionalities, and structure. Linear 30–40 kD PEGs have hydrodynamic radii of about 6–8 nm,<a onclick="showRef(event, 'ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46">(44-46)</a> which is larger than the pore size (3–5 nm) of the glomerular basement membrane. Thus, PEG modification confers metabolic stability by protecting the conjugates from proteolytic degradation<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and further extends plasma half-life by slowing renal clearance. These features have made this scaffold class an attractive choice for the design of long-acting peptide/protein therapeutics<a onclick="showRef(event, 'ref44 ref48 ref49 ref50 ref51 ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref44 ref48 ref49 ref50 ref51 ref52 ref53 ref54 ref55">(44, 48-55)</a> that can be “tuned” for the desired half-life. The utility of PEG has been validated in the clinic, and a number PEG-protein drugs are marketed as weekly or monthly therapeutics for various diseases.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div class="NLM_p">While multiple reactive sites on the phybrids are available to attach an <i>N</i>-hydroxysuccinimide-activated PEG moiety, the resulting nonspecific linkage is expected to produce a mixture of regio- or positional isomers, with each presenting a different activity profile.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> This entails stringent product characterization requirements<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> and has the potential drawback of inconsistent reproducibility. A number of site-specific PEGylation methodologies have been developed to produce single-position isomers,<a onclick="showRef(event, 'ref58 ref59 ref60 ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60 ref61 ref62 ref63">(58-63)</a> and we used the approach to generate homogeneous conjugates with precise sequence placement of the PEG moiety. Thus, the PEGylated phybrids <b>5</b> (mPEG40K-<b>1</b>) and <b>6</b> (mPEG40K-<b>2</b>) were designed to have a 40 kD PEG attached to a side chain of the linker sequence in the phybrid, which is near the preferred positions for modification of the parent peptides. Specifically, the middle glycine of the GGG linker in the phybrid was changed to a cysteine residue for coupling with a 40 kD methoxy-PEG-maleimide (Mal-mPEG40K) reagent, and the disulfide bridge in davalintide was preformed to avoid any cross-reactivity in the conjugation step (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>A). When compared to phybrids <b>1</b> and <b>2</b>, <b>5</b> showed a 100- and 74-fold loss in potency in GLP-1R and calcitoninR functional assays, respectively, while <b>6</b> was 12- and 4-fold weaker in potency in the assays. In effect, the PEGylation of <b>1</b> and <b>2</b> further compounded the loss in potency when compared to davalintide and AC3082/AC3174, the original peptide constituents of the phybrids. The overall drops in potency, compared to that of the parent peptides, were 620- and 1600-fold in GLP-1R and calcitoninR functional assays for <b>5</b> and 50- and 220-fold for <b>6</b>. Although <i>in vitro</i> potencies of phybrids comprising AC3082 (<b>1</b>) and AC3174 (<b>2</b>) are similar at both receptors, their side-chain PEGylated conjugates showed differentiation favoring AC3174 as evidenced by ∼10-fold better potencies at both receptors for <b>6</b> than <b>5</b>. This observation indicated that the extra 11 residues at the C-terminus of AC3174 may help to reduce unfavorable interactions in the PEG environment.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. (A) Side-Chain PEGylation Procedure for the Preparation of <b>6</b> and (B) Two Step Heterobifunctional PEGylation Strategy for the Preparation of <b>10</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an effort to preserve receptor potency, we envisioned the heterobifunctional PEG conjugate shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>. We synthesized a new series of molecules using a heterobifunctional PEGylation strategy that used PEGs ranging in size from 12 kD to 80 kD and functionalized with a maleimide and an <i>N</i>-hydroxysuccinimide ester (NHS ester) at their termini. DesLys1-AC2307, a bioactive and equipotent metabolite of davalintide,<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> was chosen as the amylinomimetic in this series because its α-amino group at the N-terminus is the only nucleophile available to react with an NHS ester and yield a site-specific PEGylated product. As shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>B, DesLys1-AC2307 was first coupled with the heterobifunctional Mal-PEG-NHS reagent to give Mal-PEG-desLys1-AC2307. After ion-exchange purification to remove unreacted material, the conjugate was treated with an AC3082 or AC3174 analogue that contained a cysteine extension at the C-terminus (AC3082- or AC3174-Lys(Cys)-NH<sub>2</sub>) to form the final bifunctional product via a thiol-maleimide reaction. As both reactions steps were site-specific, the final exenatide-PEG-amylinomimetic products are single regio-isomers.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Heterobifunctional PEGylation strategy and traditional options for the PEGylation of phybrid. N- or C-terminal PEGylation is not compatible with the AC3174-AC2307 phybrid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Consistent with <i>in vitro</i> results observed for side-chain PEG conjugates favoring AC3174, bifunctional conjugates with a 12 kD PEG linker and comprising AC3174 (<b>8</b>) was 10-fold more potent in GLP-1R functional assays than that comprising AC3082 (<b>7</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). We therefore chose to prepare only the AC3174 containing conjugates with larger PEG sizes and using the side-chain 40 kD PEGylated conjugate <b>6</b> as a benchmark compound to evaluate these bifunctional PEG conjugates. In AC3174-comprising series of conjugates with PEG linker sizes of 12, 30, 40, 60, and 80 kD, there appears to be a “U-shaped” PEG size/potency relationship at both receptors, with intermediate-sized PEGs exhibiting better potencies (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Conjugate <b>10</b> with a 40 kD PEG linker had equal or better potencies compared to those of conjugates with any other PEG sizes at both receptors. It displayed 3-fold and 9-fold improvements in potency at GLP-1R and calcitoninR, respectively, compared to that of <b>6</b>. This resulted in an optimized phybrid conjugate with sub- to low-nanomolar dual receptor potencies, which were within 25-fold of those of the parent peptides, and a 40 kD PEG scaffold for enhancing its <i>in vivo</i> duration of action. Two PEGylated parent peptides AC3174-mPEG40K (<b>4</b>) and mPEG40K-desLys1-AC2307 (<b>3</b>) were also prepared as controls for <b>10</b>. They were made by conjugating the precursor peptides used in <b>10</b> to monofunctional mPEG 40K reagents using the same coupling chemistries. Both control conjugates were comparable with <b>10</b> in <i>in vitro</i> assays. Finally <b>11</b>, a conjugate similar to <b>10</b> but containing an AC3174 analogue AC3174-KCG-OH that can be prepared recombinantly, displayed similar potencies.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PEG size/receptor potency relationship in the heterobifunctional PEG conjugates <b>8</b>, <b>9</b>, <b>10</b>, <b>12</b>, and <b>13</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> <i>In Vivo</i> Studies in Rodent Models</h3><div class="NLM_p">The following studies provide a comparison of the <i>in vivo</i> activities of the phybrids and their PEGylated conjugates in rodent models.</div><div class="NLM_p">A pharmacodynamic assay was developed to assess changes in glucose and body weight in Hsd/NIHS female mice over a 96 h period following subcutaneous injection of vehicle or test compound (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A–C). At doses of 250 nmol/kg, AC3174 alone, in combination with davalintide, and the phybrid <b>2</b> were all efficacious in reducing glucose and body weight. However, the effects were not sustained beyond 8 h for AC3174 and <b>2</b>, while only modest glucose lowering activity was observed after 24 h for the combination. In comparison, the bifunctional 40 kD PEGylated phybrid <b>10</b> displayed dose-dependent suppression of glucose and body weight, which was sustained for 4–5 days at doses of 80–250 nmol/kg. ED<sub>50</sub> values ranged from 2 to 9 nmol/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B1) within the first 24 h after injection and was 14 nmol/kg at 48 h. The superior receptor potency of <b>10</b> compared to that of <b>6</b> translated into improved <i>in vivo</i> efficacy for glucose and body weight reduction in mice, and was associated with a longer duration of effect at 25 and 80 nmol/kg doses.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0004.jpeg" id="GRAPHIC-d2280e1132-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <i>In vivo</i> actions on glucose and body weight in Hsd/NIHS female mice over a 96 h period following subcutaneous injection of vehicle or test compounds. *<i>p</i> < 0.05 vs vehicle. (<b>A1,2</b>) AC2307, AC3174, AC2307 + AC3174 and phybrid <b>2</b> at 250 nmol/kg; (<b>B1,2</b>) AC2993 at 2.5 nmol/kg, <b>10</b> at doses of 3, 8, 25, 80, 250 nmol/kg. ED<sub>50</sub> of change in glucose were calculated at different time points; (<b>C1,2</b>) <b>10</b> and <b>6</b> at doses of 25 and 80 nmol/kg, <sup>#</sup><i>p</i> < 0.05 vs <b>6</b> (25 nmol/kg), <sup>$</sup><i>p</i> < 0.05 vs <b>6</b> (80 nmol/kg); (<b>D1,2</b>) AC2993 at 2.5 nmol/kg, <b>4</b> and <b>10</b> at 25 nmol/kg, <sup>̂</sup><i>p</i> < 0.05 vs <b>4</b>; and (<b>E1,2</b>) <b>3</b> at 250 nmol/kg. Error bars on data points represent the standard error of the mean.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0003.jpeg jm-2013-01418s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We compared the <i>in vivo</i> effects of <b>10</b> with the PEG-conjugates of the parent peptides davalintide and AC3174 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>D,E). The PEG-AC3174 conjugate <b>4</b> (25 nmol/kg) showed the expected reductions in glucose and body weight over 24 h. At the same dose, <b>10</b> was superior in its duration of effect and in the magnitude of glucose lowering and body weight reduction. The PEG-davalintide conjugate <b>3</b> showed no significant reductions in glucose or body weight in mice when dosed at 250 nmol/kg.</div><div class="NLM_p">In a subsequent study, the effects of bifunctional PEGylated phybrid <b>10</b> and the PEG-parent conjugates <b>3</b> and <b>4</b> were studied using diet-induced obese (DIO) rats, a valid and widely used research model for human obesity.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Conjugates <b>3</b>, <b>4</b>, and <b>10</b> alone and the combination of <b>3</b> and <b>4</b> were administered once-weekly (32 nmol/kg dose for each conjugate) over two weeks. All of the conjugates were effective in reducing food intake and body weight (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Measurement of cumulative food intake during the early stage of the study indicated that <b>10</b> was more effective than <b>4</b> but not significantly different from <b>3</b> or the combination at 48 h. Body weight reduction reached a nadir at three days following the first injection before recovery and was reduced further with the second dose on day 7. DIO rats treated with the two parent conjugates reached 7% body weight loss before returning to baseline by day 22. Compound <b>10</b> was more efficacious than the two PEG-parent conjugates alone, and its weight loss effects mirrored that obtained with the combination of <b>3</b> and <b>4</b>. Thus, with <b>10</b> or the combination, the rats lost a maximum of 7–8% body weight after the first injection, further dropped to 13% following the second injection, and ended with ∼4% vehicle-corrected body weight loss after 29 days.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacodynamic actions in DIO rats on (A) food intake and (B) body weight reductions of <b>10</b>, the PEG-conjugates of the parent peptides <b>4</b> (PEG-AC3174), <b>3</b> (PEG-AC2307), and the combination of the two. Each conjugate was administered once-weekly over two weeks (on days 0 and 7 as indicated by the arrows) at a dose of 32 nmol/kg, and the effects were monitored for 29 days. *<i>p</i> < 0.05 <b>4</b> vs vehicle, <sup>̂</sup><i>p</i> < 0.05 both <b>3</b> and <b>4</b> monotherapies vs vehicle; <sup>+</sup><i>p</i> < 0.05 <b>10</b> vs vehicle and <b>4</b>; <sup>a</sup><i>p</i> < 0.05 for <b>10</b> and <b>4</b> + <b>3</b> vs vehicle, <b>4</b> and <b>3</b> monotherapy groups (days 3–29).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a dose–response study in DIO rats (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), conjugate <b>10</b>, administered at single doses of 10.7, 32, and 64 nmol/kg, elicited vehicle-corrected body weight loss of 5, 7.5, and 10% at 3 days post-injection, and ended with 3–4% loss at 21 days. Plasma concentration of the three doses of <b>10</b> in rats, measured at days 3, 7, 15, and 21, were dose-dependent and correlated with the pharmacodynamic effects. With the middle dose of 32 nmol/kg, plasma concentrations were 730 ng/mL at day 3 and 36 ng/mL at day 7. The elimination half-life (<i>t</i><sub>1/2</sub>) was determined to be 27 h using the WinNonlin Professional (version 5.2) software application with the noncompartmental model. This represented a greater than 22-fold increase in <i>t</i><sub>1/2</sub> compared to the parent phybrids (68 min for <b>1</b> and 72 min for <b>2</b>, SC injection). Conversion of rat <i>t</i><sub>1/2</sub> to human by allometric scaling methods (<i>t</i><sub>1/2</sub>(human) approximately = 4 <i>t</i><sub>1/2</sub>(rat)<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> or log<sub>10</sub><i>t</i><sub>1/2</sub>(human) = 0.906 × log<sub>10</sub><i>t</i><sub>1/2</sub>(rat) + 0.723<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a>) provided an estimated human <i>t</i><sub>1/2</sub> of ∼100 h (104.7 and 108.0 h, respectively, by using <i>t</i><sub>1/2</sub>(rat) = 27 h in the two equations), theoretically amenable to a once weekly dosing regimen.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacodynamic/pharmacokinetic studies in DIO rats measuring change in body weight with a single subcutaneous injection of <b>10</b> at doses of 10.7, 32, and 64 nmol/kg and the plasma concentration of <b>10</b> at days 3, 7, 15, and 21. *<i>p</i> < 0.05 vs vehicle (days 1–21); <sup>+</sup><i>p</i> < 0.05 vs <b>10</b> (10.7 nmol/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Bifunctional PEGylated conjugates with 30, 40, 60, and 80 kD PEGs were compared in a 19 day DIO rat study following the administration of a single 32 nmol/kg subcutaneous injection dose. The 30 kD PEG conjugate <b>9</b> was comparable to <b>10</b> in its efficacy for both food intake and body weight reduction (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). Surprisingly, the 60 and 80 kD PEG conjugates, <b>12</b> and <b>13</b>, displayed lower efficacy compared to that of <b>10</b> despite their larger PEG sizes.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Pharmacodynamic actions in DIO rats measuring change in body weight of conjugates with PEG sizes of 30 (<b>9</b>), 40 (<b>10</b>), 60 (<b>12</b>), and 80 kD (<b>13</b>) at a dose of 32 nmol/kg compared to vehicle-treated rats. *<i>p</i> < 0.05 vs vehicle, <sup>̂</sup><i>p</i> < 0.05 vs <b>12</b> and <b>13</b>; <sup>+</sup><i>p</i> < 0.05 vs <b>12</b> only.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">PEG-induced kidney vacuolation<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67, 68)</a> is a potential safety concern for PEGylated proteins. To evaluate such a possible risk for our PEGylated conjugates, female JAX C57BL 6/J mice were dosed daily for one week with 25 nmol/kg of <b>3</b> and <b>4</b> and with doses of 2.5, 8, and 25 nmol/kg of <b>10</b>. The highest dose of <b>10</b> amounts to a weekly combined dose that is ∼20 times higher than weekly doses that produce efficacious body weight reduction in Hsd/NIHS mice. While <b>4</b> and all doses of <b>10</b> but not <b>3</b> (as expected from prior mice studies) were efficacious in reducing body weight, none of the conjugates caused kidney vacuolation in any of the 6 animals per dose group (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Vacuolation and Body Weight Actions in Female JAX C57BL 6/J Mice Following Daily Subcutaneous Dosing for One Week of <b>3</b>, <b>4</b> (25 nmol/kg), or <b>10</b> (2.5, 8, and 25 nmol/kg)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">body weight change<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (%)</th><th class="rowsep1 colsep0" colspan="2" align="center">vacuole score<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose (nmol/kg)</th><th class="colsep0 rowsep0" align="center">peak change (day)</th><th class="colsep0 rowsep0" align="center">day 7</th><th class="colsep0 rowsep0" align="center">individual</th><th class="colsep0 rowsep0" align="center">average</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">0.7<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">2.3<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0, 0, 0, 0, 0, 0</td><td class="colsep0 rowsep0" align="left">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">–18.8* (4)</td><td class="colsep0 rowsep0" align="left">–16.0*</td><td class="colsep0 rowsep0" align="left">0, 0, 0, 0, 0, 0</td><td class="colsep0 rowsep0" align="left">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">–14.1* (2)</td><td class="colsep0 rowsep0" align="left">–10.2*</td><td class="colsep0 rowsep0" rowspan="3" align="left">0, 0, 0, 0, 0, 0</td><td class="colsep0 rowsep0" rowspan="3" align="left">0 all doses</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">–19.3* (2)</td><td class="colsep0 rowsep0" align="left">–11.5*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">–19.4* (2)</td><td class="colsep0 rowsep0" align="left">–13.7*</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">*<i>p</i> < 0.05 vs vehicle (PBS) unless otherwise noted.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Severity score: 1, minimum; 2, mild; 3, moderate; 4, marked.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">No significant body weight change was observed for <b>3</b>.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15208" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15208" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">PEGylation strategies have evolved over the years toward creating homogeneous site-specific PEG-peptide/protein conjugates.<a onclick="showRef(event, 'ref58 ref59 ref60 ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60 ref61 ref62 ref63">(58-63)</a> PEG size and architecture (linear or branched), conjugation chemistries, linker, and site of attachment are among the variables that are typically explored to optimize potency, efficacy, duration of action, product homogeneity, and to minimize kidney vacuolation. We desired to improve the pharmacokinetic properties of phybrids and to develop them as long-acting molecules. This presented an opportunity to explore a bifunctional PEG-based platform to ascertain the possibility of preserving potency and dual pharmacology of the phybrids when conjugated to a large PEG moiety.</div><div class="NLM_p">In order to retain receptor potency for both peptide components in PEGylated phybrids, it is requisite to minimize undesirable inter- and intramolecular steric and charge interactions that may interfere with receptor binding and activation. Our initial approach focused on site-specific PEGylation of preformed phybrids utilizing a reactive cysteine in the linker region of the molecules, with the expectation that the peptide components would be relatively unencumbered in their interaction with their receptors. To begin with, we observed a 5- to 60-fold loss in receptor potencies for the phybrids when compared to the parent exenatide analogues and davalintide. An additional 4- to 100-fold potency loss was noted after the attachment of a 40 kD PEG to the phybrids, suggesting that the receptor activities of the phybrids were being further compromised due to unfavorable steric effects (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>A). The redesigned bifunctional PEGylated conjugate <b>10</b> was found to have superior <i>in vitro</i> and <i>in vivo</i> activities compared to the initial side-chain-modified PEG conjugate <b>6</b> and was similar to unmodified phybrid <b>2</b> in its receptor potencies. We hypothesized from these findings that the PEG functionality in <b>10</b> serves as a spacer in between the two peptide components, thereby reducing undesirable peptide/peptide or peptide/receptor interactions (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>A,B). The “U-shaped” PEG size/receptor potency curves (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) indicated that the size of the intervening PEG influences the receptor activities of the phybrids, with the 40 kD PEG linker being optimal for phybrid–receptor interactions. Thus, whereas the smaller PEGs may not provide enough separation between the two peptides to freely interact with their receptors, the larger PEG sizes may be reintroducing detrimental molecular interactions. This hypothesis is further supported by <i>in vivo</i> study observations where the 60 and 80 kD conjugates <b>12</b> and <b>13</b> were less efficacious than <b>10</b> in DIO rats.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Illustration depicting potential peptide/peptide and PEG/peptide interactions. Introduction of PEG as a spacer may reduce peptide1/peptide2 interferences; (B) introduction of PEG as a spacer may reduce peptide/receptor interferences.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our DIO rat studies indicated that the bifunctional PEG phybrid <b>10</b> mediated an identical body weight reduction profile over three weeks to that obtained with the combination of PEG-parent peptides <b>3</b> and <b>4</b>. It appears that <b>10</b> behaves as a composite of <b>3</b> and <b>4</b>, with its 40 kD PEG spacer buffering the activities of the exenatide and the davalintide components. As a single molecular entity, such bifunctional PEGylated conjugates may have potential advantages as compared to the PEG–peptide combinations, which include cheaper cost of goods, a more straightforward regulatory path, and lower PEG doses for patients. This heterobifunctional PEGylation strategy could be broadly applicable to other peptide or protein hybrid templates to minimize loss of receptor functional activity. We have validated this approach with two other phybrid templates where losses in potency due to steric and charge interactions between the two peptide/protein fragments were recouped with the insertion of a 40 kD PEG spacer (unpublished results).</div><div class="NLM_p last">In summary, we developed a heterobifunctional PEGylation strategy and applied it to an exenatide-amylinomimetic phybrid template. Conjugate <b>10</b>, prepared with an intervening 40 kD PEG functionality, was superior in its receptor functional activities and in its pharmacodynamic effects compared to traditional backbone side-chain-modified PEGylated conjugates, and is comparable to a combination of corresponding parent PEG-peptides. Compound <b>10</b> is highly efficacious in reducing glucose and body weight, and its extended duration of action in rodent models holds promise as a once-weekly treatment for diabetes and/or obesity. The 1:1 stoichiometry of peptide components in our phybrid constructs has the potential limitation that it does not allow the component peptides to be independently dose titrated for efficacy. This limitation can be minimized by tuning and balancing the <i>in vitro</i> activities of the component peptides in the phybrid, such that the enhanced efficacy of combination therapy may be achieved with a single molecular entity. Our phybrid approach, together with the bifunctional PEGylation strategy described in this article, has broad applicability as a technology platform to design novel long-acting peptide therapeutics that can maximize the benefits of combination therapy. Finally, it has advantages due to a simplified regulatory path and a more convenient delivery device option when compared to alternative combination therapy approaches such as separately administered sustained release (SR) formulations of peptides, coformulations of SR peptides, or separately dosed long-acting peptides.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Materials</h3><div class="NLM_p last">Heterobifunctional PEG reagents maleimide-PEG 12 kD-<i>N</i>-hydroxysuccinimide ester (SUNBRIGHT MA-120TS) and maleimide-PEG 40 kD-<i>N</i>-hydroxysuccinimide ester (SUNBRIGHT MA-400TS) were purchased from NOF (Tokyo, Japan) and stored in a −40 °C freezer before use. Methoxy PEG 40 kD succinimidyl carboxymethyl ester (M-SCM-40K), methoxy PEG 40 kD maleimide (M-MAL-40K), maleimide-PEG 30 kD-<i>N</i>-hydroxysuccinimide ester (Mal-PEG30K-NHS), maleimide-PEG 60 kD-<i>N</i>-hydroxysuccinimide ester (Mal-PEG60K-NHS), and maleimide-PEG 80 kD-<i>N</i>-hydroxysuccinimide ester (Mal-PEG80K-NHS) were purchased from JenKem Technology USA (Allen, TX) and stored in a −40 °C freezer before use. Standard Fmoc amino acids for peptide synthesis were purchased from Genzyme pharmaceuticals. The amino acid derivatives, where side-chain protections was needed, were Fmoc-Arg(Pbf), Fmoc-Trp(Boc), Fmoc-Glu(OtBu), Fmoc-Lys(Boc), Fmoc-Gln(Trt), Fmoc-Tyr(tBu), Fmoc-Ser(tBu), Fmoc-Thr(tBu), Fmoc-His(Trt), Fmoc-Cys(Trt), Fmoc-Cys(Acm), Fmoc-Asn(Trt), and Fmoc-Asp(OtBu). Fmoc-Lys(Boc-Cys(trt))-OH, pseudoproline dipeptides Fmoc-Gly-Thr(ψMe,Mepro)-OH, and Fmoc-Leu-Ser(ψMe,Mepro)-OH were purchased from EMD Biosciences. Fmoc-Pal-PEG-amide and preloaded Fmoc-Gly-PEG-PS resins with loadings of 0.19–0.21 mmol/g were obtained from Applied Biosystems, Inc. (ABI). Rink amide resin with a loading of 0.69 mmol/g was obtained from NovaBiochem (Gibbstown, NJ). Prefilled amino acid cartridges for the ABI 433A synthesizer were purchased from Midwest Biotech (Fishers, IN). 2-(1<i>H</i>-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) was obtained from Peptide International (Louisville, KY). Trifluoroacetic acid (TFA) was obtained from Halocarbon Products (River Edge, NJ). Piperidine was obtained from Spectrum Chemicals (Gardena, CA). 2-Mercaptoethanol (ME) was obtained from MP Biomedicals (Solon, OH). <i>N</i>,<i>N</i>-Diisopropylethylamine (DIEA), <i>m</i>-cresol, triisopropylsilane (TIS), <i>t</i>-butyldimethylether (TBDME), and Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) were purchased from Acros Organics (Geel, Belgium). <i>N</i>,<i>N</i>-Dimethylformamide (DMF), <i>N</i>-methylpyrrolidone (NMP), dichloromethane (DCM), and HPLC grade acetonitrile were obtained from Fisher Scientific (Pittsburgh, PA). MacroCap SP cation exchange resin was purchased from GE Healthcare Life Sciences (Piscataway, NJ) and self-packed in a GE XK 16/20 column. One mL Mono S TM 5/50GL, 5 mL prepacked HiTrap SP HP, and 5 mL HiTrap Q HP ion exchange columns were purchased from GE Healthcare Life Sciences. Amicon centrifugal filters were purchased from Millipore (Billerica, MA).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> General Methods for Peptide Synthesis, Purification, and Analysis</h3><div class="NLM_p">Peptides were synthesized on ABI 433A synthesizers using standard FastMoc chemistry or a Protein Technologies Symphony peptide synthesizer using Fmoc chemistry. Preparative reverse-phase HPLC was performed on a Waters HPLC-MS system consisting of a Waters 2525 Prep HPLC Pump, 2767 sample manager, 2487 dual absorbance detector, and Micromass ZQ mass spectrometer with a Kromasil 250 × 21.2 mm 100–5C4 column using a linear gradient (25–50%) of buffer B in buffer A over 30 min (buffer A = 0.05% TFA in water; buffer B = 0.05% TFA in ACN) at a flow rate of 20 mL/min. Analytical reverse-phase HPLC was performed on an Agilent 1100 system using method (A) Kromasil 100 × 4.6 mm 100–5C4 and a linear gradient of buffer B in buffer A over 10 min (buffer A = 0.1% TFA in water; buffer B = 0.1% TFA in ACN) at a flow rate of 1 mL/min; method (B) 50 × 2.1 mm 100–3.5C4 column and a linear gradient of buffer B in buffer A over 15 min at a flow rate of 0.3 mL/min; and method (C) Jupiter C5, 250 × 4.6 mm, 5 μm column and a linear gradient of buffer B in buffer A (2–90%) over 34 min at a flow rate of 1.0 mL/min. Peptide molecular weight (MW) was determined by electrospray ionization mass spectrometry (ESI-MS) on an Agilent 6120 quadrupole MS attached to the Agilent 1100 HPLC system.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Peptide Synthesis</h4><div id="sec4_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i13" class="anchor-spacer"></div><h5 class="article-section__title" id="_i13"> Method A</h5><div class="NLM_p">AC3082 or AC3174 containing phybrids <b>1</b> and <b>2</b> were synthesized using standard FastMoc chemistry with optimizations on Fmoc-Pal-PEG-amide resin. Optimizations include (a) double couplings at positions Lys12 and Val20-Ile24; (b) using pseudoproline dipeptides at residues Gly4Thr5 and Leu10Ser11; (c) extended coupling times (3×) at positions Gly4Thr5, Thr7, Leu10Ser11, Lys12, Met14 (in <b>1</b> only), and Val20-Ile24. Peptide cleavage was carried out using TFA/<i>m</i>-cresol/TIS/H<sub>2</sub>O (15/2/1/2, v/v). Following TBDME precipitation and lyophilization, the crude peptide was purified in 100 mg batches using a Waters preparative HPLC-MS instrument. The fractions were analyzed by the Agilent analytical HPLC-MS instrument. Pure fractions were pooled and lyophilized. Purified peptides with free cysteine residues were dissolved in 20% acetic acid (5–7 mg/mL) and oxidized with an iodine solution (0.125 M in AcOH). A saturated thiosulfate solution was added to quench unreacted iodine. The oxidized peptides with a disulfide bond were then purified to give the final products. Characterization was performed by HPLC and ESI-MS spectral analysis (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> for HPLC and ESI-MS results, and the spectra are available in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Synthetic Details and Characterizations of Phybrids or Peptide Precursors for PEG-Conjugates</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">HPLC method</th><th class="rowsep1 colsep0" colspan="2" align="center">ESI-MS (Dalton)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">peptide</th><th class="colsep0 rowsep0" align="center">synthetic method</th><th class="colsep0 rowsep0" align="center">scale (mmol)</th><th class="colsep0 rowsep0" align="center">yield (mg)</th><th class="colsep0 rowsep0" align="center">method (gradient, %B)</th><th class="colsep0 rowsep0" align="center">purity %</th><th class="colsep0 rowsep0" align="center">calcd</th><th class="colsep0 rowsep0" align="center">found</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">1300.0</td><td class="colsep0 rowsep0" align="left">B (30–60)</td><td class="colsep0 rowsep0" align="left">>95</td><td class="colsep0 rowsep0" align="left">7072.9</td><td class="colsep0 rowsep0" align="left">7075.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">181.2</td><td class="colsep0 rowsep0" align="left">A (5–75)</td><td class="colsep0 rowsep0" align="left">>95</td><td class="colsep0 rowsep0" align="left">7946.8</td><td class="colsep0 rowsep0" align="left">7949.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AC3082-Lys(Cys)-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">129.5</td><td class="colsep0 rowsep0" align="left">B (20–50)</td><td class="colsep0 rowsep0" align="left">86.3<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">3526.0</td><td class="colsep0 rowsep0" align="left">3526.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AC3174-Lys(Cys)-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">281.4</td><td class="colsep0 rowsep0" align="left">B (30–60)</td><td class="colsep0 rowsep0" align="left">85.8<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">4399.8</td><td class="colsep0 rowsep0" align="left">4401.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AC3174-Lys-Cys-Gly-OH</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">120.0</td><td class="colsep0 rowsep0" align="left">B (30–60)</td><td class="colsep0 rowsep0" align="left">>95</td><td class="colsep0 rowsep0" align="left">4457.9</td><td class="colsep0 rowsep0" align="left">4457.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">desLys1-AC2307</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">182.0</td><td class="colsep0 rowsep0" align="left">A (5–75)</td><td class="colsep0 rowsep0" align="left">94.9</td><td class="colsep0 rowsep0" align="left">3495.9</td><td class="colsep0 rowsep0" align="left">3496.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>P-5</b></td><td class="colsep0 rowsep0" align="left">D</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">45.4</td><td class="colsep0 rowsep0" align="left">A (5–75)</td><td class="colsep0 rowsep0" align="left">97.3</td><td class="colsep0 rowsep0" align="left">7263.1</td><td class="colsep0 rowsep0" align="left">7264.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>P-6</b></td><td class="colsep0 rowsep0" align="left">E</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">C (2–90)</td><td class="colsep0 rowsep0" align="left">>95</td><td class="colsep0 rowsep0" align="left">8134.7</td><td class="colsep0 rowsep0" align="left">8136.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Contains 13.7% dimer (linked through intermolecular disulfide bond formation between the free cysteines).</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Contains 2.4% dimer.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">ND = not determined.</p></div></div></div></div><div id="sec4_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15"> Method B</h5><div class="NLM_p last">Precursor peptides AC3082-Lys(Cys)-NH<sub>2</sub>, AC3174-Lys(Cys)-NH<sub>2</sub>, and desLys1-AC2307 were synthesized using standard FastMoc chemistry on Rink amide resin. Fmoc-Lys(Boc-Cys(trt))-OH was used as the first residue for the synthesis of AC3082-Lys(Cys)-NH<sub>2</sub> and AC3174-Lys(Cys)-NH<sub>2</sub>. The cleavage and purification methods were similar to method A. The iodination step to form the disulfide bond was needed for desLys1-AC2307 but not for AC3082-Lys(Cys)-NH<sub>2</sub> and AC3174-Lys(Cys)-NH<sub>2</sub>. Characterization was performed by HPLC and ESI-mass spectral analysis (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> for HPLC and ESI-MS results, and the spectra are available in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_2_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16"> Method C</h5><div class="NLM_p last">Precursor peptide AC3174-Lys-Cys-Gly-OH was synthesized using standard FastMoc chemistry on preloaded Fmoc-Gly-PEG-PS resin. The cleavage and purification methods were similar to method A. The iodination step was not needed. Characterization was performed by HPLC and ESI-mass spectral analysis (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> for HPLC and ESI-MS results, and the spectra are available in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_2_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> Method D</h5><div class="NLM_p last">Precursor peptide of <b>5</b> (<b>P-5</b>, HGEGTFTSDLSKQLEEEAVR-LFIEWLKNGCGKC(Acm)NTATC(Acm)VLGRLSQELHRLQTYPRTNTGSNTY-NH<sub>2</sub>) was synthesized using standard FastMoc chemistry with on Fmoc-Pal-PEG-amide resin with the same optimizations as those in Method A. Fmoc-Cys(Acm)-OH was used for residues 33 and 38. The cleavage and purification methods were similar to method A. The iodination step was not needed. Characterization was performed by HPLC and ESI-mass spectral analysis (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> for HPLC and ESI-MS results, and the spectra are available in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_2_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> Method E</h5><div class="NLM_p last">Precursor peptide of <b>6</b> (<b>P-6</b>, HGEGTFTSDLSKQLEEEAVR-LFIEWLKNGGPSSGAPPPSGCGKC(Acm)NTATC(Acm)VLGRLSQELHRLQTYPRTNTGSNTY-NH<sub>2</sub>) was synthesized using standard FastMoc chemistry with ChemMatrix resin by Almac Sciences (East Lothian, Scotland, UK). Characterization was performed by HPLC and ESI-mass spectral analysis (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> for HPLC and ESI-MS results, and the spectra are available in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Method for PEG-Conjugate Purification and Characterization</h3><div class="NLM_p">FPLC purification was performed on a GE AKTA Explorer 100 system. Buffer A = 20 mM pH 4.0 NaOAc; buffer B = 20 mM pH 4.0 NaOAc, 1.0 M NaCl; buffer C = 20 mM tris, pH 8.5; and buffer D = 20 mM pH 8.5 tris, 0.5 M NaCl. PEG-conjugate molecular weight (MW) was determined by matrix-assisted laser desorption/ionization (MALDI) method on a ABI Voyager-DE STR system with sinapinic acid matrix solution. sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) was run on NuPAGE 4–12% Bis-Tris gel referenced with a Mark 12 protein standard. All compounds were determined by SDS–PAGE gel not to contain significant amounts of precursor peptides (<0.5 mol % as determined by the densitometry method using a Fluorochem gel documentation system).</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Synthesis of PEG-Conjugates</h4><div id="sec4_3_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> Synthesis of Conjugate <b>3</b> by N-Terminal PEGylation of DesLys1-AC2307</h5><div class="NLM_p">Methoxy PEG 40 kD succinimidyl carboxymethyl ester (M-SCM-40K, 250.0 mg) was dissolved in 10 mL of anhydrous DMF. DesLys1-AC2307 (25.0 mg) was added followed by 40 μL of DIEA. The reaction was allowed to sit overnight before TBDME was added to precipitate the conjugate. The crude was washed twice with ether, dried, reconstituted in 15 mL of 20 mM pH 4.0 NaOAc buffer, and then purified by FPLC with a self-packed 15 mL MacroCap SP column (gradient = 0–15%–100% buffer B in buffer A, 10 column volumes (CV) each, 3 mL/min). Fractions of the conjugate were pooled according to the SDS–PAGE gel result, dialyzed against water, and lyophilized to give 101.4 mg of <b>3</b>. Characterization was performed by MALDI and the SDS-PAGE gel (see Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> for MALDI results; the spectra are available in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Synthetic Details and Characterizations of PEG-Conjugates</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">reactant and scale</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">MALDI-MS (Dalton)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd number</th><th class="colsep0 rowsep0" align="center">precursor peptide 1 (mg)</th><th class="colsep0 rowsep0" align="center">precursor peptide 2 (mg)</th><th class="colsep0 rowsep0" align="center">PEG reagent (mg)</th><th class="colsep0 rowsep0" align="center">yield (mg)</th><th class="colsep0 rowsep0" align="center">calcd<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">found</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">desLys1-AC2307 (25.0)</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">M-SCM-40K (250.0)</td><td class="colsep0 rowsep0" align="left">101.4</td><td class="colsep0 rowsep0" align="left">43800</td><td class="colsep0 rowsep0" align="left">43860</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">AC3174-Lys (Cys)-NH<sub>2</sub> (10.2)</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">M-MAL-40K (60.0)</td><td class="colsep0 rowsep0" align="left">22.7</td><td class="colsep0 rowsep0" align="left">44500</td><td class="colsep0 rowsep0" align="left">45155</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left"><b>P-5</b> (6.7)</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">M-MAL-40K (48.0)</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">47121</td><td class="colsep0 rowsep0" align="left">45193</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left"><b>P-6</b> (6.7)</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">M-MAL-40K (48.0)</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">49000</td><td class="colsep0 rowsep0" align="left">49747</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">desLys1-AC2307 (18.2)</td><td class="colsep0 rowsep0" align="left">AC3082-Lys(Cys)-NH<sub>2</sub> (6.1)</td><td class="colsep0 rowsep0" align="left">MA-120TS (61.8)</td><td class="colsep0 rowsep0" align="left">5.7</td><td class="colsep0 rowsep0" align="left">19021</td><td class="colsep0 rowsep0" align="left">19310</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">desLys1-AC2307 (32.0)</td><td class="colsep0 rowsep0" align="left">AC3174-Lys(Cys)-NH<sub>2</sub> (6.9)</td><td class="colsep0 rowsep0" align="left">MA-120TS (108.7)</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">19894</td><td class="colsep0 rowsep0" align="left">20098</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">desLys1-AC2307 (10.0)</td><td class="colsep0 rowsep0" align="left">AC3174-Lys(Cys)-NH<sub>2</sub> (5.0)</td><td class="colsep0 rowsep0" align="left">Mal-PEG30K-NHS (100.0)</td><td class="colsep0 rowsep0" align="left">8.7</td><td class="colsep0 rowsep0" align="left">37400</td><td class="colsep0 rowsep0" align="left">36500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">desLys1-AC2307 (30.0)</td><td class="colsep0 rowsep0" align="left">AC3174-Lys(Cys)-NH<sub>2</sub> (20.0)</td><td class="colsep0 rowsep0" align="left">MA-400TS (300.0)</td><td class="colsep0 rowsep0" align="left">108.4</td><td class="colsep0 rowsep0" align="left">49500</td><td class="colsep0 rowsep0" align="left">49535</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">desLys1-AC2307 (15.0)</td><td class="colsep0 rowsep0" align="left">AC3174-LysCysGly-OH (10.0)</td><td class="colsep0 rowsep0" align="left">MA-400TS (150.0)</td><td class="colsep0 rowsep0" align="left">39.7</td><td class="colsep0 rowsep0" align="left">47952</td><td class="colsep0 rowsep0" align="left">49095</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">desLys1-AC2307 (8.0)</td><td class="colsep0 rowsep0" align="left">AC3174-Lys(Cys)-NH<sub>2</sub> (5.0)</td><td class="colsep0 rowsep0" align="left">Mal-PEG60K-NHS (150.0)</td><td class="colsep0 rowsep0" align="left">14.7</td><td class="colsep0 rowsep0" align="left">64200</td><td class="colsep0 rowsep0" align="left">63300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">desLys1-AC2307 (20.0)</td><td class="colsep0 rowsep0" align="left">AC3174-Lys(Cys)-NH<sub>2</sub> (15.0)</td><td class="colsep0 rowsep0" align="left">Mal-PEG80K-NHS (400)</td><td class="colsep0 rowsep0" align="left">42.1</td><td class="colsep0 rowsep0" align="left">88780</td><td class="colsep0 rowsep0" align="left">87500</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Calcd molecular weight (MW) of conjugate = calcd MW of precursor peptide(s) + found MW of PEG reagent supplied by vender ± reaction transformation MW change.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">NA = not applicable.</p></div></div></div></div><div id="sec4_3_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> Synthesis of Conjugate <b>4</b> by PEGylation of AC3174-Lys(Cys)-NH<sub>2</sub></h5><div class="NLM_p last">AC3174-Lys(Cys)-NH<sub>2</sub> (10.2 mg) and methoxy PEG 40 kD maleimide (M-MAL-40K, 60.0 mg) were dissolved in 5 mL 100 nM NaOAc buffer, pH 5.0 and the mixture was stirred overnight at room temperature. Ten mL of buffer C was added and the mixture was purified by FPLC with a 5 mL HiTrap Q HP column (gradient =0–30%-100% buffer D in buffer C, 20 and 10 CV respectively, 3 mL/min). Fractions of the conjugate were pooled according to SDS-PAGE gel result, dialyzed against water and lyophilized to give 22.7 mg of <b>4</b>. Characterization was performed by MALDI and SDS-PAGE gel (see Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> for MALDI results; the spectra are available in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_3_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> Synthesis of PEGylated Phybrid <b>5</b></h5><div class="NLM_p last">The precursor peptide <b>P-5</b> (prepared by method D, 6.7 mg) and methoxy PEG 40 kD maleimide (M-MAL-40K, 48.0 mg) were dissolved in 1 mL of 100 mM NaOAc buffer, pH 5.0, and the mixture was stirred overnight at 4 °C. Four mL of deionized water was added, and the mixture was purified by FPLC with a 1 mL Mono S column (gradient = 0–40%–100% buffer B in buffer A, 30 and 10 CV respectively, 1 mL/min). Fractions of the conjugate were pooled according to the SDS–PAGE gel result, dialyzed, and lyophilized to give 6.1 mg of PEG-conjugate with the Acm protection group on Cys33 and Cys38. This protected conjugate was dissolved in 2 mL of 20% AcOH, and 20 μL of iodine solution (0.125 M in AcOH) was added. The mixture was stirred for 5 min before dialysis against water. Two 100 μL samples were taken, to one of which was added 25 μL of 0.4 M TCEP, before all samples were lyophilized to give 3.1 mg of <b>5</b>. Ellman’s test displayed yellow color for the TCEP treated sample but not for the other indicating the complete removal of Acm protection groups and the formation of a disulfide bond between Cys33 and Cys38. Characterization was performed by MALDI and SDS–PAGE gel (see Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> for MALDI results; the spectra are available in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_3_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> Synthesis of PEGylated Phybrid <b>6</b></h5><div class="NLM_p last">The procedure and scale were identical to those of <b>5</b>, and the yield of <b>6</b> was 3.9 mg. Characterization was performed by MALDI and SDS–PAGE gel (see Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> for MALDI results; the spectra are available in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_3_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> General Procedure for Bifunctional PEGylation (Synthesis of <b>7</b>, <b>8</b>, <b>9</b>, <b>10</b>, <b>12</b>, and <b>13</b>)</h5><div class="NLM_p last">PEG reagent was dissolved in anhydrous DMF (30 mg/mL). DesLys1-AC2307 was added followed by DIEA (0.5% v/v). The reaction was allowed to sit overnight before TBDME was added to precipitate the conjugate. The crude was washed twice with ether, dried, reconstituted in 20 mM pH 4.0 NaOAc buffer to a peptide concentration of ∼2 mg/mL, and then purified by FPLC with a 5 mL HiTrap SP HP or a self-packed 15 mL MacroCap SP column depending on the scale (gradient = 0–15%-100% buffer B in buffer A, 10 CV each, 3 mL/min). Fractions of the intermediate conjugate desLys1-AC2307-PEG-Mal were pooled according to the SDS–PAGE gel result and used immediately for the next reaction to prevent hydrolyzation of maleimide. To the desLys1-AC2307-PEG-Mal pool was added 3082- or 3174-Lys(Cys)-NH<sub>2</sub>, and the mixture was allowed to sit overnight. The crude was concentrated by Amicon centrifugal filters (Amicon ultra15, 10K) before reconstitution in 20 mM pH 4.0 NaOAc buffer to reach a peptide concentration of ∼2 mg/mL. It was then purified by the same FPLC column (gradient = 0–100% buffer B in buffer A, 30 CV, 3 mL/min). Fractions of the final product were pooled according to MALDI and SDS–PAGE gel results, dialyzed, and lyophilized to give the final conjugates. Characterization was performed by MALDI and SDS–PAGE gel (see Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> for MALDI results; the spectra are available in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div></div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>In Vitro</i> Studies</h4><div class="NLM_p">All adenylate cyclase activation was measured with an HTRF (Homogeneous Time-Resolved Fluorescence) cell-based cAMP assay kit from CisBio (Bedford, MA) following the manufacturer’s instructions. All <sup>125</sup>I-labeld radioactive ligands used in the binding studies were from PerkinElmer (Waltham, MA). EC<sub>50</sub> and IC<sub>50</sub> values of peptides were determined by the analysis of a concentration–response curve using nonlinear regression analysis fitted to a 4-parameter model.</div><div id="sec4_3_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Calcitonin Adenylate Cyclase Activation</h5><div class="NLM_p last">Serially diluted peptides were transferred to a 384-well assay plate. HEK293 cells stably expressing the rat C1A calcitoninR were collected from cell culture flasks and resuspended in the kit stimulation buffer containing 500 μM IBMX and d2 fluorophore. Cells were added to the assay plate at a density of 10,000 per well and incubated in the dark for 30 min at ambient temperature for receptor activation. Cells were subsequently lysed by the addition of anti-cAMP Cryptate solution diluted with the kit’s conjugate/lysis buffer. After 1 to 24 h of incubation in the dark, the plate was counted on a Tecan Ultra plate reader.</div></div><div id="sec4_3_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> GLP-1 Adenylate Cyclase Activation</h5><div class="NLM_p last">Serially diluted peptides were transferred to a 384-well assay plate. The rat thyroid C-cell line, 6–23 cells, endogenously expressing the rat GLP-1 receptor were collected from cell culture flasks and resuspended in the kit’s stimulation buffer containing 500 μM IBMX and the d2 fluorophore. Cells were added to the assay plate at a density of 12,500 per well. The rest of the experiment was carried out as described above.</div></div><div id="sec4_3_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> CalcitoninR Binding</h5><div class="NLM_p last">Membranes prepared from HEK293 cells stably expressing the rat C1A calcitoninR were incubated with 50 pM <sup>125</sup>I-human calcitonin (labeled at Tyr12, 2200 Ci/mmol) and serially diluted test peptide for 60 min at ambient temperature. Well contents were collected onto a 96-well glass fiber plate using a PerkinElmer plate harvester. Dried glass fiber plates were combined with scintillant and counted on a MicroBeta scintillation counter from PerkinElmer.</div></div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>In Vivo</i> Studies</h4><div id="sec4_3_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> PK Studies for Phybrids <b>1</b> and <b>2</b></h5><div class="NLM_p">Male Sprague–Dawley rats (CRL/CD rats, Charles River Laboratories, Wilmington, MA) were housed two animals per cage and maintained on standard rodent chow ad libitum and provided with water bottles. The age of the animals at the onset of dosing was approximately 9 weeks. Test compounds were given intravenously (0.1 mg/kg, <i>n</i> = 6) or subcutaneously (0.3 mg/kg, <i>n</i> = 6), and blood samples were collected from 3 animals in alternative cohorts into vials containing potassium (K<sub>2</sub>) EDTA at multiple time points (5, 10, 15, 30, 60, 90, 120, 180, and 240 min for <b>1</b> and 3, 9, 15, 30, 60, 90, 120, 180, 240, and 360 min for <b>2</b>) following IV administration or prior to dosing and at multiple time points (5, 10, 20, 30, 60, 90, 120, 180, 240, and 360 min for <b>1</b> and 10, 20, 45, 60, 90, 120, 180, 240, and 360 min for <b>2</b>) following SC administration. Plasma concentration results were determined by a two-site “sandwich” ELISA method, which used two monoclonal antibodies to detect the full length phybrid molecule. The capture antibody was muEXE04:03-06.11 directed against N-terminal residues of exenatide (GTFTSDLSKQ), and the detection antibody was muF025-27.04 (biotinylated) directed against C-terminal residues of davalintide (GSNTY). In this ELISA format, muEXE04:02-08.04 was coated on to a 96-well plate and then blocked using bovine serum albumin (BSA). Standards and samples were added to designated sample wells on the plate at a 3-fold minimum required dilution. The captured phybrid was detected by the subsequent additions (with washing between steps) of biotinylated antibody (muF025-27.04), streptavidin-horse radish peroxidase, and tetramethylbenzidine substrate (TMB). The absorbance of the color obtained following the addition of sulfuric acid was measured using a Molecular Devices Versamax ELISA reader. Using SoftMax Pro analytical software, the optical density (OD) was correlated with the concentration using the calibration curve defined in the same assay. The rat standard curve was generated with a concentration range of 100–5000 pg/mL. Pharmacokinetic parameters were calculated using the WinNonlin Professional (version 5.2) computer software application (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Percent absolute bioavailability was calculated as 100·(AUC<sub>SC</sub>·Dose<sub>IV</sub>/AUC<sub>IV</sub>·Dose<sub>SC</sub>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters of Phybrids <b>1</b> and <b>2</b> Following Intravenous or Subcutaneous Administration in Male Sprague–Dawley Rats<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">intravenous (0.1 mg/kg)</th><th class="rowsep1 colsep0" colspan="2" align="center">subcutaneous (0.3 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>2</b></th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>2</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub></td><td class="colsep0 rowsep0" align="left">41 min</td><td class="colsep0 rowsep0" align="left">50 min</td><td class="colsep0 rowsep0" align="left">68 min</td><td class="colsep0 rowsep0" align="left">72 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>0</sub> (pg/mL)</td><td class="colsep0 rowsep0" align="left">1,395,170</td><td class="colsep0 rowsep0" align="left">2,511,412</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0-∞</sub> (pg·h/mL)</td><td class="colsep0 rowsep0" align="left">242,982</td><td class="colsep0 rowsep0" align="left">270,630</td><td class="colsep0 rowsep0" align="left">531,965</td><td class="colsep0 rowsep0" align="left">408,722</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">6.2</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d</sub> (mL/kg)</td><td class="colsep0 rowsep0" align="left">141</td><td class="colsep0 rowsep0" align="left">139</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (pg/mL)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">275,333</td><td class="colsep0 rowsep0" align="left">198,113</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">30 min</td><td class="colsep0 rowsep0" align="left">45 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">absolute bioavailability %</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">50</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Abbreviations: AUC = area under the concentration–time curve from time zero through the last quantifiable sample (0–<i>t</i>), or from zero to time infinity (0–∞); <i>C</i><sub>max</sub> = maximum observed plasma concentration over the dosing interval; <i>C</i><sub>0</sub> = estimated initial concentration; CL = total body clearance; <i>t</i><sub>1/2</sub> = half-life of elimination; <i>T</i><sub>max</sub> = time to <i>C</i><sub>max</sub>; <i>V</i><sub>d</sub> = volume of distribution.</p></div></div></div></div><div id="sec4_3_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> Hsd/NIHS Female Mice Studies</h5><div class="NLM_p last">A subcutaneous injection of either 200 μL of PBS vehicle or test article was given immediately following baseline glucose (<i>t</i> = 0) to Hsd/NIHS female mice (<i>n</i> = 9). Tail blood glucose samples were measured at <i>t</i> = 2, 4, 8, 24, 48, 72, and 96 h post-dose using OneTouch Ultra (LifeScan, Inc., a Johnson & Johnson Company, Milpitas, CA). Body weight was measured daily. Significant test sample effects and sample-to-sample comparisons were identified by analysis of variance (ANOVA, <i>p</i> < 0.05), followed by Dunnett’s post-test using GraphPad Prism, version 4.00, for Windows (GraphPad Software, San Diego CA).</div></div><div id="sec4_3_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> DIO Rat PK/PD Studies</h5><div class="NLM_p last">Male Sprague–Dawley rats (CRL/CD rats, Charles River Laboratories, Wilmington, MA) were individually housed and maintained on a high fat diet (32% kcal from fat; D12266B Research Diets, Brunswick, NJ) for a range of approximately 8–11 weeks. Mean body weights at the beginning of the study were 478 ± 4 g, 475 ± 2 g, and 504 ± 5g for the experiments in Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, respectively. Vehicle (10% DMSO in sterile 0.9% saline) and test compounds were given subcutaneously (1 mL/kg). Food intake and body weight were measured several times per week during all experiments. For the PK study of <b>10</b>, blood was drawn for plasma analysis of <b>10</b> via tail vein on days 3, 7, and 15 and via cardiac puncture on day 21. Plasma concentration results were determined by a ELISA method similar to that described for <b>1</b> and <b>2</b> except that the capture antibody was muEXE04:02-08.04 directed against C-terminal residues of exenatide (GGPSSGAPPPS), and the rat standard curve was generated with a concentration range of 200–102,400 pg/mL. Pharmacokinetic parameters were calculated using the WinNonlin Professional (version 5.2) noncompartmental model. Data were analyzed using two-way ANOVA with Bonferroni posthoc comparisons. Significance was assumed for <i>p</i> < 0.05. Graphs were generated using Prism 5 for Windows (Graphpad Software, San Diego, CA). All data points are expressed as the mean ± SEM.</div></div><div id="sec4_3_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Kidney Vacuolation Assay</h5><div class="NLM_p last">Female JAX C57BL 6/J mice were dosed with vehicle (PBS) and test compounds via subcutaneous injection daily for seven consecutive days. The dose administered to mice in each group is shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Body weight was measured daily. All animals survived to the scheduled necropsy on study day 7. Mice were humanely euthanized by CO<sub>2</sub> overdose followed by cervical dislocation. Following euthanasia, kidneys from all groups were collected, weighed, and preserved in 10% formalin. Tissues were sent to the Charles River Laboratories, Pathology Associates, Durham, North Carolina facility for processing and histopathological evaluation. Kidneys were trimmed, processed, embedded in paraffin, sectioned at approximately 5 μm, and stained with hematoxylin and eosin. The resulting glass slides were examined by a board-certified veterinary pathologist (DACVP), and all microscopic pathology findings were entered into Microsoft Office Excel (version 2003 SP2). Gross lesions were entered into Microsoft Office Excel (version 2003 SP2) retrospectively from the necropsy records provided by the test facility. Histopathological evaluation was performed by the undersigned veterinary pathologist on all submitted kidneys for all animals. In tables listing the findings for individual animals, findings were given a severity grade based on a scale of 1–4 (minimal < mild < moderate < marked).</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37"><a href="/doi/suppl/10.1021/jm401418s">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17317" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17317" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">HPLC-MS of all phybrids and peptide precursors, MALDI-MS, and SDS–PAGE gel of all conjugates associated with this article is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401418s/suppl_file/jm401418s_si_001.pdf">jm401418s_si_001.pdf (3.06 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm401418s" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47531" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47531" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chengzao Sun</span> - <span class="hlFld-Affiliation affiliation">Amylin Pharmaceuticals,
LLC, 9625 Towne Centre
Drive, San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e9aa818c878e938886a98e84888085c78a8684"><span class="__cf_email__" data-cfemail="afecc7cac1c8d5cec0efc8c2cec6c381ccc0c2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James L. Trevaskis</span> - <span class="hlFld-Affiliation affiliation">Amylin Pharmaceuticals,
LLC, 9625 Towne Centre
Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolyn M. Jodka</span> - <span class="hlFld-Affiliation affiliation">Amylin Pharmaceuticals,
LLC, 9625 Towne Centre
Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Swetha Neravetla</span> - <span class="hlFld-Affiliation affiliation">Amylin Pharmaceuticals,
LLC, 9625 Towne Centre
Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pete Griffin</span> - <span class="hlFld-Affiliation affiliation">Amylin Pharmaceuticals,
LLC, 9625 Towne Centre
Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kui Xu</span> - <span class="hlFld-Affiliation affiliation">Amylin Pharmaceuticals,
LLC, 9625 Towne Centre
Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Wang</span> - <span class="hlFld-Affiliation affiliation">Amylin Pharmaceuticals,
LLC, 9625 Towne Centre
Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David G. Parkes</span> - <span class="hlFld-Affiliation affiliation">Amylin Pharmaceuticals,
LLC, 9625 Towne Centre
Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce Forood</span> - <span class="hlFld-Affiliation affiliation">Amylin Pharmaceuticals,
LLC, 9625 Towne Centre
Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soumitra S. Ghosh</span> - <span class="hlFld-Affiliation affiliation">Amylin Pharmaceuticals,
LLC, 9625 Towne Centre
Drive, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2280e2827-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18065" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18065" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge the expert technical assistance of Julie A. Hoyt, Jon Athanacio, Cara Ngo, Jenne Pierce, and Pam Smith. We also thank the staff of the Comparative Medicine facility at Amylin Pharmaceuticals, LLC for assistance with animal care.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 68 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Mack, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soares, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Athanacio, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turek, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedulin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jodka, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roland, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lwin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laugero, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterniti, J. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight</span> <span class="citation_source-journal">Int. J. Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Fijo.2009.238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=385-395&author=C.+M.+Mackauthor=C.+J.+Soaresauthor=J.+K.+Wilsonauthor=J.+R.+Athanacioauthor=V.+F.+Turekauthor=J.+L.+Trevaskisauthor=J.+D.+Rothauthor=P.+A.+Smithauthor=B.+Gedulinauthor=C.+M.+Jodkaauthor=B.+L.+Rolandauthor=S.+H.+Adamsauthor=A.+Lwinauthor=J.+Herichauthor=K.+D.+Laugeroauthor=C.+Vuauthor=R.+Pittnerauthor=J.+R.+Paternitiauthor=M.+Hanleyauthor=S.+Ghoshauthor=D.+G.+Parkes&title=Davalintide+%28AC2307%29%2C+a+novel+amylin-mimetic+peptide%3A+enhanced+pharmacological+properties+over+native+amylin+to+reduce+food+intake+and+body+weight"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight</span></div><div class="casAuthors">Mack, C. M.; Soares, C. J.; Wilson, J. K.; Athanacio, J. R.; Turek, V. F.; Trevaskis, J. L.; Roth, J. D.; Smith, P. A.; Gedulin, B.; Jodka, C. M.; Roland, B. L.; Adams, S. H.; Lwin, A.; Herich, J.; Laugero, K. D.; Vu, C.; Pittner, R.; Paterniti, J. R., Jr.; Hanley, M.; Ghosh, S.; Parkes, D. G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Obesity</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">385-395</span>CODEN:
                <span class="NLM_cas:coden">IJOBDP</span>;
        ISSN:<span class="NLM_cas:issn">0307-0565</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objective: The current set of studies describe the in vivo metabolic actions of the novel amylin-mimetic peptide davalintide (AC2307) in rodents and compares these effects with those of the native peptide.  Research design and methods: The anti-obesity effects of davalintide were examd. after i.p. injection or sustained peripheral infusion through s.c. implanted osmotic pumps.  The effect of davalintide on food intake after lesioning of the area postrema (AP) and neuronal activation as measured by c-Fos, were also investigated.  Results: Similar to amylin, davalintide bound with high affinity to amylin, calcitonin and calcitonin gene-related peptide receptors.  Acutely, davalintide displayed greater suppression of dark-cycle feeding and an extended duration of action compared with amylin (23 vs. 6 h).  Davalintide had no effect on locomotor activity or kaolin consumption at doses that decreased food intake.  Davalintide-induced wt. loss through infusion was dose dependent, durable up to 8 wk, fat-specific and lean-sparing, and was assocd. with a shift in food preference away from high-fat (palatable) chow.  Metabolic rate was maintained during active wt. loss.  Both davalintide and amylin failed to suppress food intake after lesioning of the AP and activated similar brain nuclei, with davalintide displaying an extended duration of c-Fos expression compared with amylin (8 vs. 2 h).  Conclusion: Davalintide displayed enhanced in vivo metabolic activity over amylin while retaining the beneficial properties possessed by the native mol.  In vitro receptor binding, c-Fos expression and AP lesion studies suggest that the metabolic actions of davalintide and amylin occur through activation of similar neuronal pathways.  International Journal of Obesity (2010) 34, 385-395; doi:10.1038/ijo.2009.238; published online 24 Nov. 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmq7OMUf0qq7Vg90H21EOLACvtfcHk0ljnI-KAYEgP9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFCrsrs%253D&md5=d9005c9cae2413347a146763bb6870af</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fijo.2009.238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fijo.2009.238%26sid%3Dliteratum%253Aachs%26aulast%3DMack%26aufirst%3DC.%2BM.%26aulast%3DSoares%26aufirst%3DC.%2BJ.%26aulast%3DWilson%26aufirst%3DJ.%2BK.%26aulast%3DAthanacio%26aufirst%3DJ.%2BR.%26aulast%3DTurek%26aufirst%3DV.%2BF.%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DSmith%26aufirst%3DP.%2BA.%26aulast%3DGedulin%26aufirst%3DB.%26aulast%3DJodka%26aufirst%3DC.%2BM.%26aulast%3DRoland%26aufirst%3DB.%2BL.%26aulast%3DAdams%26aufirst%3DS.%2BH.%26aulast%3DLwin%26aufirst%3DA.%26aulast%3DHerich%26aufirst%3DJ.%26aulast%3DLaugero%26aufirst%3DK.%2BD.%26aulast%3DVu%26aufirst%3DC.%26aulast%3DPittner%26aufirst%3DR.%26aulast%3DPaterniti%26aufirst%3DJ.%2BR.%26aulast%3DHanley%26aufirst%3DM.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3DDavalintide%2520%2528AC2307%2529%252C%2520a%2520novel%2520amylin-mimetic%2520peptide%253A%2520enhanced%2520pharmacological%2520properties%2520over%2520native%2520amylin%2520to%2520reduce%2520food%2520intake%2520and%2520body%2520weight%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2010%26volume%3D34%26spage%3D385%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Pan, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxton, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yung, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tom, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDougall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claus, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clairmont, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, J. P.</span><span> </span><span class="NLM_article-title">Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">12506</span><span class="NLM_x">–</span> <span class="NLM_lpage">12515</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=12506-12515&author=C.+Q.+Panauthor=J.+M.+Buxtonauthor=S.+L.+Yungauthor=I.+Tomauthor=L.+Yangauthor=H.+Chenauthor=M.+MacDougallauthor=A.+Bellauthor=T.+H.+Clausauthor=K.+B.+Clairmontauthor=J.+P.+Whelan&title=Design+of+a+long+acting+peptide+functioning+as+both+a+glucagon-like+peptide-1+receptor+agonist+and+a+glucagon+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DC.%2BQ.%26aulast%3DBuxton%26aufirst%3DJ.%2BM.%26aulast%3DYung%26aufirst%3DS.%2BL.%26aulast%3DTom%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMacDougall%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DA.%26aulast%3DClaus%26aufirst%3DT.%2BH.%26aulast%3DClairmont%26aufirst%3DK.%2BB.%26aulast%3DWhelan%26aufirst%3DJ.%2BP.%26atitle%3DDesign%2520of%2520a%2520long%2520acting%2520peptide%2520functioning%2520as%2520both%2520a%2520glucagon-like%2520peptide-1%2520receptor%2520agonist%2520and%2520a%2520glucagon%2520receptor%2520antagonist%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D12506%26epage%3D12515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Day, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaway, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gidda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findeisen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruemmer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hembree, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abplanalp, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruehl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockie, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogueiras, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfluger, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschop, M. H.</span><span> </span><span class="NLM_article-title">A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">757</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Fnchembio.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=19597507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=749-757&author=J.+W.+Dayauthor=N.+Ottawayauthor=J.+T.+Pattersonauthor=V.+Gelfanovauthor=D.+Smileyauthor=J.+Giddaauthor=H.+Findeisenauthor=D.+Bruemmerauthor=D.+J.+Druckerauthor=N.+Chaudharyauthor=J.+Hollandauthor=J.+Hembreeauthor=W.+Abplanalpauthor=E.+Grantauthor=J.+Ruehlauthor=H.+Wilsonauthor=H.+Kirchnerauthor=S.+H.+Lockieauthor=S.+Hofmannauthor=S.+C.+Woodsauthor=R.+Nogueirasauthor=P.+T.+Pflugerauthor=D.+Perez-Tilveauthor=R.+DiMarchiauthor=M.+H.+Tschop&title=A+new+glucagon+and+GLP-1+co-agonist+eliminates+obesity+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</span></div><div class="casAuthors">Day, Jonathan W.; Ottaway, Nickki; Patterson, James T.; Gelfanov, Vasily; Smiley, David; Gidda, Jas; Findeisen, Hannes; Bruemmer, Dennis; Drucker, Daniel J.; Chaudhary, Nilika; Holland, Jenna; Hembree, Jazzminn; Abplanalp, William; Grant, Erin; Ruehl, Jennifer; Wilson, Hilary; Kirchner, Henriette; Lockie, Sarah Haas; Hofmann, Susanna; Woods, Stephen C.; Nogueiras, Ruben; Pfluger, Paul T.; Perez-Tilve, Diego; DiMarchi, Richard; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">749-757</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the efficacy of a new peptide with agonism at the glucagon and GLP-1 receptors that has potent, sustained satiation-inducing and lipolytic effects.  Selective chem. modification to glucagon resulted in a loss of specificity, with minimal change to inherent activity.  The structural basis for the co-agonism appears to be a combination of local positional interactions and a change in secondary structure.  Two co-agonist peptides differing from each other only in their level of glucagon receptor agonism were studied in rodent obesity models.  Administration of PEGylated peptides once per wk normalized adiposity and glucose tolerance in diet-induced obese mice.  Redn. of body wt. was achieved by a loss of body fat resulting from decreased food intake and increased energy expenditure.  These preclin. studies indicate that when full GLP-1 agonism is augmented with an appropriate degree of glucagon receptor activation, body fat redn. can be substantially enhanced without any overt adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4K1-_eVTTKbVg90H21EOLACvtfcHk0liHrmMyMD6BMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D&md5=74b57672bfd375dd4d073624a25eab9b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.209%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DJ.%2BW.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DPatterson%26aufirst%3DJ.%2BT.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DGidda%26aufirst%3DJ.%26aulast%3DFindeisen%26aufirst%3DH.%26aulast%3DBruemmer%26aufirst%3DD.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DChaudhary%26aufirst%3DN.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DHembree%26aufirst%3DJ.%26aulast%3DAbplanalp%26aufirst%3DW.%26aulast%3DGrant%26aufirst%3DE.%26aulast%3DRuehl%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DH.%26aulast%3DKirchner%26aufirst%3DH.%26aulast%3DLockie%26aufirst%3DS.%2BH.%26aulast%3DHofmann%26aufirst%3DS.%26aulast%3DWoods%26aufirst%3DS.%2BC.%26aulast%3DNogueiras%26aufirst%3DR.%26aulast%3DPfluger%26aufirst%3DP.%2BT.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DDiMarchi%26aufirst%3DR.%26aulast%3DTschop%26aufirst%3DM.%2BH.%26atitle%3DA%2520new%2520glucagon%2520and%2520GLP-1%2520co-agonist%2520eliminates%2520obesity%2520in%2520rodents%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D749%26epage%3D757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Pocai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrington, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tota, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sountis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoprete, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capito, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicchi, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SinhaRoy, R.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2258</span><span class="NLM_x">–</span> <span class="NLM_lpage">2266</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2009&pages=2258-2266&author=A.+Pocaiauthor=P.+E.+Carringtonauthor=J.+R.+Adamsauthor=M.+Wrightauthor=G.+Eiermannauthor=L.+Zhuauthor=X.+Duauthor=A.+Petrovauthor=M.+E.+Lassmanauthor=G.+Jiangauthor=F.+Liuauthor=C.+Millerauthor=L.+M.+Totaauthor=G.+Zhouauthor=X.+Zhangauthor=M.+M.+Sountisauthor=A.+Santopreteauthor=E.+Capitoauthor=G.+G.+Chicchiauthor=N.+Thornberryauthor=E.+Bianchiauthor=A.+Pessiauthor=D.+J.+Marshauthor=R.+SinhaRoy&title=Glucagon-like+peptide+1%2Fglucagon+receptor+dual+agonism+reverses+obesity+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DAdams%26aufirst%3DJ.%2BR.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DLassman%26aufirst%3DM.%2BE.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DTota%26aufirst%3DL.%2BM.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSountis%26aufirst%3DM.%2BM.%26aulast%3DSantoprete%26aufirst%3DA.%26aulast%3DCapito%26aufirst%3DE.%26aulast%3DChicchi%26aufirst%3DG.%2BG.%26aulast%3DThornberry%26aufirst%3DN.%26aulast%3DBianchi%26aufirst%3DE.%26aulast%3DPessi%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DSinhaRoy%26aufirst%3DR.%26atitle%3DGlucagon-like%2520peptide%25201%252Fglucagon%2520receptor%2520dual%2520agonism%2520reverses%2520obesity%2520in%2520mice%26jtitle%3DDiabetes%26date%3D2009%26volume%3D58%26spage%3D2258%26epage%3D2266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Bhat, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, V. A.</span><span> </span><span class="NLM_article-title">A novel GIP-Oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1662</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2013&pages=1655-1662&author=V.+K.+Bhatauthor=B.+D.+Kerrauthor=P.+R.+Flattauthor=V.+A.+Gault&title=A+novel+GIP-Oxyntomodulin+hybrid+peptide+acting+through+GIP%2C+glucagon+and+GLP-1+receptors+exhibits+weight+reducing+and+anti-diabetic+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DV.%2BK.%26aulast%3DKerr%26aufirst%3DB.%2BD.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DGault%26aufirst%3DV.%2BA.%26atitle%3DA%2520novel%2520GIP-Oxyntomodulin%2520hybrid%2520peptide%2520acting%2520through%2520GIP%252C%2520glucagon%2520and%2520GLP-1%2520receptors%2520exhibits%2520weight%2520reducing%2520and%2520anti-diabetic%2520properties%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D85%26spage%3D1655%26epage%3D1662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Bhat, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, V. A.</span><span> </span><span class="NLM_article-title">A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice</span> <span class="citation_source-journal">Diabetologia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1417</span><span class="NLM_x">–</span> <span class="NLM_lpage">1424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1417-1424&author=V.+K.+Bhatauthor=B.+D.+Kerrauthor=S.+Vasuauthor=P.+R.+Flattauthor=V.+A.+Gault&title=A+DPP-IV-resistant+triple-acting+agonist+of+GIP%2C+GLP-1+and+glucagon+receptors+with+potent+glucose-lowering+and+insulinotropic+actions+in+high-fat-fed+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DV.%2BK.%26aulast%3DKerr%26aufirst%3DB.%2BD.%26aulast%3DVasu%26aufirst%3DS.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DGault%26aufirst%3DV.%2BA.%26atitle%3DA%2520DPP-IV-resistant%2520triple-acting%2520agonist%2520of%2520GIP%252C%2520GLP-1%2520and%2520glucagon%2520receptors%2520with%2520potent%2520glucose-lowering%2520and%2520insulinotropic%2520actions%2520in%2520high-fat-fed%2520mice%26jtitle%3DDiabetologia%26date%3D2013%26volume%3D56%26spage%3D1417%26epage%3D1424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Mack, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Athanacio, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jodka, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide</span> <span class="citation_source-journal">Diabetes Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1105</span><span class="NLM_x">–</span> <span class="NLM_lpage">1113</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1111%2Fj.1463-1326.2011.01465.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Glt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1105-1113&author=C.+M.+Mackauthor=P.+A.+Smithauthor=J.+R.+Athanacioauthor=K.+Xuauthor=J.+K.+Wilsonauthor=J.+M.+Reynoldsauthor=C.+M.+Jodkaauthor=M.+G.+Luauthor=D.+G.+Parkes&title=Glucoregulatory+effects+and+prolonged+duration+of+action+of+davalintide%3A+a+novel+amylinomimetic+peptide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide</span></div><div class="casAuthors">Mack, C. M.; Smith, P. A.; Athanacio, J. R.; Xu, K.; Wilson, J. K.; Reynolds, J. M.; Jodka, C. M.; Lu, M. G. W.; Parkes, D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1105-1113</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims: Davalintide is a second-generation amylinomimetic peptide possessing enhanced pharmacol. properties over rat amylin to reduce food intake in preclin. models.  The current expts. in rats describe addnl. glucoregulatory actions of davalintide consistent with amylin agonism, and explore the duration of action of these effects.  Methods: S.c. (SC) injection of davalintide slowed gastric emptying with equal potency to amylin (ED50's = 2.3 and 4.1 μg/kg).  This effect was maintained for 8 h with davalintide, but not amylin.  I.p. injection of davalintide also reduced food intake with a potency similar to amylin (ED50's = 5.0 and 11.3 μg/kg).  Consistent with amylin agonism, davalintide (10 μg/kg, SC) suppressed the plasma glucagon response over 90 min following an i.v. arginine bolus in anesthetized rats.  The elimination t1/2 of davalintide (200 μg/kg, SC) was 26 min, similar to the t1/2 of amylin, suggesting that pharmacokinetic-independent mechanisms contribute to davalintide's enhanced duration of action.  Binding kinetic studies using 125I davalintide revealed no appreciable dissocn. from the amylin nucleus accumbens receptor after 7 h while 125I rat amylin did dissoc. from this receptor (Koff = 0.013/min).  Sustained SC infusion of davalintide (275 μg/kg/day) or amylin (300) decreased plasma glucose after an oral glucose challenge at 2 wk (by 27 and 31%) and suppressed gastric emptying at 3 wk (by 29 and 47%), demonstrating durable glucoregulatory actions of both peptides.  Conclusions: These data show glucoregulatory properties of davalintide consistent with amylin agonism and suggest that slowed receptor dissocn. plays a role in davalintide's prolonged pharmacodynamic actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQA3U1lLApkrVg90H21EOLACvtfcHk0ljzvfGKVqiSaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Glt7rK&md5=abd7d900c627ecf99451a9264e935c2c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2011.01465.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2011.01465.x%26sid%3Dliteratum%253Aachs%26aulast%3DMack%26aufirst%3DC.%2BM.%26aulast%3DSmith%26aufirst%3DP.%2BA.%26aulast%3DAthanacio%26aufirst%3DJ.%2BR.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DJ.%2BK.%26aulast%3DReynolds%26aufirst%3DJ.%2BM.%26aulast%3DJodka%26aufirst%3DC.%2BM.%26aulast%3DLu%26aufirst%3DM.%2BG.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3DGlucoregulatory%2520effects%2520and%2520prolonged%2520duration%2520of%2520action%2520of%2520davalintide%253A%2520a%2520novel%2520amylinomimetic%2520peptide%26jtitle%3DDiabetes%2520Obes.%2520Metab.%26date%3D2011%26volume%3D13%26spage%3D1105%26epage%3D1113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Papo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahti, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, J. R.</span><span> </span><span class="NLM_article-title">Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">14067</span><span class="NLM_x">–</span> <span class="NLM_lpage">14072</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=14067-14072&author=N.+Papoauthor=A.+P.+Silvermanauthor=J.+L.+Lahtiauthor=J.+R.+Cochran&title=Antagonistic+VEGF+variants+engineered+to+simultaneously+bind+to+and+inhibit+VEGFR2+and+alphavbeta3+integrin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPapo%26aufirst%3DN.%26aulast%3DSilverman%26aufirst%3DA.%2BP.%26aulast%3DLahti%26aufirst%3DJ.%2BL.%26aulast%3DCochran%26aufirst%3DJ.%2BR.%26atitle%3DAntagonistic%2520VEGF%2520variants%2520engineered%2520to%2520simultaneously%2520bind%2520to%2520and%2520inhibit%2520VEGFR2%2520and%2520alphavbeta3%2520integrin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D14067%26epage%3D14072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Foote, J.</span><span> </span><span class="NLM_article-title">Immunology. Isomeric antibodies</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">1327</span><span class="NLM_x">–</span> <span class="NLM_lpage">1328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=1327-1328&author=J.+Foote&title=Immunology.+Isomeric+antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DJ.%26atitle%3DImmunology.%2520Isomeric%2520antibodies%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D1327%26epage%3D1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">James, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roversi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawfik, D. S.</span><span> </span><span class="NLM_article-title">Antibody multispecificity mediated by conformational diversity</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">1362</span><span class="NLM_x">–</span> <span class="NLM_lpage">1367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1126%2Fscience.1079731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=12610298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsFWrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=1362-1367&author=L.+C.+Jamesauthor=P.+Roversiauthor=D.+S.+Tawfik&title=Antibody+multispecificity+mediated+by+conformational+diversity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody Multispecificity Mediated by Conformational Diversity</span></div><div class="casAuthors">James, Leo C.; Roversi, Pietro; Tawfik, Dan S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5611</span>),
    <span class="NLM_cas:pages">1362-1367</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A single antibody was shown to adopt different binding-site conformations and thereby bind unrelated antigens.  Anal. by both x-ray crystallog. and pre-steady-state kinetics revealed an equil. between different preexisting isomers, one of which possessed a promiscuous, low-affinity binding site for arom. ligands, including the immunizing hapten.  A subsequent induced-fit isomerization led to high-affinity complexes with a deep and narrow binding site.  A protein antigen identified by repertoire selection made use of an unrelated antibody isomer with a wide, shallow binding site.  Conformational diversity, whereby one sequence adopts multiple structures and multiple functions, can increase the effective size of the antibody repertoire but may also lead to autoimmunity and allergy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSE9e1ICjx9rVg90H21EOLACvtfcHk0ljzvfGKVqiSaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsFWrsrs%253D&md5=f696b3d1a9773f94563868a49e2e75a2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.1079731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1079731%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DL.%2BC.%26aulast%3DRoversi%26aufirst%3DP.%26aulast%3DTawfik%26aufirst%3DD.%2BS.%26atitle%3DAntibody%2520multispecificity%2520mediated%2520by%2520conformational%2520diversity%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D1362%26epage%3D1367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Baker, M.</span><span> </span><span class="NLM_article-title">Upping the ante on antibodies</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1065</span><span class="NLM_x">–</span> <span class="NLM_lpage">1072</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1065-1072&author=M.+Baker&title=Upping+the+ante+on+antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DM.%26atitle%3DUpping%2520the%2520ante%2520on%2520antibodies%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1065%26epage%3D1072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ying, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grinnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clabbers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santora, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Taber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunes, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakorafas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarcsa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murtaza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghayur, T.</span><span> </span><span class="NLM_article-title">Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1290</span><span class="NLM_x">–</span> <span class="NLM_lpage">1297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1290-1297&author=C.+Wuauthor=H.+Yingauthor=C.+Grinnellauthor=S.+Bryantauthor=R.+Millerauthor=A.+Clabbersauthor=S.+Boseauthor=D.+McCarthyauthor=R.+R.+Zhuauthor=L.+Santoraauthor=R.+Davis-Taberauthor=Y.+Kunesauthor=E.+Fungauthor=A.+Schwartzauthor=P.+Sakorafasauthor=J.+Guauthor=E.+Tarcsaauthor=A.+Murtazaauthor=T.+Ghayur&title=Simultaneous+targeting+of+multiple+disease+mediators+by+a+dual-variable-domain+immunoglobulin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DYing%26aufirst%3DH.%26aulast%3DGrinnell%26aufirst%3DC.%26aulast%3DBryant%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DClabbers%26aufirst%3DA.%26aulast%3DBose%26aufirst%3DS.%26aulast%3DMcCarthy%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DR.%2BR.%26aulast%3DSantora%26aufirst%3DL.%26aulast%3DDavis-Taber%26aufirst%3DR.%26aulast%3DKunes%26aufirst%3DY.%26aulast%3DFung%26aufirst%3DE.%26aulast%3DSchwartz%26aufirst%3DA.%26aulast%3DSakorafas%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DTarcsa%26aufirst%3DE.%26aulast%3DMurtaza%26aufirst%3DA.%26aulast%3DGhayur%26aufirst%3DT.%26atitle%3DSimultaneous%2520targeting%2520of%2520multiple%2520disease%2520mediators%2520by%2520a%2520dual-variable-domain%2520immunoglobulin%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D1290%26epage%3D1297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Chames, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baty, D.</span><span> </span><span class="NLM_article-title">Bispecific antibodies for cancer therapy: the light at the end of the tunnel?</span> <span class="citation_source-journal">MAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=539-547&author=P.+Chamesauthor=D.+Baty&title=Bispecific+antibodies+for+cancer+therapy%3A+the+light+at+the+end+of+the+tunnel%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChames%26aufirst%3DP.%26aulast%3DBaty%26aufirst%3DD.%26atitle%3DBispecific%2520antibodies%2520for%2520cancer%2520therapy%253A%2520the%2520light%2520at%2520the%2520end%2520of%2520the%2520tunnel%253F%26jtitle%3DMAbs%26date%3D2009%26volume%3D1%26spage%3D539%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Fitzgerald, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugovskoy, A.</span><span> </span><span class="NLM_article-title">Rational engineering of antibody therapeutics targeting multiple oncogene pathways</span> <span class="citation_source-journal">MAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=299-309&author=J.+Fitzgeraldauthor=A.+Lugovskoy&title=Rational+engineering+of+antibody+therapeutics+targeting+multiple+oncogene+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DJ.%26aulast%3DLugovskoy%26aufirst%3DA.%26atitle%3DRational%2520engineering%2520of%2520antibody%2520therapeutics%2520targeting%2520multiple%2520oncogene%2520pathways%26jtitle%3DMAbs%26date%3D2011%26volume%3D3%26spage%3D299%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Lafleur, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramyan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakaraj, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kankanala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaritskaya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puffer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buasen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaithamana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnette, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roschke, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiener, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilbert, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbas, C. F.</span><span> </span><span class="NLM_article-title">Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides</span> <span class="citation_source-journal">MAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">208</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=208-218&author=D.+W.+Lafleurauthor=D.+Abramyanauthor=P.+Kanakarajauthor=R.+G.+Smithauthor=R.+R.+Shahauthor=G.+Wangauthor=X.+T.+Yaoauthor=S.+Kankanalaauthor=E.+Boydauthor=L.+Zaritskayaauthor=V.+Namauthor=B.+A.+Pufferauthor=P.+Buasenauthor=S.+Kaithamanaauthor=A.+F.+Burnetteauthor=R.+Krishnamurthyauthor=D.+Patelauthor=V.+V.+Roschkeauthor=P.+A.+Kienerauthor=D.+M.+Hilbertauthor=C.+F.+Barbas&title=Monoclonal+antibody+therapeutics+with+up+to+five+specificities%3A+Functional+enhancement+through+fusion+of+target-specific+peptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLafleur%26aufirst%3DD.%2BW.%26aulast%3DAbramyan%26aufirst%3DD.%26aulast%3DKanakaraj%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DR.%2BG.%26aulast%3DShah%26aufirst%3DR.%2BR.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DYao%26aufirst%3DX.%2BT.%26aulast%3DKankanala%26aufirst%3DS.%26aulast%3DBoyd%26aufirst%3DE.%26aulast%3DZaritskaya%26aufirst%3DL.%26aulast%3DNam%26aufirst%3DV.%26aulast%3DPuffer%26aufirst%3DB.%2BA.%26aulast%3DBuasen%26aufirst%3DP.%26aulast%3DKaithamana%26aufirst%3DS.%26aulast%3DBurnette%26aufirst%3DA.%2BF.%26aulast%3DKrishnamurthy%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DRoschke%26aufirst%3DV.%2BV.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DHilbert%26aufirst%3DD.%2BM.%26aulast%3DBarbas%26aufirst%3DC.%2BF.%26atitle%3DMonoclonal%2520antibody%2520therapeutics%2520with%2520up%2520to%2520five%2520specificities%253A%2520Functional%2520enhancement%2520through%2520fusion%2520of%2520target-specific%2520peptides%26jtitle%3DMAbs%26date%3D2013%26volume%3D5%26spage%3D208%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Davidson, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bate, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Exenatide</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=713-714&author=M.+B.+Davidsonauthor=G.+Bateauthor=P.+Kirkpatrick&title=Exenatide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DM.%2BB.%26aulast%3DBate%26aufirst%3DG.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DExenatide%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D713%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dritselis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Liraglutide</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=267-268&author=D.+J.+Druckerauthor=A.+Dritselisauthor=P.+Kirkpatrick&title=Liraglutide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DDritselis%26aufirst%3DA.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DLiraglutide%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D267%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Pullman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darsow, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frias, J. P.</span><span> </span><span class="NLM_article-title">Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes</span> <span class="citation_source-journal">Vasc. Health Risk Manag.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.2147%2Fvhrm.2006.2.3.203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlars77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=203-212&author=J.+Pullmanauthor=T.+Darsowauthor=J.+P.+Frias&title=Pramlintide+in+the+management+of+insulin-using+patients+with+type+2+and+type+1+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes</span></div><div class="casAuthors">Pullman, John; Darsow, Tamara; Frias, Juan P.</div><div class="citationInfo"><span class="NLM_cas:title">Vascular Health and Risk Management</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-212</span>CODEN:
                <span class="NLM_cas:coden">VHRMAT</span>;
        ISSN:<span class="NLM_cas:issn">1176-6344</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  In patients with diabetes, dysregulation of multiple glucoregulatory hormones results in chronic hyperglycemia and an array of assocd. micro vascular and macrovascular complications.  Optimization of glycemic control, both overall (glycosylated Hb [A1C]) and in the postprandial period, may reduce the risk of long-term vascular complications.  However, despite significant recent therapeutic advances, most patients with diabetes are unable to attain and/or maintain normal or near-normal glycemia with insulin therapy alone.  Pramlintide, an analog of amylin, is the first in a new class of pharmaceutical agents and is indicated as an adjunct to mealtime insulin for the treatment of patients with type 1 and type 2 diabetes.  By mimicking the actions of the naturally occurring hormone amylin, pramlintide complements insulin by regulating the appearance of glucose into the circulation after meals via three primary mechanisms of action: slowing gastric emptying, suppressing inappropriate post-meal glucagon secretion, and increasing satiety.  In long-term clin. trials, adjunctive pramlintide treatment resulted in improved postprandial glucose control and significantly reduced A1C and body wt. compared with insulin alone.  The combination of insulin and pramlintide may provide a more physiol. balanced approach to managing diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYuz2pRbDx7LVg90H21EOLACvtfcHk0lhLo4ZgQPA0mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlars77J&md5=ce380e30a64ce506c884783623a430fe</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2147%2Fvhrm.2006.2.3.203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fvhrm.2006.2.3.203%26sid%3Dliteratum%253Aachs%26aulast%3DPullman%26aufirst%3DJ.%26aulast%3DDarsow%26aufirst%3DT.%26aulast%3DFrias%26aufirst%3DJ.%2BP.%26atitle%3DPramlintide%2520in%2520the%2520management%2520of%2520insulin-using%2520patients%2520with%2520type%25202%2520and%2520type%25201%2520diabetes%26jtitle%3DVasc.%2520Health%2520Risk%2520Manag.%26date%3D2006%26volume%3D2%26spage%3D203%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Lebovitz, H. E.</span><span> </span><span class="NLM_article-title">Adjunct therapy for type 1 diabetes mellitus</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">326</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Fnrendo.2010.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=20404854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsVGmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=326-334&author=H.+E.+Lebovitz&title=Adjunct+therapy+for+type+1+diabetes+mellitus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Adjunct therapy for type 1 diabetes mellitus</span></div><div class="casAuthors">Lebovitz, Harold E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">326-334</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Insulin replacement therapy in type 1 diabetes mellitus (T1DM) leads to peripheral hyperinsulinemia, which is assocd. with potentially serious metabolic complications, such as increased hypoglycemia, wt. gain and postprandial hyperglucagonemia.  This Review discusses adjunctive therapies to minimize these complications in patients with T1DM, with a focus on the islet amyloid polypeptide analog pramlintide.  Insulin replacement therapy in type 1 diabetes mellitus (T1DM) is nonphysiol.  Hyperinsulinemia is generated in the periphery to achieve normal insulin concns. in the liver.  This mismatch results in increased hypoglycemia, increased food intake with wt. gain, and insufficient regulation of postprandial glucose excursions.  Islet amyloid polypeptide is a hormone synthesized in pancreatic β cells and cosecreted with insulin.  Circulating islet amyloid polypeptide binds to receptors located in the hindbrain and increases satiety, delays gastric emptying and suppresses glucagon secretion.  Thus, islet amyloid polypeptide complements the effects of insulin.  T1DM is a state of both islet amyloid polypeptide and insulin deficiency.  Pramlintide, a synthetic analog of islet amyloid polypeptide, can replace this hormone in patients with T1DM.  When administered as adjunctive therapy to such patients treated with insulin, pramlintide decreases food intake and causes wt. loss.  Pramlintide therapy is also assocd. with suppression of glucagon secretion and delayed gastric emptying, both of which decrease postprandial plasma glucose excursions.  Pramlintide therapy improves glycemic control and lessens wt. gain.  Agents that decrease intestinal carbohydrate digestion (alpha-glucosidase inhibitors) or decrease insulin resistance (metformin) might be alternative adjunctive therapies in T1DM, though its benefits are marginally supported by clin. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJXVrVnp5fSLVg90H21EOLACvtfcHk0lglG7BdVfLJlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsVGmsbY%253D&md5=c58dc70e0ae7a4d94a102dc077b68b03</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2010.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2010.49%26sid%3Dliteratum%253Aachs%26aulast%3DLebovitz%26aufirst%3DH.%2BE.%26atitle%3DAdjunct%2520therapy%2520for%2520type%25201%2520diabetes%2520mellitus%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2010%26volume%3D6%26spage%3D326%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Tschop, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span> </span><span class="NLM_article-title">Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1309</span><span class="NLM_x">–</span> <span class="NLM_lpage">1314</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=1309-1314&author=M.+H.+Tschopauthor=R.+D.+DiMarchi&title=Outstanding+Scientific+Achievement+Award+Lecture+2011%3A+defeating+diabesity%3A+the+case+for+personalized+combinatorial+therapies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTschop%26aufirst%3DM.%2BH.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DOutstanding%2520Scientific%2520Achievement%2520Award%2520Lecture%25202011%253A%2520defeating%2520diabesity%253A%2520the%2520case%2520for%2520personalized%2520combinatorial%2520therapies%26jtitle%3DDiabetes%26date%3D2012%26volume%3D61%26spage%3D1309%26epage%3D1314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turek, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">“Weighing in” on synergy: preclinical research on neurohormonal anti-obesity combinations</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1350</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2Fj.brainres.2010.01.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKiurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1350&publication_year=2010&pages=86-94&author=J.+D.+Rothauthor=J.+L.+Trevaskisauthor=V.+F.+Turekauthor=D.+G.+Parkes&title=%E2%80%9CWeighing+in%E2%80%9D+on+synergy%3A+preclinical+research+on+neurohormonal+anti-obesity+combinations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">"Weighing in" on synergy: Preclinical research on neurohormonal anti-obesity combinations</span></div><div class="casAuthors">Roth, Jonathan D.; Trevaskis, James L.; Turek, Victoria F.; Parkes, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1350</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86-94</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Active wt. loss and the maintenance of a wt.-reduced state elicit potent counter-regulatory responses in multiple neurochem. pathways rendering monotherapy-based anti-obesity agents relatively ineffective.  Herein, we highlight potential strategies for overcoming counter-regulatory responses to states of neg. energy balance using combinatorial approaches.  We discuss methodol. and practical considerations for preclin. modeling of additive/synergistic wt. loss combinations that have emerged in our translational research program aimed at identifying naturally occurring neurohormonal synergies.  As an example of synergy, pharmacol. and mechanistic findings with the combined administration of the β-cell hormone amylin and the adipokine leptin are reviewed.  Finally, we briefly discuss what the future landscape of neurohormonal anti-obesity combinations may hold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmZ5KmVGM2L7Vg90H21EOLACvtfcHk0lglG7BdVfLJlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKiurnM&md5=6f2fc186489db41ee5d10cea7fe91ea5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2010.01.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2010.01.027%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DTurek%26aufirst%3DV.%2BF.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3D%25E2%2580%259CWeighing%2520in%25E2%2580%259D%2520on%2520synergy%253A%2520preclinical%2520research%2520on%2520neurohormonal%2520anti-obesity%2520combinations%26jtitle%3DBrain%2520Res.%26date%3D2010%26volume%3D1350%26spage%3D86%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Cegla, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, S. R.</span><span> </span><span class="NLM_article-title">Gut-brain cross-talk in appetite regulation</span> <span class="citation_source-journal">Curr. Opin. Clin. Nutr. Metab. Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">588</span><span class="NLM_x">–</span> <span class="NLM_lpage">593</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1097%2FMCO.0b013e32833b64a3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A280%3ADC%252BC3cjktVejsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=588-593&author=J.+Ceglaauthor=T.+M.+Tanauthor=S.+R.+Bloom&title=Gut-brain+cross-talk+in+appetite+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Gut-brain cross-talk in appetite regulation</span></div><div class="casAuthors">Cegla Jaimini; Tan Tricia M; Bloom Stephen R</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in clinical nutrition and metabolic care</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">588-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  To review the role of gut hormones involved in appetite regulation and their potential in the treatment of obesity.  RECENT FINDINGS:  The medical treatment of obesity has been fraught with challenges.  With two centrally acting agents having been recently withdrawn from the market, new therapies are required.  The gut hormones are especially promising therapeutic targets.  This article looks at the interplay between gut and brain which mediates the regulation of appetite and energy expenditure.  Some recent developments that point the way towards the future development of gut hormone analogues as treatments for obesity are reviewed.  SUMMARY:  Our understanding of the interaction between gut hormones and the neuronal circuits controlling appetite regulation has made great advances over recent years.  This knowledge is essential if these peptides are to become potential obesity therapies, both from an efficacy and safety perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRx-vmpR40IMvLc4ARHEmzfW6udTcc2eaiCkCro97a87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjktVejsA%253D%253D&md5=ae6a4adbf32a6a7dd7cf130eb0cab0ce</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1097%2FMCO.0b013e32833b64a3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCO.0b013e32833b64a3%26sid%3Dliteratum%253Aachs%26aulast%3DCegla%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DT.%2BM.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26atitle%3DGut-brain%2520cross-talk%2520in%2520appetite%2520regulation%26jtitle%3DCurr.%2520Opin.%2520Clin.%2520Nutr.%2520Metab.%2520Care%26date%3D2010%26volume%3D13%26spage%3D588%26epage%3D593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Neary, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druce, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semjonous, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipsson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghatei, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, S. R.</span><span> </span><span class="NLM_article-title">Peptide YY3–36 and glucagon-like peptide-17–36 inhibit food intake additively</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">5120</span><span class="NLM_x">–</span> <span class="NLM_lpage">5127</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2005&pages=5120-5127&author=N.+M.+Nearyauthor=C.+J.+Smallauthor=M.+R.+Druceauthor=A.+J.+Parkauthor=S.+M.+Ellisauthor=N.+M.+Semjonousauthor=C.+L.+Dakinauthor=K.+Filipssonauthor=F.+Wangauthor=A.+S.+Kentauthor=G.+S.+Frostauthor=M.+A.+Ghateiauthor=S.+R.+Bloom&title=Peptide+YY3%E2%80%9336+and+glucagon-like+peptide-17%E2%80%9336+inhibit+food+intake+additively"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeary%26aufirst%3DN.%2BM.%26aulast%3DSmall%26aufirst%3DC.%2BJ.%26aulast%3DDruce%26aufirst%3DM.%2BR.%26aulast%3DPark%26aufirst%3DA.%2BJ.%26aulast%3DEllis%26aufirst%3DS.%2BM.%26aulast%3DSemjonous%26aufirst%3DN.%2BM.%26aulast%3DDakin%26aufirst%3DC.%2BL.%26aulast%3DFilipsson%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKent%26aufirst%3DA.%2BS.%26aulast%3DFrost%26aufirst%3DG.%2BS.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26atitle%3DPeptide%2520YY3%25E2%2580%259336%2520and%2520glucagon-like%2520peptide-17%25E2%2580%259336%2520inhibit%2520food%2520intake%2520additively%26jtitle%3DEndocrinology%26date%3D2005%26volume%3D146%26spage%3D5120%26epage%3D5127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Talsania, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anini, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span> </span><span class="NLM_article-title">Peripheral exendin-4 and peptide YY3–36 synergistically reduce food intake through different mechanisms in mice</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">3748</span><span class="NLM_x">–</span> <span class="NLM_lpage">3756</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2005&pages=3748-3756&author=T.+Talsaniaauthor=Y.+Aniniauthor=S.+Siuauthor=D.+J.+Druckerauthor=P.+L.+Brubaker&title=Peripheral+exendin-4+and+peptide+YY3%E2%80%9336+synergistically+reduce+food+intake+through+different+mechanisms+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTalsania%26aufirst%3DT.%26aulast%3DAnini%26aufirst%3DY.%26aulast%3DSiu%26aufirst%3DS.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26atitle%3DPeripheral%2520exendin-4%2520and%2520peptide%2520YY3%25E2%2580%259336%2520synergistically%2520reduce%2520food%2520intake%2520through%2520different%2520mechanisms%2520in%2520mice%26jtitle%3DEndocrinology%26date%3D2005%26volume%3D146%26spage%3D3748%26epage%3D3756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Reidelberger, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haver, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apenteng, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anders, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steenson, S. M.</span><span> </span><span class="NLM_article-title">Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats</span> <span class="citation_source-journal">Obesity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Foby.2010.136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Wkt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=121-127&author=R.+D.+Reidelbergerauthor=A.+C.+Haverauthor=B.+A.+Apentengauthor=K.+L.+Andersauthor=S.+M.+Steenson&title=Effects+of+exendin-4+alone+and+with+peptide+YY%283-36%29+on+food+intake+and+body+weight+in+diet-induced+obese+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Exendin-4 Alone and With Peptide YY3-36 on Food Intake and Body Weight in Diet-Induced Obese Rats</span></div><div class="casAuthors">Reidelberger, Roger D.; Haver, Alvin C.; Apenteng, Bettye A.; Anders, Krista L.; Steenson, Sharalyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-127</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Significant wt. loss following Roux-en-Y gastric bypass surgery (RYGB) in obese humans correlates with enhanced secretion of anorexigenic gut hormones glucagon-like peptide-1 (GLP-1) and peptide YY3-36 (PYY3-36).  Our aim here was to identify a dosing strategy for i.p. (IP) infusion of GLP-1 homolog exendin-4 alone and with PYY3-36 that produces a sustained redn. in daily food intake and body wt. in diet-induced obese (DIO) rats.  We tested 12 exendin-4 strategies over 10 wk.  Exendin-4 infused during the first and last 3 h of the dark period at 15-20 pmol/h (0.15 nmol/kg/day) produced a sustained 24 ± 1% redn. in daily food intake for 17 days, and decreased body wt. by 7%.  In a sep. group of DIO rats, none of seven dosing strategies combining exendin-4 and PYY3-36 produced a similar redn. in daily food intake for >10 days.  The subsequent decline in efficacies of exendin-4 alone and with PYY3-36 on food intake and body wt. in each expt. suggested possible receptor downregulation and tolerance to treatments.  However, when treatments were discontinued for 1 day following losses in efficacies, daily food intake significantly increased.  Together, these results demonstrate that (i) intermittent IP infusion of a low dose of exendin-4 can produce a relatively prolonged redn. in daily food intake and body wt. in DIO rats, (ii) co-infusion of exendin-4 and PYY3-36 does not further prolong this response, and (iii) activation of an orexigenic mechanism gradually occurs to counteract the inhibitory effects of exendin-4 alone and with PYY3-36 on food intake and body wt.  Obesity (2011) 19 1, 121-127. doi:10.1038/oby.2010.136.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUYiytOvmcurVg90H21EOLACvtfcHk0lgiidEQ3hYwrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Wkt73N&md5=cd9d65e9d53150cd6aa900c289e69021</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Foby.2010.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foby.2010.136%26sid%3Dliteratum%253Aachs%26aulast%3DReidelberger%26aufirst%3DR.%2BD.%26aulast%3DHaver%26aufirst%3DA.%2BC.%26aulast%3DApenteng%26aufirst%3DB.%2BA.%26aulast%3DAnders%26aufirst%3DK.%2BL.%26aulast%3DSteenson%26aufirst%3DS.%2BM.%26atitle%3DEffects%2520of%2520exendin-4%2520alone%2520and%2520with%2520peptide%2520YY%25283-36%2529%2520on%2520food%2520intake%2520and%2520body%2520weight%2520in%2520diet-induced%2520obese%2520rats%26jtitle%3DObesity%26date%3D2011%26volume%3D19%26spage%3D121%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Bello, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemm, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ofeldt, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T. H.</span><span> </span><span class="NLM_article-title">Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates</span> <span class="citation_source-journal">Am. J. Physiol. Regul. Integr. Comp. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">R945</span><span class="NLM_x">–</span> <span class="NLM_lpage">R952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2010&pages=R945-R952&author=N.+T.+Belloauthor=M.+H.+Kemmauthor=E.+M.+Ofeldtauthor=T.+H.+Moran&title=Dose+combinations+of+exendin-4+and+salmon+calcitonin+produce+additive+and+synergistic+reductions+in+food+intake+in+nonhuman+primates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DN.%2BT.%26aulast%3DKemm%26aufirst%3DM.%2BH.%26aulast%3DOfeldt%26aufirst%3DE.%2BM.%26aulast%3DMoran%26aufirst%3DT.%2BH.%26atitle%3DDose%2520combinations%2520of%2520exendin-4%2520and%2520salmon%2520calcitonin%2520produce%2520additive%2520and%2520synergistic%2520reductions%2520in%2520food%2520intake%2520in%2520nonhuman%2520primates%26jtitle%3DAm.%2520J.%2520Physiol.%2520Regul.%2520Integr.%2520Comp.%2520Physiol.%26date%3D2010%26volume%3D299%26spage%3DR945%26epage%3DR952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Lutz, T. A.</span><span> </span><span class="NLM_article-title">The interaction of amylin with other hormones in the control of eating</span> <span class="citation_source-journal">Diabetes Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1111%2Fj.1463-1326.2012.01670.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs1SrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=99-111&author=T.+A.+Lutz&title=The+interaction+of+amylin+with+other+hormones+in+the+control+of+eating"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The interaction of amylin with other hormones in the control of eating</span></div><div class="casAuthors">Lutz, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-111</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Twenty years of research established amylin as an important control of energy homeostasis.  Amylin controls nutrient and energy fluxes by reducing energy intake, by modulating nutrient utilization via an inhibition of postprandial glucagon secretion and by increasing energy disposal via a prevention of compensatory decreases of energy expenditure in wt. reduced individuals.  Like many other gastrointestinal hormones, amylin is secreted in response to meals and it reduces eating by promoting meal-ending satiation.  Not surprisingly, amylin interacts with many of these hormones to control eating.  These interactions seem to occur at different levels because amylin seems to mediate the eating inhibitory effect of some of these gastrointestinal hormones, and the combination of some of these hormones seems to lead to a stronger redn. in eating than single hormones alone.  Amylin's effect on eating is thought to be mediated by a stimulation of specific amylin receptors in the area postrema.  Secondary brain sites that were defined to mediate amylin action - and hence potential addnl. sites of interaction with other hormones - include the nucleus of the solitary tract, the lateral parabrachial nucleus, the lateral hypothalamic area and other hypothalamic nuclei.  The focus of this review is to summarize the current knowledge of amylin interactions in the control of eating.  In most cases, these interactions have only been studied at a descriptive rather than a mechanistic level and despite the clear knowledge on primary sites of amylin action, the interaction sites between amylin and other hormones are often unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMp801SIRndbVg90H21EOLACvtfcHk0lgiidEQ3hYwrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs1SrtA%253D%253D&md5=ccfa089623388f1dca3de6031e9a53b4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2012.01670.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2012.01670.x%26sid%3Dliteratum%253Aachs%26aulast%3DLutz%26aufirst%3DT.%2BA.%26atitle%3DThe%2520interaction%2520of%2520amylin%2520with%2520other%2520hormones%2520in%2520the%2520control%2520of%2520eating%26jtitle%3DDiabetes%2520Obes.%2520Metab.%26date%3D2013%26volume%3D15%26spage%3D99%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Zuger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forster, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riediger, T.</span><span> </span><span class="NLM_article-title">Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli</span> <span class="citation_source-journal">Physiol. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">112–113C</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112%E2%80%93113C&publication_year=2013&pages=61-69&author=D.+Zugerauthor=K.+Forsterauthor=T.+A.+Lutzauthor=T.+Riediger&title=Amylin+and+GLP-1+target+different+populations+of+area+postrema+neurons+that+are+both+modulated+by+nutrient+stimuli"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZuger%26aufirst%3DD.%26aulast%3DForster%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DT.%2BA.%26aulast%3DRiediger%26aufirst%3DT.%26atitle%3DAmylin%2520and%2520GLP-1%2520target%2520different%2520populations%2520of%2520area%2520postrema%2520neurons%2520that%2520are%2520both%2520modulated%2520by%2520nutrient%2520stimuli%26jtitle%3DPhysiol.%2520Behav.%26date%3D2013%26volume%3D112%25E2%2580%2593113C%26spage%3D61%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turek, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span> </span><span class="NLM_article-title">Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin?</span> <span class="citation_source-journal">Physiol. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2010&pages=187-195&author=J.+L.+Trevaskisauthor=V.+F.+Turekauthor=P.+S.+Griffinauthor=C.+Wittmerauthor=D.+G.+Parkesauthor=J.+D.+Roth&title=Multi-hormonal+weight+loss+combinations+in+diet-induced+obese+rats%3A+therapeutic+potential+of+cholecystokinin%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DTurek%26aufirst%3DV.%2BF.%26aulast%3DGriffin%26aufirst%3DP.%2BS.%26aulast%3DWittmer%26aufirst%3DC.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26atitle%3DMulti-hormonal%2520weight%2520loss%2520combinations%2520in%2520diet-induced%2520obese%2520rats%253A%2520therapeutic%2520potential%2520of%2520cholecystokinin%253F%26jtitle%3DPhysiol.%2520Behav.%26date%3D2010%26volume%3D100%26spage%3D187%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Irwin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span> </span><span class="NLM_article-title">Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice</span> <span class="citation_source-journal">Diabetes Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">650</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1111%2Fdom.12079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=23388064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFelsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=650-659&author=N.+Irwinauthor=K.+Hunterauthor=I.+A.+Montgomeryauthor=P.+R.+Flatt&title=Comparison+of+independent+and+combined+metabolic+effects+of+chronic+treatment+with+%28pGlu-Gln%29-CCK-8+and+long-acting+GLP-1+and+GIP+mimetics+in+high+fat-fed+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice</span></div><div class="casAuthors">Irwin, N.; Hunter, K.; Montgomery, I. A.; Flatt, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">650-659</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim: The incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and cholecystokinin (CCK) are gastrointestinal peptides with important physiol. effects.  However, rapid enzymic degrdn. results in short-lived biol. actions.  Methods: This study has examd. metabolic actions of exendin-4, GIP[mPEG] and a novel CCK-8 analog, (pGlu-Gln)-CCK-8 as enzymically stable forms of GLP-1, GIP and CCK, resp.  Results: All peptides significantly (p < 0.01-p < 0.001) stimulated insulin secretion from BRIN BD11 cells, and acute in vivo expts. confirmed prominent antihyperglycemic and insulinotropic responses to GLP-1 or GIP receptor activation in normal mice.  Twice daily injection of (pGlu-Gln)-CCK-8 alone and in combination with exendin-4 or GIP[mPEG] in high fat-fed mice significantly decreased accumulated food intake (p < 0.05-p < 0.01), body wt. gain (p < 0.05-p < 0.01) and improved (p < 0.05) insulin sensitivity in high fat-fed mice.  However, there was no evidence for superior effects compared to (pGlu-Gln)-CCK-8 alone.  Combined treatment of (pGlu-Gln)-CCK-8 and exendin-4 resulted in significantly (p < 0.05) lowered circulating glucose levels and improved (p < 0.05) i.p. glucose tolerance.  These effects were superior to either treatment regime alone but not assocd. with altered insulin concns.  A single injection of (pGlu-Gln)-CCK-8, or combined with exendin-4, significantly (p < 0.05) lowered blood glucose levels 24 h post injection in untreated high fat-fed mice.  Conclusion: This study highlights the potential of (pGlu-Gln)-CCK-8 alone and in combination with incretin hormones for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpImTJPp-ycwrVg90H21EOLACvtfcHk0lhfn4SF2Yxckw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFelsLo%253D&md5=08c9dec0813fe020feca849431ea4d65</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fdom.12079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12079%26sid%3Dliteratum%253Aachs%26aulast%3DIrwin%26aufirst%3DN.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DMontgomery%26aufirst%3DI.%2BA.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26atitle%3DComparison%2520of%2520independent%2520and%2520combined%2520metabolic%2520effects%2520of%2520chronic%2520treatment%2520with%2520%2528pGlu-Gln%2529-CCK-8%2520and%2520long-acting%2520GLP-1%2520and%2520GIP%2520mimetics%2520in%2520high%2520fat-fed%2520mice%26jtitle%3DDiabetes%2520Obes.%2520Metab.%26date%3D2013%26volume%3D15%26spage%3D650%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roland, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koda, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A. D.</span><span> </span><span class="NLM_article-title">Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">7257</span><span class="NLM_x">–</span> <span class="NLM_lpage">7262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1073%2Fpnas.0706473105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=18458326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=7257-7262&author=J.+D.+Rothauthor=B.+L.+Rolandauthor=R.+L.+Coleauthor=J.+L.+Trevaskisauthor=C.+Weyerauthor=J.+E.+Kodaauthor=C.+M.+Andersonauthor=D.+G.+Parkesauthor=A.+D.+Baron&title=Leptin+responsiveness+restored+by+amylin+agonism+in+diet-induced+obesity%3A+evidence+from+nonclinical+and+clinical+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from non-clinical and clinical studies</span></div><div class="casAuthors">Roth, Jonathan D.; Roland, Barbara L.; Cole, Rebecca L.; Trevaskis, James L.; Weyer, Christian; Koda, Joy E.; Anderson, Christen M.; Parkes, David G.; Baron, Alain D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7257-7262</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Body wt. is regulated by complex neurohormonal interactions between endocrine signals of long-term adiposity (e.g., leptin, a hypothalamic signal) and short-term satiety (e.g., amylin, a hindbrain signal).  We report that concurrent peripheral administration of amylin and leptin elicits synergistic, fat-sp. wt. loss in leptin-resistant, diet-induced obese rats.  Wt. loss synergy was specific to amylin treatment, compared with other anorexigenic peptides, and dissociable from amylin's effect on food intake.  The addn. of leptin after amylin pretreatment elicited further wt. loss, compared with either monotherapy condition.  In a 24-wk randomized, double-blind, clin. proof-of-concept study in overweight/obese subjects, coadministration of recombinant human leptin and the amylin analog Pramlintide elicited 12.7% mean wt. loss, significantly more than was obsd. with either treatment alone (P < 0.01).  In obese rats, amylin pretreatment partially restored hypothalamic leptin signaling (pSTAT3 immunoreactivity) within the ventromedial, but not the arcuate nucleus and up-regulated basal and leptin-stimulated signaling in the hindbrain area postrema.  These findings provide both nonclin. and clin. evidence that amylin agonism restored leptin responsiveness in diet-induced obesity, suggesting that integrated neurohormonal approaches to obesity pharmacotherapy may facilitate greater wt. loss by harnessing naturally occurring synergies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_oX_fM8x6RrVg90H21EOLACvtfcHk0lhA57Z4PtGlIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLw%253D&md5=16de45e90b9abf99bc23c79ef1805ff2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0706473105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0706473105%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DRoland%26aufirst%3DB.%2BL.%26aulast%3DCole%26aufirst%3DR.%2BL.%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DWeyer%26aufirst%3DC.%26aulast%3DKoda%26aufirst%3DJ.%2BE.%26aulast%3DAnderson%26aufirst%3DC.%2BM.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DBaron%26aufirst%3DA.%2BD.%26atitle%3DLeptin%2520responsiveness%2520restored%2520by%2520amylin%2520agonism%2520in%2520diet-induced%2520obesity%253A%2520evidence%2520from%2520nonclinical%2520and%2520clinical%2520studies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D7257%26epage%3D7262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span> </span><span class="NLM_article-title">Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">5679</span><span class="NLM_x">–</span> <span class="NLM_lpage">5687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2008&pages=5679-5687&author=J.+L.+Trevaskisauthor=T.+Coffeyauthor=R.+Coleauthor=C.+Leiauthor=C.+Wittmerauthor=B.+Walshauthor=C.+Weyerauthor=J.+Kodaauthor=A.+D.+Baronauthor=D.+G.+Parkesauthor=J.+D.+Roth&title=Amylin-mediated+restoration+of+leptin+responsiveness+in+diet-induced+obesity%3A+magnitude+and+mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DCoffey%26aufirst%3DT.%26aulast%3DCole%26aufirst%3DR.%26aulast%3DLei%26aufirst%3DC.%26aulast%3DWittmer%26aufirst%3DC.%26aulast%3DWalsh%26aufirst%3DB.%26aulast%3DWeyer%26aufirst%3DC.%26aulast%3DKoda%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%2BD.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26atitle%3DAmylin-mediated%2520restoration%2520of%2520leptin%2520responsiveness%2520in%2520diet-induced%2520obesity%253A%2520magnitude%2520and%2520mechanisms%26jtitle%3DEndocrinology%26date%3D2008%26volume%3D149%26spage%3D5679%26epage%3D5687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Chan, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weyer, C.</span><span> </span><span class="NLM_article-title">It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development</span> <span class="citation_source-journal">J. Invest. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">777</span><span class="NLM_x">–</span> <span class="NLM_lpage">783</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2009&pages=777-783&author=J.+L.+Chanauthor=J.+D.+Rothauthor=C.+Weyer&title=It+takes+two+to+tango%3A+combined+amylin%2Fleptin+agonism+as+a+potential+approach+to+obesity+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development</span></div><div class="casAuthors">Chan, Jean L.; Roth, Jonathan D.; Weyer, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">777-783</span>CODEN:
                <span class="NLM_cas:coden">JINVFI</span>;
        ISSN:<span class="NLM_cas:issn">1081-5589</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The discovery of leptin in 1994 was a seminal event in obesity research.  It helped to establish that body wt. is tightly regulated by a complex neurohormonal feedback system and that obesity should be viewed as a disorder with a strong biol. basis rather than simply the result of poor lifestyle choices and lack of willpower.  Leptin, secreted from adipocytes, acts as a prototypic long-term (tonic) adiposity signal.  Although nonclin. and clin. studies have provided unequivocal evidence that leptin plays a unique, pivotal role in body wt. regulation, efforts to develop recombinant leptin (metreleptin) as a monotherapy for obesity have proven unsuccessful.  Amylin, secreted from pancreatic β-cells, fulfills the criteria for a short-term (episodic) satiety signal.  The amylin analog pramlintide elicits sustained redns. in food intake and body wt. in obese rodents and humans.  A translational research program aimed at elucidating the interaction between different islet-, gut-, and adipocyte-derived hormones led to the discovery that combined amylin/leptin agonism induces marked, synergistic, fat-sp. wt. loss in leptin-resistant diet-induced obese rodents.  In obese humans, combination treatment with pramlintide/metreleptin led to an approx. 13% wt. loss after 24 wk, significantly more than after treatment with pramlintide or metreleptin alone.  Collectively, these findings suggest that combined amylin/leptin agonism may have therapeutic utility as part of an integrated, neurohormonal approach to obesity pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBni213syHjLVg90H21EOLACvtfcHk0lhA57Z4PtGlIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsrjP&md5=852e145bd52c893c49c112b0509d9c48</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BL.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DWeyer%26aufirst%3DC.%26atitle%3DIt%2520takes%2520two%2520to%2520tango%253A%2520combined%2520amylin%252Fleptin%2520agonism%2520as%2520a%2520potential%2520approach%2520to%2520obesity%2520drug%2520development%26jtitle%3DJ.%2520Invest.%2520Med.%26date%3D2009%26volume%3D57%26spage%3D777%26epage%3D783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koda, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span> </span><span class="NLM_article-title">Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats</span> <span class="citation_source-journal">Obesity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Foby.2009.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=19543217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sqt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=21-26&author=J.+L.+Trevaskisauthor=C.+Leiauthor=J.+E.+Kodaauthor=C.+Weyerauthor=D.+G.+Parkesauthor=J.+D.+Roth&title=Interaction+of+leptin+and+amylin+in+the+long-term+maintenance+of+weight+loss+in+diet-induced+obese+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of Leptin and Amylin in the Long-term Maintenance of Weight Loss in Diet-induced Obese Rats</span></div><div class="casAuthors">Trevaskis, James L.; Lei, Chunli; Koda, Joy E.; Weyer, Christian; Parkes, David G.; Roth, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-26</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have previously shown that combined amylin + leptin agonism elicits synergistic wt. loss in diet-induced obese (DIO) rats.  Here, we assessed the comparative efficacy of amylin, leptin, or amylin + leptin in the maintenance of amylin + leptin-mediated wt. loss.  DIO rats pretreated with the combination of rat amylin (50 μg/kg/day) and murine leptin (125 μg/kg/day) for 4 wk were subsequently infused with either vehicle, amylin, leptin, or amylin + leptin for an addnl. 4 wk.  Food intake, body wt., body compn., plasma parameters, and the expression of key metabolic genes in liver and white adipose tissue (WAT) were assessed.  Amylin + leptin treatment (weeks 0-4) reduced body wt. to 87.5% of baseline.  Rats subsequently maintained on vehicle or leptin regained all wt. (to 104.2 and 101.2% of baseline, resp.), those maintained on amylin had partial wt. regain (97.0%).  By contrast, wt. loss was largely maintained with continued amylin + leptin treatment (91.4%), assocd. with a 10% decrease in adiposity.  Cumulative food intake (weeks 5-8) was reduced by amylin and amylin + leptin, but not by leptin alone.  Amylin + leptin, but not amylin or leptin alone, reduced plasma triglycerides (by 55%), total cholesterol (by 19%), and insulin (by 57%) compared to vehicle.  Amylin + leptin also reduced hepatic stearoyl-CoA desaturase-1 (Scd1) mRNA, and increased WAT mRNA levels of adiponectin, fatty acid synthase (Fasn), and lipoprotein lipase (Lpl).  We conclude that, in DIO rats, maintenance of amylin + leptin-mediated wt. loss requires continued treatment with both agonists, and is accompanied by sustained improvements in body compn., and indexes of lipid metab. and insulin sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppo5IndLLHNLVg90H21EOLACvtfcHk0lg6QZ_NS-ItTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sqt7vP&md5=cdc490cd6cd0dc1540ffc66103571c35</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Foby.2009.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foby.2009.187%26sid%3Dliteratum%253Aachs%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DLei%26aufirst%3DC.%26aulast%3DKoda%26aufirst%3DJ.%2BE.%26aulast%3DWeyer%26aufirst%3DC.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26atitle%3DInteraction%2520of%2520leptin%2520and%2520amylin%2520in%2520the%2520long-term%2520maintenance%2520of%2520weight%2520loss%2520in%2520diet-induced%2520obese%2520rats%26jtitle%3DObesity%26date%3D2010%26volume%3D18%26spage%3D21%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Young, A. A.</span><span class="NLM_x"> (</span><span class="NLM_year">2005</span><span class="NLM_x">) </span> <span class="citation_source-book">Amylin: Physiology and Pharmacology</span>; <span class="NLM_publisher-name">Elsevier Academic Press</span>, <span class="NLM_publisher-loc">San Diego, CA</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=A.+A.+Young&title=Amylin%3A+Physiology+and+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DA.%2BA.%26date%3D2005%26btitle%3DAmylin%253A%2520Physiology%2520and%2520Pharmacology%26pub%3DElsevier%2520Academic%2520Press" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Riediger, T.; Lutz, T. A.; Schmid, H. A.; Scharrer, E.</span><span> </span><span class="NLM_article-title">The Area Postrema as a Major Target for Peptides Controlling Food Intake</span>;  <span class="citation_source-book">Abstracts</span>; <span class="NLM_publisher-name">New Orleans: Society for Neuroscience</span>: <span class="NLM_publisher-loc">Washington, DC</span>;<span class="NLM_x"> </span><span class="NLM_year">2000</span><span class="NLM_x">, </span>pp  <span class="NLM_fpage">369.310</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=369.310&author=T.+Riediger&author=T.+A.+Lutz&author=H.+A.+Schmid&author=E.+Scharrer&title=Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRiediger%26aufirst%3DT.%26atitle%3DThe%2520Area%2520Postrema%2520as%2520a%2520Major%2520Target%2520for%2520Peptides%2520Controlling%2520Food%2520Intake%26btitle%3DAbstracts%26pub%3DNew%2520Orleans%253A%2520Society%2520for%2520Neuroscience%26date%3D2000%26spage%3D369.310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Hargrove, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lwin, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herich, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedulin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jodka, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCowen, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. M.</span><span> </span><span class="NLM_article-title">Biological activity of AC3174, a peptide analog of exendin-4</span> <span class="citation_source-journal">Regul. Pept.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2Fj.regpep.2006.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Kqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2007&pages=113-119&author=D.+M.+Hargroveauthor=E.+S.+Kendallauthor=J.+M.+Reynoldsauthor=A.+N.+Lwinauthor=J.+P.+Herichauthor=P.+A.+Smithauthor=B.+R.+Gedulinauthor=S.+D.+Flanaganauthor=C.+M.+Jodkaauthor=J.+A.+Hoytauthor=K.+M.+McCowenauthor=D.+G.+Parkesauthor=C.+M.+Anderson&title=Biological+activity+of+AC3174%2C+a+peptide+analog+of+exendin-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Biological activity of AC3174, a peptide analog of exendin-4</span></div><div class="casAuthors">Hargrove, Diane M.; Kendall, Eric S.; Reynolds, James M.; Lwin, Aung N.; Herich, John P.; Smith, Pamela A.; Gedulin, Bronislava R.; Flanagan, Shawn D.; Jodka, Carolyn M.; Hoyt, Julie A.; McCowen, Kevin M.; Parkes, David G.; Anderson, Christen M.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">113-119</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Exenatide, the active ingredient of BYETTA (exenatide injection), is an incretin mimetic that has been developed for the treatment of patients with type 2 diabetes.  Exenatide binds to and activates the known GLP-1 receptor with a potency comparable to that of the mammalian incretin GLP-1(7-36), thereby acting as a glucoregulatory agent.  AC 3174 is an analog of exenatide with leucine substituted for methionine at position 14, [Leu14]exendin-4.  The purpose of these studies was to evaluate the glucoregulatory activity and pharmacokinetics of AC 3174.  In RINm5f cell membranes, the potency of AC 3174 for the displacement of [125I]GLP-1 and activation of adenylate cyclase was similar to that of exenatide and GLP-1.  In vivo, AC 3174, administered as a single i.p. injection, significantly decreased plasma glucose concn. and glucose excursion following the administration of an oral glucose challenge in both non-diabetic (C57BL/6) and diabetic db/db mice.  The magnitude of glucose lowering of AC 3174 was comparable to exenatide.  The ED50 values of AC 3174 for glucose lowering (60 min post-dose) were 1.2 μg/kg in db/db mice and 1.3 μg/kg in C57BL/6 mice.  AC 3174 has insulinotropic activity in vivo.  Administration of AC 3174 resulted in a 4-fold increase in insulin concns. in normal mice following an i.p. glucose challenge.  AC 3174 was also shown to inhibit food intake and decrease gastric emptying in rodent models.  AC 3174 was stable in human plasma (>90% of parent peptide was present after 5 h of incubation).  In rats, the in vivo half-life of AC 3174 was 42-43 min following s.c. administration.  In summary, AC 3174 is an analog of exenatide that binds to the GLP-1 receptor in vitro and shares many of the biol. and glucoregulatory activities of exenatide and GLP-1 in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNG3k4BU7axLVg90H21EOLACvtfcHk0ljmFFfXhIlMMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Kqsro%253D&md5=5cc26bf4188689814949a4881f3770f3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.regpep.2006.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.regpep.2006.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DHargrove%26aufirst%3DD.%2BM.%26aulast%3DKendall%26aufirst%3DE.%2BS.%26aulast%3DReynolds%26aufirst%3DJ.%2BM.%26aulast%3DLwin%26aufirst%3DA.%2BN.%26aulast%3DHerich%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%2BA.%26aulast%3DGedulin%26aufirst%3DB.%2BR.%26aulast%3DFlanagan%26aufirst%3DS.%2BD.%26aulast%3DJodka%26aufirst%3DC.%2BM.%26aulast%3DHoyt%26aufirst%3DJ.%2BA.%26aulast%3DMcCowen%26aufirst%3DK.%2BM.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DAnderson%26aufirst%3DC.%2BM.%26atitle%3DBiological%2520activity%2520of%2520AC3174%252C%2520a%2520peptide%2520analog%2520of%2520exendin-4%26jtitle%3DRegul.%2520Pept.%26date%3D2007%26volume%3D141%26spage%3D113%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broyde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats</span> <span class="citation_source-journal">Cardiovasc. Diabetol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1186%2F1475-2840-9-32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A280%3ADC%252BC3cjltV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=32&author=Q.+Liuauthor=L.+Adamsauthor=A.+Broydeauthor=R.+Fernandezauthor=A.+D.+Baronauthor=D.+G.+Parkes&title=The+exenatide+analogue+AC3174+attenuates+hypertension%2C+insulin+resistance%2C+and+renal+dysfunction+in+Dahl+salt-sensitive+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats</span></div><div class="casAuthors">Liu Que; Adams Lisa; Broyde Anatoly; Fernandez Rayne; Baron Alain D; Parkes David G</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular diabetology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Activation of glucagon-like peptide-1 (GLP-1) receptors improves insulin sensitivity and induces vasodilatation and diuresis.  AC3174 is a peptide analogue with pharmacologic properties similar to the GLP-1 receptor agonist, exenatide.  Hypothetically, chronic AC3174 treatment could attenuate salt-induced hypertension, cardiac morbidity, insulin resistance, and renal dysfunction in Dahl salt-sensitive (DSS) rats.  METHODS:  DSS rats were fed low salt (LS, 0.3% NaCl) or high salt (HS, 8% NaCl) diets.  HS rats were treated with vehicle, AC3174 (1.7 pmol/kg/min), or GLP-1 (25 pmol/kg/min) for 4 weeks via subcutaneous infusion.  Other HS rats received captopril (150 mg/kg/day) or AC3174 plus captopril.  RESULTS:  HS rat survival was improved by all treatments except GLP-1.  Systolic blood pressure (SBP) was lower in LS rats and in GLP-1, AC3174, captopril, or AC3174 plus captopril HS rats than in vehicle HS rats (p < 0.05).  AC3174 plus captopril attenuated the deleterious effects of high salt on posterior wall thickness, LV mass, and the ratio of LV mass to body weight (P < or = 0.05).  In contrast, GLP-1 had no effect on these cardiovascular parameters.  All treatments reduced LV wall stress.  GLP-1, AC3174, captopril, or AC3174 plus captopril normalized fasting insulin and HOMA-IR (P < or = 0.05).  AC3174, captopril, or AC3174 plus captopril improved renal function (P < or = 0.05).  Renal morphology in HS rats was associated with extensive sclerosis.  Monotherapy with AC3174, captopril, or GLP-1 attenuated renal damage.  However, AC3174 plus captopril produced the most effective improvement.  CONCLUSIONS:  Thus, AC3174 had antihypertensive, cardioprotective, insulin-sensitizing, and renoprotective effects in the DSS hypertensive rat model.  Furthermore, AC3174 improved animal survival, an effect not observed with GLP-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSh3L1gBSfSRkGy1nwu7K2mfW6udTcc2ebLqahFPmvNr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjltV2rsw%253D%253D&md5=eddd218bd506005f16b9ba5ac7ed9723</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F1475-2840-9-32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2840-9-32%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DAdams%26aufirst%3DL.%26aulast%3DBroyde%26aufirst%3DA.%26aulast%3DFernandez%26aufirst%3DR.%26aulast%3DBaron%26aufirst%3DA.%2BD.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3DThe%2520exenatide%2520analogue%2520AC3174%2520attenuates%2520hypertension%252C%2520insulin%2520resistance%252C%2520and%2520renal%2520dysfunction%2520in%2520Dahl%2520salt-sensitive%2520rats%26jtitle%3DCardiovasc.%2520Diabetol.%26date%3D2010%26volume%3D9%26spage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broyde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polizzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure</span> <span class="citation_source-journal">Cardiovasc. Diabetol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1186%2F1475-2840-9-76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252Fhtl2ksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=76&author=Q.+Liuauthor=C.+Andersonauthor=A.+Broydeauthor=C.+Polizziauthor=R.+Fernandezauthor=A.+Baronauthor=D.+G.+Parkes&title=Glucagon-like+peptide-1+and+the+exenatide+analogue+AC3174+improve+cardiac+function%2C+cardiac+remodeling%2C+and+survival+in+rats+with+chronic+heart+failure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure</span></div><div class="casAuthors">Liu Que; Anderson Christen; Broyde Anatoly; Polizzi Clara; Fernandez Rayne; Baron Alain; Parkes David G</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular diabetology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Accumulating evidence suggests glucagon-like peptide-1 (GLP-1) exerts cardioprotective effects in animal models of myocardial infarction (MI).  We hypothesized that chronic treatment with GLP-1 or the exenatide analog AC3174 would improve cardiac function, cardiac remodeling, insulin sensitivity, and exercise capacity (EC) in rats with MI-induced chronic heart failure (CHF) caused by coronary artery ligation.  METHODS:  Two weeks post-MI, male Sprague-Dawley rats were treated with GLP-1 (2.5 or 25 pmol/kg/min), AC3174 (1.7 or 5 pmol/kg/min) or vehicle via subcutaneous infusion for 11 weeks.  Cardiac function and morphology were assessed by echocardiography during treatment.  Metabolic, hemodynamic, exercise-capacity, and body composition measurements were made at study end.  RESULTS:  Compared with vehicle-treated rats with CHF, GLP-1 or AC3174 significantly improved cardiac function, including left ventricular (LV) ejection fraction, and end diastolic pressure.  Cardiac dimensions also improved as evidenced by reduced LV end diastolic and systolic volumes and reduced left atrial volume.  Vehicle-treated CHF rats exhibited fasting hyperglycemia and hyperinsulinemia.  In contrast, GLP-1 or AC3174 normalized fasting plasma insulin and glucose levels.  GLP-1 or AC3174 also significantly reduced body fat and fluid mass and improved exercise capacity and respiratory efficiency.  Four of 16 vehicle control CHF rats died during the study compared with 1 of 44 rats treated with GLP-1 or AC3174.  The cellular mechanism by which GLP-1 or AC3174 exert cardioprotective effects appears unrelated to changes in GLUT1 or GLUT4 translocation or expression.  CONCLUSIONS:  Chronic treatment with either GLP-1 or AC3174 showed promising cardioprotective effects in a rat model of CHF.  Hence, GLP-1 receptor agonists may represent a novel approach for the treatment of patients with CHF or cardiovascular disease associated with type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWFW2DXHgIRdXdcedVHT5tfW6udTcc2easkr4SmY6dZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252Fhtl2ksg%253D%253D&md5=6171b45c408d0c6cc41598551619d13b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2F1475-2840-9-76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2840-9-76%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DAnderson%26aufirst%3DC.%26aulast%3DBroyde%26aufirst%3DA.%26aulast%3DPolizzi%26aufirst%3DC.%26aulast%3DFernandez%26aufirst%3DR.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3DGlucagon-like%2520peptide-1%2520and%2520the%2520exenatide%2520analogue%2520AC3174%2520improve%2520cardiac%2520function%252C%2520cardiac%2520remodeling%252C%2520and%2520survival%2520in%2520rats%2520with%2520chronic%2520heart%2520failure%26jtitle%3DCardiovasc.%2520Diabetol.%26date%3D2010%26volume%3D9%26spage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Lopez de Maturana, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willshaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntzsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, D.</span><span> </span><span class="NLM_article-title">The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">10195</span><span class="NLM_x">–</span> <span class="NLM_lpage">10200</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=10195-10200&author=R.+Lopez+de+Maturanaauthor=A.+Willshawauthor=A.+Kuntzschauthor=R.+Rudolphauthor=D.+Donnelly&title=The+isolated+N-terminal+domain+of+the+glucagon-like+peptide-1+%28GLP-1%29+receptor+binds+exendin+peptides+with+much+higher+affinity+than+GLP-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%2Bde%2BMaturana%26aufirst%3DR.%26aulast%3DWillshaw%26aufirst%3DA.%26aulast%3DKuntzsch%26aufirst%3DA.%26aulast%3DRudolph%26aufirst%3DR.%26aulast%3DDonnelly%26aufirst%3DD.%26atitle%3DThe%2520isolated%2520N-terminal%2520domain%2520of%2520the%2520glucagon-like%2520peptide-1%2520%2528GLP-1%2529%2520receptor%2520binds%2520exendin%2520peptides%2520with%2520much%2520higher%2520affinity%2520than%2520GLP-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D10195%26epage%3D10200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Westermark, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westermark, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betsholtz, C.</span><span> </span><span class="NLM_article-title">Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">5036</span><span class="NLM_x">–</span> <span class="NLM_lpage">5040</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1073%2Fpnas.87.13.5036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=2195544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK3cXkslWnsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=5036-5040&author=P.+Westermarkauthor=U.+Engstromauthor=K.+H.+Johnsonauthor=G.+T.+Westermarkauthor=C.+Betsholtz&title=Islet+amyloid+polypeptide%3A+pinpointing+amino+acid+residues+linked+to+amyloid+fibril+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Islet amyloid polypeptide:  pinpointing amino acid residues linked to amyloid fibril formation</span></div><div class="casAuthors">Westermark, Per; Engstroem, Ulla; Johnson, Kenneth H.; Westermark, Gunilla T.; Betsholtz, Christer</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5036-40</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Islet amyloid polypeptide (IAPP), a putative polypeptide hormone, is a product of pancreatic β-cells and the major constituent of the amyloid deposits seen mainly in islets of type 2 diabetic humans and diabetic cats.  The connection between IAPP amyloid formation and diabetes is unknown, but a limited segment of the IAPP mol., positions 20-29, seems responsible for the aggregation to fibrils.  Differences in the amino acid sequence of this region probably det. whether or not islet amyloid can develop in a particular species.  Amyloid fibril formation can be mimicked in vitro with the aid of synthetic peptides.  Thus, peptides corresponding to IAPP positions 20-29 of human and cat, species that develop IAPP-derived islet amyloid, form amyloid-like fibrils in vitro.  The corresponding IAPP segment from three rodent species that do not develop IAPP-derived amyloid did not give rise to fibrils.  Substitution of the human IAPP-(20-29) decapeptide with one or two amino acid residues from species without islet amyloid generally reduced the capacity to form fibrils.  The sequence Ala-Ile-Leu-Ser-Ser, corresponding to positions 25-29 of human IAPP, is strongly amyloidogenic.  A proline-for-serine substitution is position 28, as in several rodents, almost completely inhibits formation of amyloid fibrils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolCo5Arch1sLVg90H21EOLACvtfcHk0lgvRDFFQe0Zwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkslWnsL0%253D&md5=bdde90227d7efb3fe6cb5e9a94dc0f66</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.13.5036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.13.5036%26sid%3Dliteratum%253Aachs%26aulast%3DWestermark%26aufirst%3DP.%26aulast%3DEngstrom%26aufirst%3DU.%26aulast%3DJohnson%26aufirst%3DK.%2BH.%26aulast%3DWestermark%26aufirst%3DG.%2BT.%26aulast%3DBetsholtz%26aufirst%3DC.%26atitle%3DIslet%2520amyloid%2520polypeptide%253A%2520pinpointing%2520amino%2520acid%2520residues%2520linked%2520to%2520amyloid%2520fibril%2520formation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1990%26volume%3D87%26spage%3D5036%26epage%3D5040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Roberts, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockburn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schofield, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foot, E. A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">9662</span><span class="NLM_x">–</span> <span class="NLM_lpage">9666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1073%2Fpnas.86.24.9662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=2690069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK3cXls12ksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1989&pages=9662-9666&author=A.+N.+Robertsauthor=B.+Leightonauthor=J.+A.+Toddauthor=D.+Cockburnauthor=P.+N.+Schofieldauthor=R.+Suttonauthor=S.+Holtauthor=Y.+Boydauthor=A.+J.+Dayauthor=E.+A.+Foot&title=Molecular+and+functional+characterization+of+amylin%2C+a+peptide+associated+with+type+2+diabetes+mellitus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus</span></div><div class="casAuthors">Roberts, A. N.; Leighton, B.; Todd, J. A.; Cockburn, D.; Schofield, P. N.; Sutton, R.; Holt, S.; Boyd, Y.; Day, A. J.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9662-6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The 37-amino acid peptide called amylin is a major component of the islet amyloid deposited in the pancreases of persons with type 2 diabetes mellitus.  The isolation of a partial cDNA clone and a phage λ genomic clone of the coding region of the amylin gene is reported.  The DNA sequence encodes a protein sequence identical to that of amylin isolated from the amyloid found in the diabetic pancreas; amylin is likely to be synthesized as a precursor peptide, now named proamylin.  The amylin gene was demonstrated to be present on chromosome 12, and it is probably transcribed in the islets of Langerhans.  The sequences of the genes for amylin and the calcitonin gene-related peptides (CGRPs) show strong similarity, esp. over their 5' coding regions, where both peptides have a conserved intramol. SS bridge, and also over their 3' coding regions, where the presence of a glycine codon strongly suggests that the carboxyl-terminal residue of amylin, like that of CGRP, is amidated.  To examine the functional relevance of these posttranslational modifications, the biol. activity of amylin synthesized with or without the SS bridge and/or amidation was measured.  Both features were necessary for full biol. activity, thereby confirming the functional importance of those regions of the mol. whose sequences are conserved at both the protein and genetic levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofk2TFc0dVV7Vg90H21EOLACvtfcHk0lgvRDFFQe0Zwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls12ksL4%253D&md5=42233943d47c9460f4f0cbcaccbd77b5</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1073%2Fpnas.86.24.9662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.86.24.9662%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DA.%2BN.%26aulast%3DLeighton%26aufirst%3DB.%26aulast%3DTodd%26aufirst%3DJ.%2BA.%26aulast%3DCockburn%26aufirst%3DD.%26aulast%3DSchofield%26aufirst%3DP.%2BN.%26aulast%3DSutton%26aufirst%3DR.%26aulast%3DHolt%26aufirst%3DS.%26aulast%3DBoyd%26aufirst%3DY.%26aulast%3DDay%26aufirst%3DA.%2BJ.%26aulast%3DFoot%26aufirst%3DE.%2BA.%26atitle%3DMolecular%2520and%2520functional%2520characterization%2520of%2520amylin%252C%2520a%2520peptide%2520associated%2520with%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1989%26volume%3D86%26spage%3D9662%26epage%3D9666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soares, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">Amylin-based pharmacotherapy - past, present & future</span> <span class="citation_source-journal">Immunol., Endocr. Metab. Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.2174%2F187152208787169189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFCqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=317-324&author=J.+D.+Rothauthor=C.+M.+Mackauthor=C.+J.+Soaresauthor=S.+S.+Ghoshauthor=D.+G.+Parkes&title=Amylin-based+pharmacotherapy+-+past%2C+present+%26+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Amylin-based pharmacotherapy - past, present & future</span></div><div class="casAuthors">Roth, Jonathan D.; Mack, Christine M.; Soares, Christopher J.; Ghosh, Soumitra S.; Parkes, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-324</span>CODEN:
                <span class="NLM_cas:coden">IEMACA</span>;
        ISSN:<span class="NLM_cas:issn">1871-5222</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  We briefly summarize evidence from non-clin. and clin. studies that amylin agonism has a physiol. role in glucose and body wt. regulation.  Next, the amylin analog Pramlintide is highlighted as part of an integrated neurohormonal therapeutic approach in both diabetes and wt. management.  Finally, attributes of, and analoging strategies to, the amylin mol. are discussed with the goal of improving targeted properties leading to the development of an optimized therapeutic candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBaiPlpYK3e7Vg90H21EOLACvtfcHk0lgvRDFFQe0Zwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFCqsLg%253D&md5=185188f2385352571403133fcd6cf1dd</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F187152208787169189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152208787169189%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DMack%26aufirst%3DC.%2BM.%26aulast%3DSoares%26aufirst%3DC.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%2BS.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3DAmylin-based%2520pharmacotherapy%2520-%2520past%252C%2520present%2520%2526%2520future%26jtitle%3DImmunol.%252C%2520Endocr.%2520Metab.%2520Agents%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D317%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Caliceti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, F. M.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates</span> <span class="citation_source-journal">Adv. Drug. Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">–</span> <span class="NLM_lpage">1277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2FS0169-409X%2803%2900108-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=14499706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1yqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2003&pages=1261-1277&author=P.+Calicetiauthor=F.+M.+Veronese&title=Pharmacokinetic+and+biodistribution+properties+of+poly%28ethylene+glycol%29-protein+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates</span></div><div class="casAuthors">Caliceti, Paolo; Veronese, Francesco M.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1261-1277</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Peptide and protein PEGylation is usually undertaken to improve the biopharmaceutical properties of these drugs and, to date, several examples of conjugates with long permanence in the body as well as with localization ability in disease sites were reported.  Although a no. of studies on the in vivo behavior and fate of conjugates were performed, forecasting their pharmacokinetics is a difficult task since the pharmacokinetic profile is detd. by a no. of parameters which include physiol. and anatomical aspects of the recipient and physico-chem. properties of the deriv.  The most relevant perturbations of the protein mol. following PEG conjugation are: size enlargement, protein surface and glycosylation function masking, charge modification, and epitope shielding.  In particular, size enlargement slows down kidney ultrafiltration and promotes the accumulation into permeable tissues by the passive enhanced permeation and retention mechanism.  Charge and glycosylation function masking is revealed predominantly in reduced phagocytosis by the RES and liver cells.  Protein shielding reduces proteolysis and immune system recognition, which are important routes of elimination.  The specific effect of PEGylation on protein physico-chem. and biol. properties is strictly detd. by protein and polymer properties as well as by the adopted PEGylation strategy.  Relevant parameters to be considered in protein-polymer conjugates are: protein structure, mol. wt. and compn., polymer mol. wt. and shape, no. of linked polymer chains and conjugation chem.  The examples reported in this review show that general considerations could be useful in developing a target product, although significant deviations from the expected results can not be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUnGBuleSog7Vg90H21EOLACvtfcHk0ljmLP0C8GL4jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1yqsb0%253D&md5=d26bf5b68a7aa9d1f4f0d10feb3e9593</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2803%2900108-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252803%252900108-X%26sid%3Dliteratum%253Aachs%26aulast%3DCaliceti%26aufirst%3DP.%26aulast%3DVeronese%26aufirst%3DF.%2BM.%26atitle%3DPharmacokinetic%2520and%2520biodistribution%2520properties%2520of%2520poly%2528ethylene%2520glycol%2529-protein%2520conjugates%26jtitle%3DAdv.%2520Drug.%2520Delivery%2520Rev.%26date%3D2003%26volume%3D55%26spage%3D1261%26epage%3D1277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Fee, C. J.</span><span> </span><span class="NLM_article-title">Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules</span> <span class="citation_source-journal">Biotechnol. Bioeng.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">731</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1002%2Fbit.21482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=17461424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1WntrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2007&pages=725-731&author=C.+J.+Fee&title=Size+comparison+between+proteins+PEGylated+with+branched+and+linear+poly%28ethylene+glycol%29+molecules"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules</span></div><div class="casAuthors">Fee, Conan J.</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology and Bioengineering</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">725-731</span>CODEN:
                <span class="NLM_cas:coden">BIBIAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3592</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Therapeutic proteins conjugated with branched poly(ethylene glycol) (PEG) have extended in vivo circulation half-lives compared to linear PEG-proteins, thought to be due partly to a greater hydrodynamic vol. of branched PEG-proteins, which reduces the glomerular sieving coeff.  In this paper, viscosity radii of PEGylated α-lactalbumin (Mr = 14.2 kDa) and bovine serum albumin (Mr = 67 kDa) prepd. with linear and branched PEGs (with nominal mol. wts. 5, 10, 20 and 40 kDa) were compared exptl. using size exclusion chromatog. (SEC).  PEG adduct:protein mol. wt. ratios of the PEGylated proteins covered the range 1:12 to 6:1.  Direct comparisons of exptl. measured viscosity radii were found to be misleading due to differences between actual and nominal mol. wts. of the PEG reagents used.  Comparison with predicted viscosity radii shows that there is no significant difference between the viscosity radii of branched and linear PEG-proteins having the same total mol. wt. of PEG adducts.  Therefore, longer in vivo circulation half-lives of branched PEG-proteins compared to linear PEG-proteins are not explained by size difference.  It is also calcd. that the mol. size cut-off for glomerular filtration, 60 Å for a 30 kDa PEG, matches the 30-50 Å size range for the pores of the glomerular basement membrane.  Finally, it is confirmed that prediction of PEG-protein viscosity radii should be based upon conservation of the total PEG adduct surface area to vol. ratio for both linear and branched PEG-proteins regardless of PEGylation extent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogxSksulLTmLVg90H21EOLACvtfcHk0ljmLP0C8GL4jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1WntrnN&md5=7b2c65d12b11caeae6766175534aedb5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fbit.21482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbit.21482%26sid%3Dliteratum%253Aachs%26aulast%3DFee%26aufirst%3DC.%2BJ.%26atitle%3DSize%2520comparison%2520between%2520proteins%2520PEGylated%2520with%2520branched%2520and%2520linear%2520poly%2528ethylene%2520glycol%2529%2520molecules%26jtitle%3DBiotechnol.%2520Bioeng.%26date%3D2007%26volume%3D98%26spage%3D725%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Fee, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Alstine, J. M.</span><span> </span><span class="NLM_article-title">Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1304</span><span class="NLM_x">–</span> <span class="NLM_lpage">1313</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049843w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptVyrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=1304-1313&author=C.+J.+Feeauthor=J.+M.+Van+Alstine&title=Prediction+of+the+viscosity+radius+and+the+size+exclusion+chromatography+behavior+of+PEGylated+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of the Viscosity Radius and the Size Exclusion Chromatography Behavior of PEGylated Proteins</span></div><div class="casAuthors">Fee, Conan J.; Van Alstine, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1304-1313</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Size exclusion chromatog. (SEC) was used to det. the viscosity radii of equiv. spheres for proteins covalently grafted with poly(ethylene glycol) (PEG).  The viscosity radius of such PEGylated proteins was found to depend on the mol. wt. of the native protein and the total wt. of grafted PEG but not on PEG mol. wt., or PEG-to-protein molar grafting ratio.  Results suggest grafted PEG's form a dynamic layer over the surface of proteins.  The geometry of this layer results in a surface area-to-vol. ratio approx. equal to that of a randomly coiled PEG mol. of equiv. total mol. wt.  Two simple methods are given to predict the viscosity radius of PEGylated proteins.  Both methods accurately predicted (3% abs. error) the viscosity radii of various PEG-proteins produced using three native proteins, α-lactalbumin (14.2 kDa MW), β-lactoglobulin dimer (37.4 kDa MW), and bovine serum albumin (66.7 kDa MW), three PEG reagents (2400, 5600, and 22500 MW), and molar grafting ratios of 0 to 8.  Accurate viscosity radius prediction allows calcn. of the distribution coeff., Kav, for PEG-proteins in SEC.  The suitability of a given SEC step for the anal. or preparative fractionation of different PEGylated protein mixts. may therefore be assessed math.  The methods and results offer insight to several factors related to the prodn., purifn., and uses of PEGylated proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3SWkNNnDioLVg90H21EOLACvtfcHk0lgbTW-urm_30Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptVyrtLo%253D&md5=a6c55e97ec1af032a6d885e0c3144627</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fbc049843w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049843w%26sid%3Dliteratum%253Aachs%26aulast%3DFee%26aufirst%3DC.%2BJ.%26aulast%3DVan%2BAlstine%26aufirst%3DJ.%2BM.%26atitle%3DPrediction%2520of%2520the%2520viscosity%2520radius%2520and%2520the%2520size%2520exclusion%2520chromatography%2520behavior%2520of%2520PEGylated%2520proteins%26jtitle%3DBioconjugate%2520Chem.%26date%3D2004%26volume%3D15%26spage%3D1304%26epage%3D1313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Nakaoka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaoka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikada, Y.</span><span> </span><span class="NLM_article-title">Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1997&pages=253-261&author=R.+Nakaokaauthor=Y.+Tabataauthor=T.+Yamaokaauthor=Y.+Ikada&title=Prolongation+of+the+serum+half-life+period+of+superoxide+dismutase+by+poly%28ethylene+glycol%29+modification"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakaoka%26aufirst%3DR.%26aulast%3DTabata%26aufirst%3DY.%26aulast%3DYamaoka%26aufirst%3DT.%26aulast%3DIkada%26aufirst%3DY.%26atitle%3DProlongation%2520of%2520the%2520serum%2520half-life%2520period%2520of%2520superoxide%2520dismutase%2520by%2520poly%2528ethylene%2520glycol%2529%2520modification%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D1997%26volume%3D46%26spage%3D253%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Kochendoerfer, G.</span><span> </span><span class="NLM_article-title">Chemical and biological properties of polymer-modified proteins</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1253</span><span class="NLM_x">–</span> <span class="NLM_lpage">1261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1517%2F14712598.3.8.1253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=14640951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlels7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=1253-1261&author=G.+Kochendoerfer&title=Chemical+and+biological+properties+of+polymer-modified+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical and biological properties of polymer-modified proteins</span></div><div class="casAuthors">Kochendoerfer, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1253-1261</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review and discussion.  Modification with polymers such as polyethylene glycol (PEG) can increase circulating lifetime, reduce immunogenicity and simplify the handling of pharmaceutical proteins.  These benefits are currently exploited in six marketed polymer-modified protein therapeutics and about a dozen product candidates in clin. trials.  However, traditional protein modification techniques are restricted by the limited control over polymer structure and the location and no. of polymer attachment sites.  New technol., in the form of chem. protein synthesis and the generation of precision polymers, has been applied to generate synthetic erythropoiesis protein.  This promising treatment for anemia has been synthesized with precision polymer modification methodol. to improve the target protein pharmaceutical.  The chem. and biol. properties of proteins prepd. by both traditional and novel approaches are contrasted in this discussion of chem. protein synthesis and polymer modification in protein drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM2eta3Q4x2rVg90H21EOLACvtfcHk0lgbTW-urm_30Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlels7Y%253D&md5=561a76e21906688a901909652e9db12c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1517%2F14712598.3.8.1253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.3.8.1253%26sid%3Dliteratum%253Aachs%26aulast%3DKochendoerfer%26aufirst%3DG.%26atitle%3DChemical%2520and%2520biological%2520properties%2520of%2520polymer-modified%2520proteins%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2003%26volume%3D3%26spage%3D1253%26epage%3D1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Ryan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantovani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddleton, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brayden, D. J.</span><span> </span><span class="NLM_article-title">Advances in PEGylation of important biotech molecules: delivery aspects</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1517%2F17425247.5.4.371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=18426380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFajsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=371-383&author=S.+M.+Ryanauthor=G.+Mantovaniauthor=X.+Wangauthor=D.+M.+Haddletonauthor=D.+J.+Brayden&title=Advances+in+PEGylation+of+important+biotech+molecules%3A+delivery+aspects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in PEGylation of important biotech molecules: delivery aspects</span></div><div class="casAuthors">Ryan, Sinead M.; Mantovani, Giuseppe; Wang, Xuexuan; Haddleton, David M.; Brayden, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Delivery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-383</span>CODEN:
                <span class="NLM_cas:coden">EODDAW</span>;
        ISSN:<span class="NLM_cas:issn">1742-5247</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Although various injected peptide and protein therapeutics have been developed successfully over the past 25 years, several pharmacokinetic and immunol. challenges are still encountered that can limit the efficacy of both novel and established biotech mols.  PEGylation is a popular technique to address such properties.  PEGylated drugs exhibit prolonged half-life, higher stability, water soly., lower immunogenicity and antigenicity, as well as potential for specific cell targeting.  Although PEGylated drug conjugates have been on the market for many years, the technol. has steadily developed in respect of site-specific chem., chain length, mol. wts. and purity of conjugate.  These developments have occurred in parallel to improvements in physicochem. methods of characterization.  This review will discuss recent achievements in PEGylation processes with an emphasis on novel PEG-drugs constructs, the unrealized potential of PEGylation for non-injected routes of delivery, and also on PEGylated versions of polymeric nanoparticles, including dendrimers and liposomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOmtIPVBXgwrVg90H21EOLACvtfcHk0liFy9vvD4CYdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFajsrs%253D&md5=76ab582c4c0b501df850542ead6bda3d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1517%2F17425247.5.4.371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425247.5.4.371%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DS.%2BM.%26aulast%3DMantovani%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHaddleton%26aufirst%3DD.%2BM.%26aulast%3DBrayden%26aufirst%3DD.%2BJ.%26atitle%3DAdvances%2520in%2520PEGylation%2520of%2520important%2520biotech%2520molecules%253A%2520delivery%2520aspects%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2008%26volume%3D5%26spage%3D371%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Fishburn, C. S.</span><span> </span><span class="NLM_article-title">The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">4167</span><span class="NLM_x">–</span> <span class="NLM_lpage">4183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1002%2Fjps.21278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=18200508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sgt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2008&pages=4167-4183&author=C.+S.+Fishburn&title=The+pharmacology+of+PEGylation%3A+balancing+PD+with+PK+to+generate+novel+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics</span></div><div class="casAuthors">Fishburn, C. Simone</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4167-4183</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Conjugation of macromols. to polyethylene glycol (PEG) has emerged recently as an effective strategy to alter the pharmacokinetic (PK) profiles of a variety of drugs, and thereby to improve their therapeutic potential.  PEG conjugation increases retention of drugs in the circulation by protecting against enzymic digestion, slowing filtration by the kidneys and reducing the generation of neutralizing antibodies.  Often, PEGylation leads to a loss in binding affinity due to steric interference with the drug-target binding interaction.  This loss in potency is offset by the longer circulating half-life of the drugs, and the resulting change in PK-PD profile has led in some cases to enabling of drugs that otherwise could not be developed, and in others to improvements in existing drugs.  Thus, whereas most approaches to drug development seek to increase the activity of drugs directly, the creation of PEGylated drugs seeks to balance the pharmacodynamic (PD) and pharmacokinetic properties to produce novel therapies that will meet with both increased efficacy and greater compliance in the clin. setting.  This review examines some of the PEGylated drugs developed in recent years, and highlights some of the different strategies taken to employ PEG to maximize the overall PK-PD profiles of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC7WViWdoJF7Vg90H21EOLACvtfcHk0liFy9vvD4CYdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sgt7rI&md5=d5e71d245c490eb575d9eda654badd45</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fjps.21278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21278%26sid%3Dliteratum%253Aachs%26aulast%3DFishburn%26aufirst%3DC.%2BS.%26atitle%3DThe%2520pharmacology%2520of%2520PEGylation%253A%2520balancing%2520PD%2520with%2520PK%2520to%2520generate%2520novel%2520therapeutics%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D97%26spage%3D4167%26epage%3D4183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Bailon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, C. Y.</span><span> </span><span class="NLM_article-title">PEG-modified biopharmaceuticals</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1517%2F17425240802650568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=19236204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktVahsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=1-16&author=P.+Bailonauthor=C.+Y.+Won&title=PEG-modified+biopharmaceuticals"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">PEG-modified biopharmaceuticals</span></div><div class="casAuthors">Bailon, Pascal; Won, Chee-Youb</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Delivery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-16</span>CODEN:
                <span class="NLM_cas:coden">EODDAW</span>;
        ISSN:<span class="NLM_cas:issn">1742-5247</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  PEGylation is a process in which one or more units of chem. activated polyethylene glycol reacts with a biomol., usually a protein, peptide, small mol. or oligonucleotide, creating a putative new mol. entity possessing physicochem. and physiol. characteristics that are distinct from its predecessor mols.  In recent years, PEGylation has been used not only as a drug delivery technol. but used also as a drug modification technol. to transform existing biopharmaceuticals clin. more efficacious than before their PEGylation.  PEGylation bestows several useful properties upon the native mol., resulting in improved pharmacokinetic and pharmacodynamic properties, which in turn enable the native mol. to achieve max. clin. potency.  In addn., PEGylation results in sustained clin. response with minimal dose and less frequency of dosing, leading to improved quality of life via increased patient compliance and reduced cost.  During the course of development of various pegylated protein therapeutics, several new insights have been gained.  This review article focuses on the approaches, strategies and the utilization of modern PEGylation concepts in the design and development of well-characterized pegylated protein therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf5II9oQ0hJLVg90H21EOLACvtfcHk0ljbSCY1YiLR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktVahsw%253D%253D&md5=acb7ff4e9a7e77a6135f47be428a46bf</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1517%2F17425240802650568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425240802650568%26sid%3Dliteratum%253Aachs%26aulast%3DBailon%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DC.%2BY.%26atitle%3DPEG-modified%2520biopharmaceuticals%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2009%26volume%3D6%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Kang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deluca, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. C.</span><span> </span><span class="NLM_article-title">Emerging PEGylated drugs</span> <span class="citation_source-journal">Expert Opin. Emerg. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">–</span> <span class="NLM_lpage">380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1517%2F14728210902907847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=19453284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Siu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=363-380&author=J.+S.+Kangauthor=P.+P.+Delucaauthor=K.+C.+Lee&title=Emerging+PEGylated+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging PEGylated drugs</span></div><div class="casAuthors">Kang, Jung Seok; De Luca, Patrick P.; Lee, Kang Choon</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">363-380</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  PEGylation is a pharmaceutical technol. that involves the covalent attachment of polyethylene glycol (PEG) to a drug to improve its pharmacokinetic, pharmacodynamic, and immunol. profiles, and thus, enhance its therapeutic effect.  Currently, PEGylation is used to modify proteins, peptides, oligonucleotides, antibody fragments, and small org. mols.  Research groups are striving to improve the consistencies of PEGylated drugs and to PEGylate commercialized proteins and small org. mols.  Furthermore, the PEGylations of novel medications, like oligonucleotides and antibody fragments, are being pursued to improve their bioavailabilities.  This active research in the PEGylation field and the continued growth of the biopharmaceutical market predicts that PEGylated drugs have a bright future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFgW3aHbmjMrVg90H21EOLACvtfcHk0ljbSCY1YiLR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Siu7c%253D&md5=2e7546517bbc9f2c5c48cefdfbc5c999</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1517%2F14728210902907847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728210902907847%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DDeluca%26aufirst%3DP.%2BP.%26aulast%3DLee%26aufirst%3DK.%2BC.%26atitle%3DEmerging%2520PEGylated%2520drugs%26jtitle%3DExpert%2520Opin.%2520Emerg.%2520Drugs%26date%3D2009%26volume%3D14%26spage%3D363%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Jevsevar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunstelj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porekar, V. G.</span><span> </span><span class="NLM_article-title">PEGylation of therapeutic proteins</span> <span class="citation_source-journal">Biotechnol J</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">128</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1002%2Fbiot.200900218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=20069580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVSlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=113-128&author=S.+Jevsevarauthor=M.+Kunsteljauthor=V.+G.+Porekar&title=PEGylation+of+therapeutic+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylation of therapeutic proteins</span></div><div class="casAuthors">Jevsevar, Simona; Kunstelj, Menci; Porekar, Vladka Gaberc</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-128</span>CODEN:
                <span class="NLM_cas:coden">BJIOAM</span>;
        ISSN:<span class="NLM_cas:issn">1860-6768</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Since the first PEGylated product was approved by the Food and Drug Administration in 1990, PEGylation has been widely used as a post-prodn. modification methodol. for improving biomedical efficacy and physicochem. properties of therapeutic proteins.  Applicability and safety of this technol. have been proven by use of various PEGylated pharmaceuticals for many years.  It is expected that PEGylation, as the most established technol. for extension of drug residence in the body, will play an important role in the next generation therapeutics, such as peptides, protein nanobodies and scaffolds, which due to their diminished mol. size need half-life extension.  This review focuses on several factors important in the prodn. of PEGylated biopharmaceuticals enabling efficient prepn. of highly purified PEG-protein conjugates that have to meet stringent regulatory criteria for their use in human therapy.  Areas addressed are PEG properties, the specificity of PEGylation reactions, sepn. and large-scale purifn., the availability and anal. of PEG reagents, anal. of PEG-protein conjugates, the consistency of products and processes and approaches used for rapid screening of pharmacokinetic properties of PEG-protein conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqjWpYHBYTybVg90H21EOLACvtfcHk0liWGMqkFSqokA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVSlsw%253D%253D&md5=ad29019bc10b1d52ef883f9f6f3f27ce</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fbiot.200900218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbiot.200900218%26sid%3Dliteratum%253Aachs%26aulast%3DJevsevar%26aufirst%3DS.%26aulast%3DKunstelj%26aufirst%3DM.%26aulast%3DPorekar%26aufirst%3DV.%2BG.%26atitle%3DPEGylation%2520of%2520therapeutic%2520proteins%26jtitle%3DBiotechnol%2520J%26date%3D2010%26volume%3D5%26spage%3D113%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Milla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dosio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattel, L.</span><span> </span><span class="NLM_article-title">PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.2174%2F138920012798356934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=21892917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVehs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=105-119&author=P.+Millaauthor=F.+Dosioauthor=L.+Cattel&title=PEGylation+of+proteins+and+liposomes%3A+a+powerful+and+flexible+strategy+to+improve+the+drug+delivery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery</span></div><div class="casAuthors">Milla, Paola; Dosio, Franco; Cattel, Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-119</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  PEGylation is one of the most successful strategies to improve the delivery of therapeutic mols. such as proteins, macromol. carriers, small drugs, oligonucleotides, and other biomols.  PEGylation increase the size and mol. wt. of conjugated biomols. and improves their pharmacokinetics and pharmacodynamics by increasing water soly., protecting from enzymic degrdn., reducing renal clearance and limiting immunogenic and antigenic reactions.  PEGylated mols. show increased half-life, decreased plasma clearance, and different biodistribution, in comparison with non-PEGylated counterparts.  These features appear to be very useful for therapeutic proteins, since the high stability and very low immunogenicity of PEGylated proteins result in sustained clin. response with minimal dose and less frequent administration.  PEGylation of liposomes improves not only the stability and circulation time, but also the "passive" targeting ability on tumoral tissues, through a process known as the enhanced permeation retention effect, able to improve the therapeutic effects and reduce the toxicity of encapsulated drug.  The mol. wt., shape, reactivity, specificity, and type of bond of PEG moiety are crucial in detg. the effect on PEGylated mols. and, at present, researchers have the chance to select among tens of PEG derivs. and PEG conjugation technologies, to design the best PEGylation strategy for each particular application.  The aim of the present review will be to elucidate the principles of PEGylation chem. and to describe the already marketed PEGylated proteins and liposomes by focusing the attention to some enlightening examples of how this technol. could dramatically influence the clin. application of therapeutic biomols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD88shv9IG2rVg90H21EOLACvtfcHk0liWGMqkFSqokA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVehs7o%253D&md5=92fc417438250224d434ec53bb2107b0</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.2174%2F138920012798356934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012798356934%26sid%3Dliteratum%253Aachs%26aulast%3DMilla%26aufirst%3DP.%26aulast%3DDosio%26aufirst%3DF.%26aulast%3DCattel%26aufirst%3DL.%26atitle%3DPEGylation%2520of%2520proteins%2520and%2520liposomes%253A%2520a%2520powerful%2520and%2520flexible%2520strategy%2520to%2520improve%2520the%2520drug%2520delivery%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D105%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Pasut, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, F. M.</span><span> </span><span class="NLM_article-title">State of the art in PEGylation: the great versatility achieved after forty years of research</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">461</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2Fj.jconrel.2011.10.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=22094104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1emu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2012&pages=461-472&author=G.+Pasutauthor=F.+M.+Veronese&title=State+of+the+art+in+PEGylation%3A+the+great+versatility+achieved+after+forty+years+of+research"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">State of the art in PEGylation: The great versatility achieved after forty years of research</span></div><div class="casAuthors">Pasut, Gianfranco; Veronese, Francesco M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">461-472</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the recent years, protein PEGylation has become an established and highly refined technol. by moving forward from initial simple random coupling approaches based on conjugation at the level of lysine ε-amino group.  Nevertheless, amino PEGylation is still yielding important conjugates, currently in clin. practice, where the degree of homogeneity was improved by optimizing the reaction conditions and implementing the purifn. processes.  However, the current research is mainly focused on methods of site-selective PEGylation that allow the obtainment of a single isomer, thus highly increasing the degree of homogeneity and the preservation of bioactivity.  Protein N-terminus and free cysteines were the first sites exploited for selective PEGylation but currently further positions can be addressed thanks to approaches like bridging PEGylation (disulfide bridges), enzymic PEGylation (glutamines and C-terminus) and glycoPEGylation (sites of O- and N-glycosylation or the glycans of a glycoprotein).  Furthermore, by combining the tools of genetic engineering with specific PEGylation approaches, the polymer can be basically coupled at any position on the protein surface, owing to the substitution of a properly chosen amino acid in the sequence with a natural or unnatural amino acid bearing an orthogonal reactive group.  On the other hand, PEGylation has not achieved the same success in the delivery of small drugs, despite the large interest and several studies in this field.  Targeted conjugates and PEGs for combination therapy might represent the promising answers for the so far unmet needs of PEG as carrier of small drugs.  This review presents a thorough panorama of recent advances in the field of PEGylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_K0FgZe0yr7Vg90H21EOLACvtfcHk0lif1OgRILWNsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1emu7g%253D&md5=6c43f93f9acfb6b72833818ed751d089</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2011.10.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2011.10.037%26sid%3Dliteratum%253Aachs%26aulast%3DPasut%26aufirst%3DG.%26aulast%3DVeronese%26aufirst%3DF.%2BM.%26atitle%3DState%2520of%2520the%2520art%2520in%2520PEGylation%253A%2520the%2520great%2520versatility%2520achieved%2520after%2520forty%2520years%2520of%2520research%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2012%26volume%3D161%26spage%3D461%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Grace, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delorenzo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wylie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannon-Carlson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Indelicato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voloch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordens, R.</span><span> </span><span class="NLM_article-title">Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">6327</span><span class="NLM_x">–</span> <span class="NLM_lpage">6336</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=6327-6336&author=M.+J.+Graceauthor=S.+Leeauthor=S.+Bradshawauthor=J.+Chapmanauthor=J.+Spondauthor=S.+Coxauthor=M.+Delorenzoauthor=D.+Brassardauthor=D.+Wylieauthor=S.+Cannon-Carlsonauthor=C.+Cullenauthor=S.+Indelicatoauthor=M.+Volochauthor=R.+Bordens&title=Site+of+pegylation+and+polyethylene+glycol+molecule+size+attenuate+interferon-alpha+antiviral+and+antiproliferative+activities+through+the+JAK%2FSTAT+signaling+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrace%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DBradshaw%26aufirst%3DS.%26aulast%3DChapman%26aufirst%3DJ.%26aulast%3DSpond%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DS.%26aulast%3DDelorenzo%26aufirst%3DM.%26aulast%3DBrassard%26aufirst%3DD.%26aulast%3DWylie%26aufirst%3DD.%26aulast%3DCannon-Carlson%26aufirst%3DS.%26aulast%3DCullen%26aufirst%3DC.%26aulast%3DIndelicato%26aufirst%3DS.%26aulast%3DVoloch%26aufirst%3DM.%26aulast%3DBordens%26aufirst%3DR.%26atitle%3DSite%2520of%2520pegylation%2520and%2520polyethylene%2520glycol%2520molecule%2520size%2520attenuate%2520interferon-alpha%2520antiviral%2520and%2520antiproliferative%2520activities%2520through%2520the%2520JAK%252FSTAT%2520signaling%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D6327%26epage%3D6336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Dhalluin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leuthold, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gsell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senn, H.</span><span> </span><span class="NLM_article-title">Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">504</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049781%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslKlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=504-517&author=C.+Dhalluinauthor=A.+Rossauthor=L.+A.+Leutholdauthor=S.+Foserauthor=B.+Gsellauthor=F.+Mullerauthor=H.+Senn&title=Structural+and+biophysical+characterization+of+the+40+kDa+PEG-interferon-alpha2a+and+its+individual+positional+isomers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-α2a and Its Individual Positional Isomers</span></div><div class="casAuthors">Dhalluin, Christophe; Ross, Alfred; Leuthold, Luc-Alexis; Foser, Stefan; Gsell, Bernard; Mueller, Francis; Senn, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">504-517</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The human recombinant Interferon-α2a (IFNα2a) is a potent drug (Roferon-A) to treat various types of cancer and viral diseases including Hepatitis B/C infections.  To improve the pharmacol. properties of the drug, a new pegylated form of IFNα2a was developed (PEGASYS).  This 40 kDa PEG-conjugated IFNα2a (40PEG-IFNα2a) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side chain of IFNα2a.  40PEG-IFNα2a is a mixt. of mainly six monopegylated positional isomers modified at K31, K134, K131, K121, K164, and K70, resp.  Here we report the detailed structural and biophys. characterization of 40PEG-IFNα2a and its positional isomers, in comparison with IFNα2a, using NMR spectroscopy, anal. ultracentrifugation, CD, fluorescence spectroscopy, and differential scanning calorimetry.  Our results show that the three-dimensional structure of IFNα2a is not modified by the presence of the polymer in all positional isomers constituting 40PEG-IFNα2a.  Regardless of where the PEG-polymer is attached, it adopts a very mobile and flexible random coil conformation, producing a shield for the protein without a permanent coverage of the protein surface.  Hydrodynamic data indicate that the protein-attached PEG has a slightly more compact random-coil structure than the free PEG-polymer.  Our results also provide evidence of significant structural and physicochem. advantages conferred by the pegylation: increase of the effective hydrodynamic vol. and modification of the mol. shape, higher temp. stability, and reduced tendency for aggregation.  These results are of tremendous pharmacol. interest and benefit as was clin. shown with PEGASYS.  This study constitutes a new std. for the characterization of pegylated proteins and enables an important step toward the understanding on a mol. level of the binding of 40PEG-IFNα2a and its positional isomers to its cellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrak82Mw0wqNbVg90H21EOLACvtfcHk0lif1OgRILWNsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslKlsr8%253D&md5=94dea271170d173257f370026078b60a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fbc049781%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049781%252B%26sid%3Dliteratum%253Aachs%26aulast%3DDhalluin%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DA.%26aulast%3DLeuthold%26aufirst%3DL.%2BA.%26aulast%3DFoser%26aufirst%3DS.%26aulast%3DGsell%26aufirst%3DB.%26aulast%3DMuller%26aufirst%3DF.%26aulast%3DSenn%26aufirst%3DH.%26atitle%3DStructural%2520and%2520biophysical%2520characterization%2520of%2520the%252040%2520kDa%2520PEG-interferon-alpha2a%2520and%2520its%2520individual%2520positional%2520isomers%26jtitle%3DBioconjugate%2520Chem.%26date%3D2005%26volume%3D16%26spage%3D504%26epage%3D517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Gaertner, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offord, R. E.</span><span> </span><span class="NLM_article-title">Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc950074d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK28XivVartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=38-44&author=H.+F.+Gaertnerauthor=R.+E.+Offord&title=Site-specific+attachment+of+functionalized+poly%28ethylene+glycol%29+to+the+amino+terminus+of+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins</span></div><div class="casAuthors">Gaertner, Hubert F.; Offord, Robin E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-44</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A convenient method for the construction of site-specifically modified poly(ethylene glycol)-protein conjugates is described.  This method relies on the ability to generate a reactive carbonyl group in place of the terminal amino group.  If the protein has N-terminal serine or threonine, this can be done by very mild periodate oxidn. and generates a glyoxylyl group.  A method less restricted by the nature of the N-terminal residue, but which requires somewhat harsher conditions, is metal-catalyzed transamination, which gives a keto group.  The N-terminal-introduced reactive carbonyl group specifically reacts, under mild acidic conditions, with an aminooxy-functionalized poly(ethylene glycol) to form a stable oxime bond.  Using polymers of different size and shape (linear or multibranched), various conjugates of IL-8, G-CSF, and IL-1ra were constructed and further characterized with respect to their biol. activity and pharmacokinetic behavior in rats.  Unlike most previous methods, this approach places a single PEG chain at a defined site on the protein.  It should therefore be more likely to conserve biol. activity when the latter depends on interaction with another macromol. (unlike enzymic activity which often survives multiple PEGylation).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgD3maoTsawLVg90H21EOLACvtfcHk0lg4KB3sfMnGeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivVartw%253D%253D&md5=7d2ba2397b3c10544089ad7ebf5ad926</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fbc950074d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc950074d%26sid%3Dliteratum%253Aachs%26aulast%3DGaertner%26aufirst%3DH.%2BF.%26aulast%3DOfford%26aufirst%3DR.%2BE.%26atitle%3DSite-specific%2520attachment%2520of%2520functionalized%2520poly%2528ethylene%2520glycol%2529%2520to%2520the%2520amino%2520terminus%2520of%2520proteins%26jtitle%3DBioconjugate%2520Chem.%26date%3D1996%26volume%3D7%26spage%3D38%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Kinstler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molineux, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treuheit, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladd, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gegg, C.</span><span> </span><span class="NLM_article-title">Mono-N-terminal poly(ethylene glycol)-protein conjugates</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2FS0169-409X%2802%2900023-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=12052710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFKiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=477-485&author=O.+Kinstlerauthor=G.+Molineuxauthor=M.+Treuheitauthor=D.+Laddauthor=C.+Gegg&title=Mono-N-terminal+poly%28ethylene+glycol%29-protein+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Mono-N-terminal poly(ethylene glycol)-protein conjugates</span></div><div class="casAuthors">Kinstler, Olaf; Molineux, Graham; Treuheit, Michael; Ladd, David; Gegg, Colin</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  A site-directed method of joining proteins to poly(ethylene glycol) is presented which allows for the prepn. of essentially homogeneous PEG-protein derivs. with a single PEG chain conjugated to the amine terminus of the protein.  This selectivity is achieved by conducting the reductive alkylation of proteins with PEG-aldehydes at lower pH.  Working examples demonstrating the application of this method to improve the delivery characteristics and therapeutic value of several proteins are provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbaIeOowSudLVg90H21EOLACvtfcHk0lg4KB3sfMnGeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFKiu7k%253D&md5=bf32d0cad1c048a0da5aa83c5eb93b09</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2802%2900023-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252802%252900023-6%26sid%3Dliteratum%253Aachs%26aulast%3DKinstler%26aufirst%3DO.%26aulast%3DMolineux%26aufirst%3DG.%26aulast%3DTreuheit%26aufirst%3DM.%26aulast%3DLadd%26aufirst%3DD.%26aulast%3DGegg%26aufirst%3DC.%26atitle%3DMono-N-terminal%2520poly%2528ethylene%2520glycol%2529-protein%2520conjugates%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D477%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Shaunak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijayarangam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidelberger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zloh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brocchini, S.</span><span> </span><span class="NLM_article-title">Site-specific PEGylation of native disulfide bonds in therapeutic proteins</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">312</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Fnchembio786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=16633351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkslemuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=312-313&author=S.+Shaunakauthor=A.+Godwinauthor=J.+W.+Choiauthor=S.+Balanauthor=E.+Pedoneauthor=D.+Vijayarangamauthor=S.+Heidelbergerauthor=I.+Teoauthor=M.+Zlohauthor=S.+Brocchini&title=Site-specific+PEGylation+of+native+disulfide+bonds+in+therapeutic+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific PEGylation of native disulfide bonds in therapeutic proteins</span></div><div class="casAuthors">Shaunak, Sunil; Godwin, Antony; Choi, Ji-Won; Balan, Sibu; Pedone, Elisa; Vijayarangam, Damotharan; Heidelberger, Sibylle; Teo, Ian; Zloh, Mire; Brocchini, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">312-313</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Native disulfide bonds in therapeutic proteins are crucial for tertiary structure and biol. activity and are therefore considered unsuitable for chem. modification.  We show that native disulfides in human interferon α-2b and in a fragment of an antibody to CD4+ can be modified by site-specific bisalkylation of the two cysteine sulfur atoms to form a three-carbon PEGylated bridge.  The yield of PEGylated protein is high, and tertiary structure and biol. activity are retained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrGCvU5zTVVbVg90H21EOLACvtfcHk0lgsVI--rOEx5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkslemuro%253D&md5=7ce78a8100d6b9393c87724b573a015a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnchembio786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio786%26sid%3Dliteratum%253Aachs%26aulast%3DShaunak%26aufirst%3DS.%26aulast%3DGodwin%26aufirst%3DA.%26aulast%3DChoi%26aufirst%3DJ.%2BW.%26aulast%3DBalan%26aufirst%3DS.%26aulast%3DPedone%26aufirst%3DE.%26aulast%3DVijayarangam%26aufirst%3DD.%26aulast%3DHeidelberger%26aufirst%3DS.%26aulast%3DTeo%26aufirst%3DI.%26aulast%3DZloh%26aufirst%3DM.%26aulast%3DBrocchini%26aufirst%3DS.%26atitle%3DSite-specific%2520PEGylation%2520of%2520native%2520disulfide%2520bonds%2520in%2520therapeutic%2520proteins%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D312%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Brocchini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zloh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaunak, S.</span><span> </span><span class="NLM_article-title">Disulfide bridge based PEGylation of proteins</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2Fj.addr.2007.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=17920720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyit7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=3-12&author=S.+Brocchiniauthor=A.+Godwinauthor=S.+Balanauthor=J.+W.+Choiauthor=M.+Zlohauthor=S.+Shaunak&title=Disulfide+bridge+based+PEGylation+of+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Disulfide bridge based PEGylation of proteins</span></div><div class="casAuthors">Brocchini, Steve; Godwin, Antony; Balan, Sibu; Choi, Ji-won; Zloh, Mire; Shaunak, Sunil</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-12</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  PEGylation is a clin. proven strategy for increasing the therapeutic efficacy of protein-based medicines.  Our approach to site-specific PEGylation exploits the thiol selective chem. of the two cysteine sulfur atoms from an accessible disulfide.  It involves two key steps: (1) disulfide redn. to release the two cystine thiols, and (2) bis-alkylation to give a three-carbon bridge to which PEG is covalently attached.  During this process, irreversible denaturation of the protein does not occur.  Mechanistically, the conjugation is conducted by a sequential, interactive bis-alkylation using α,β-unsatd.-β'-mono-sulfone functionalized PEG reagents.  The combination of: - (a) maintaining the protein's tertiary structure after redn. of a disulfide, (b) bis-thiol selectivity of the PEG reagent, and (c) PEG assocd. steric shielding ensure that only one PEG mol. is conjugated at each disulfide.  Our studies have shown that peptides, proteins, enzymes and antibody fragments can be site-specifically PEGylated using a native and accessible disulfide without destroying the mols.' tertiary structure or abolishing its biol. activity.  As the stoichiometric efficiency of our approach also enables recycling of any unreacted protein, it offers the potential to make PEGylated biopharmaceuticals as cost-effective medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIQH8-GN_2O7Vg90H21EOLACvtfcHk0lgsVI--rOEx5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyit7vP&md5=7b88a509897ed35ab3a8cc1b1609f271</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DBrocchini%26aufirst%3DS.%26aulast%3DGodwin%26aufirst%3DA.%26aulast%3DBalan%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DJ.%2BW.%26aulast%3DZloh%26aufirst%3DM.%26aulast%3DShaunak%26aufirst%3DS.%26atitle%3DDisulfide%2520bridge%2520based%2520PEGylation%2520of%2520proteins%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2008%26volume%3D60%26spage%3D3%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Fontana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spolaore, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, F. M.</span><span> </span><span class="NLM_article-title">Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2Fj.addr.2007.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=17916398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyit7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=13-28&author=A.+Fontanaauthor=B.+Spolaoreauthor=A.+Meroauthor=F.+M.+Veronese&title=Site-specific+modification+and+PEGylation+of+pharmaceutical+proteins+mediated+by+transglutaminase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase</span></div><div class="casAuthors">Fontana, Angelo; Spolaore, Barbara; Mero, Anna; Veronese, Francesco M.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-28</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Transglutaminase (TGase, E.C. 2.3.2.13) catalyzes acyl transfer reactions between the γ-carboxamide groups of protein-bound glutamine (Gln) residues, which serve as acyl donors, and primary amines, resulting in the formation of new γ-amides of glutamic acid and ammonia.  By using an amino-deriv. of poly(ethylene glycol) (PEG-NH2) as substrate for the enzymic reaction with TGase it is possible to covalently bind the PEG polymer to proteins of pharmaceutical interest.  In our lab., we have conducted expts. aimed to modify proteins of known structure using TGase and, surprisingly, we were able to obtain site-specific modification or PEGylation of protein-bound Gln residue(s) in the protein substrates.  For example, in apomyoglobin (apoMb, myoglobin devoid of heme) only Gln91 was modified and in human growth hormone only Gln40 and Gln141, despite these proteins having many more Gln residues.  Moreover, we noticed that these proteins suffered highly selective limited proteolysis phenomena at the same chain regions being attacked by TGase.  We have analyzed also the results of other published expts. of TGase-mediated modification or PEGylation of several proteins in terms of protein structure and dynamics, among them α-lactalbumin and interleukin-2, as well as disordered proteins.  A noteworthy correlation was obsd. between chain regions of high temp. factor (B-factor) detd. crystallog. and sites of TGase attack and limited proteolysis, thus emphasizing the role of chain mobility or local unfolding in dictating site-specific enzymic modification.  We propose that enhanced chain flexibility favors limited enzymic reactions on polypeptide substrates by TGases and proteases, as well as by other enzymes involved in a no. of site-specific post-translational modifications of proteins, such as phosphorylation and glycosylation.  Therefore, it is possible to predict the site(s) of TGase-mediated modification and PEGylation of a therapeutic protein on the basis of its structure and dynamics and, consequently, the likely effects of modifications on the functional properties of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHfUAyNBhASrVg90H21EOLACvtfcHk0lgsVI--rOEx5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyit7vN&md5=fc7253a60058e436c29008041f768754</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DA.%26aulast%3DSpolaore%26aufirst%3DB.%26aulast%3DMero%26aufirst%3DA.%26aulast%3DVeronese%26aufirst%3DF.%2BM.%26atitle%3DSite-specific%2520modification%2520and%2520PEGylation%2520of%2520pharmaceutical%2520proteins%2520mediated%2520by%2520transglutaminase%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2008%26volume%3D60%26spage%3D13%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, F.</span><span> </span><span class="NLM_article-title">Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives</span> <span class="citation_source-journal">BioDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=209-215&author=C.+Zhangauthor=X.+L.+Yangauthor=Y.+H.+Yuanauthor=J.+Puauthor=F.+Liao&title=Site-specific+PEGylation+of+therapeutic+proteins+via+optimization+of+both+accessible+reactive+amino+acid+residues+and+PEG+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DX.%2BL.%26aulast%3DYuan%26aufirst%3DY.%2BH.%26aulast%3DPu%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DF.%26atitle%3DSite-specific%2520PEGylation%2520of%2520therapeutic%2520proteins%2520via%2520optimization%2520of%2520both%2520accessible%2520reactive%2520amino%2520acid%2520residues%2520and%2520PEG%2520derivatives%26jtitle%3DBioDrugs%26date%3D2012%26volume%3D26%26spage%3D209%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellows, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkey, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. W.</span><span> </span><span class="NLM_article-title">Simultaneous quantification of davalintide, a novel amylin-mimetic peptide, and its active metabolite in beagle and rat plasma by online SPE and LC-MS/MS</span> <span class="citation_source-journal">Bioanalysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span><span class="NLM_x">–</span> <span class="NLM_lpage">2152</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=2141-2152&author=Y.+Wangauthor=Y.+Quauthor=C.+L.+Bellowsauthor=J.+S.+Ahnauthor=J.+L.+Burkeyauthor=S.+W.+Taylor&title=Simultaneous+quantification+of+davalintide%2C+a+novel+amylin-mimetic+peptide%2C+and+its+active+metabolite+in+beagle+and+rat+plasma+by+online+SPE+and+LC-MS%2FMS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DBellows%26aufirst%3DC.%2BL.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DBurkey%26aufirst%3DJ.%2BL.%26aulast%3DTaylor%26aufirst%3DS.%2BW.%26atitle%3DSimultaneous%2520quantification%2520of%2520davalintide%252C%2520a%2520novel%2520amylin-mimetic%2520peptide%252C%2520and%2520its%2520active%2520metabolite%2520in%2520beagle%2520and%2520rat%2520plasma%2520by%2520online%2520SPE%2520and%2520LC-MS%252FMS%26jtitle%3DBioanalysis%26date%3D2012%26volume%3D4%26spage%3D2141%26epage%3D2152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Caldwell, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masucci, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hageman, W.</span><span> </span><span class="NLM_article-title">Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?</span> <span class="citation_source-journal">Eur. J. Drug Metab. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1007%2FBF03190588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=15230342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Kksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=133-143&author=G.+W.+Caldwellauthor=J.+A.+Masucciauthor=Z.+Yanauthor=W.+Hageman&title=Allometric+scaling+of+pharmacokinetic+parameters+in+drug+discovery%3A+can+human+CL%2C+Vss+and+t1%2F2+be+predicted+from+in-vivo+rat+data%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in-vivo rat data?</span></div><div class="casAuthors">Caldwell, Gary W.; Masucci, John A.; Yan, Zhengyin; Hageman, William</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-143</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Medecine et Hygiene</span>)
        </div><div class="casAbstract">In a drug discovery environment, reasonable go/no-go human in-vivo pharmacokinetic (PK) decisions must be made in a timely manner with a min. amt. of animal in-vivo or in-vitro data.  We have investigated the accuracy of the in-vivo correlation between rat and human for the prediction of the total systemic clearance (CL), the vol. of distribution at steady state (Vss), and the half-life (t1/2) using simple allometric scaling techniques.  We have shown, using a large diverse set of drugs, that a fixed exponent allometric scaling approach can be used to predict human in-vivo PK parameters CL, Vss and t1/2 solely from rat in-vivo PK data with acceptable accuracy for making go/no-go decisions in drug discovery.  Human in-vivo PK predictions can be obtained using the simple allometric scaling relationships CLHuman ≈ 40 CLRat (L/h), Vss Human ≈ 200 Vss Rat (L), and t1/2 Human ≈ 4 t1/2 Rat (hr).  The av. fold error for human CL predictions for N = 176 drugs was 2.25 with 79% of the drugs having a fold error less than 3.  The av. fold error for human Vss predictions for N = 144 drugs was 1.85 with 84% of the drugs having a fold error less than 3.  The av. fold error for human t1/2 predictions for N = 145 drugs was 2.05 with 76% of the drugs having a fold error less than 3.  Using these simple allometric relationships, the sorting of drug candidates into a low/medium/high/very high human classification scheme was also possible from rat data.  Since these simple allometric relationships between rat and human CL, Vss, and t1/2 are reasonably accurate, easy to remember and simple to calc., these equations should be useful for making early go/no-go in-vivo human PK decisions for drug discovery candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKsbTCr5uXfbVg90H21EOLACvtfcHk0lh9CsYN_VXAcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Kksrw%253D&md5=d760f54997912a7c14c6022190477f10</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2FBF03190588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03190588%26sid%3Dliteratum%253Aachs%26aulast%3DCaldwell%26aufirst%3DG.%2BW.%26aulast%3DMasucci%26aufirst%3DJ.%2BA.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DHageman%26aufirst%3DW.%26atitle%3DAllometric%2520scaling%2520of%2520pharmacokinetic%2520parameters%2520in%2520drug%2520discovery%253A%2520can%2520human%2520CL%252C%2520Vss%2520and%2520t1%252F2%2520be%2520predicted%2520from%2520in-vivo%2520rat%2520data%253F%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2004%26volume%3D29%26spage%3D133%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silber, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rance, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wastall, P.</span><span> </span><span class="NLM_article-title">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+human+pharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0lh9CsYN_VXAcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Bendele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seely, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennello, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shopp, G.</span><span> </span><span class="NLM_article-title">Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1093%2Ftoxsci%2F42.2.152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=9579027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK1cXislKlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=152-157&author=A.+Bendeleauthor=J.+Seelyauthor=C.+Richeyauthor=G.+Sennelloauthor=G.+Shopp&title=Short+communication%3A+renal+tubular+vacuolation+in+animals+treated+with+polyethylene-glycol-conjugated+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins</span></div><div class="casAuthors">Bendele, Alison; Seely, Jim; Richey, Carl; Sennello, Gina; Shopp, George</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-157</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">During toxicol. evaluation of a dimeric PEG-linked protein, tumor necrosis factor binding protein (TNF-bp), vacuolation of renal cortical tubular epithelium was seen in male and female Sprague-Dawley rats (200-300 g) given i.v. doses of 40, 20, or 10 mg/kg every other day for 3 mo.  Tubular lesions in rats treated with 20 or 40 mg/kg for 3 mo were only partially reversible after a 2-mo recovery period.  Despite the presence of marked vacuolation, there were no changes in BUN, creatinine, urinalysis parameters, urinary NAG, urinary B2-microglobulin, or fractional sodium excretion.  Single i.v. doses ≥20 mg/kg TNF-bp caused similar but milder-changes.  However, equiv. doses of PEG alone or the non-PEG-linked TNF-bp did not cause light microscopic evidence of vacuolation.  Treatment of rats with another PEG-linked protein of similar mol. wt. resulted in similar changes.  Immunostaining for TNF-bp revealed positivity in the apical cytoplasm of renal tubular epithelium within 1 h of i.v. dosing.  Immunostaining of kidneys from chronically dosed rats indicated that protein was present in some vacuoles as long as dosing continued; however, kidneys from animals on a reversibility study had vacuoles but no immunostaining for TNF-bp.  These results, along with a study that showed more severe lesions with PEG- linked proteins of lower mol. wt. and minimal if any lesions with PEG-linked proteins >70 kDa, suggest that TNF-bp is filtered through the glomerulus and that the protein with attached PEG is reabsorbed by the proximal tubules.  Vacuolation may be a result of fluid distension of lysosomes due to the hygroscopic nature of PEG.  These studies demonstrated that PEG-linked proteins have the capacity to induce renal tubular vacuolation at high doses.  However, the change was not assocd. with alteration of clin. pathol. or functional markers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobOPWYC0AWV7Vg90H21EOLACvtfcHk0lhPjw9W67G3-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislKlsbo%253D&md5=008e9d1e4ac6aa10b306e8d57bcffd60</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2F42.2.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252F42.2.152%26sid%3Dliteratum%253Aachs%26aulast%3DBendele%26aufirst%3DA.%26aulast%3DSeely%26aufirst%3DJ.%26aulast%3DRichey%26aufirst%3DC.%26aulast%3DSennello%26aufirst%3DG.%26aulast%3DShopp%26aufirst%3DG.%26atitle%3DShort%2520communication%253A%2520renal%2520tubular%2520vacuolation%2520in%2520animals%2520treated%2520with%2520polyethylene-glycol-conjugated%2520proteins%26jtitle%3DToxicol.%2520Sci.%26date%3D1998%26volume%3D42%26spage%3D152%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Conover, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lejeune, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shum, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shorr, R. G.</span><span> </span><span class="NLM_article-title">Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat</span> <span class="citation_source-journal">Artif. Cells, Blood Substitutes Immobil. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">611</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.3109%2F10731199609118885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=8922229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK28XnsFSju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=599-611&author=C.+Conoverauthor=L.+Lejeuneauthor=R.+Linbergauthor=K.+Shumauthor=R.+G.+Shorr&title=Transitional+vacuole+formation+following+a+bolus+infusion+of+PEG-hemoglobin+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat</span></div><div class="casAuthors">Conover, Charles; Lejeune, Laura; Linberg, Rita; Shum, Kwok; Shorr, Robert G. L.</div><div class="citationInfo"><span class="NLM_cas:title">Artificial Cells, Blood Substitutes, and Immobilization Biotechnology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">599-611</span>CODEN:
                <span class="NLM_cas:coden">ABSBE4</span>;
        ISSN:<span class="NLM_cas:issn">1073-1199</span>.
    
            (<span class="NLM_cas:orgname">Dekker</span>)
        </div><div class="casAbstract">This study was designed to assess the morphol. effects of a bolus infusion of PEG-Hb on the heart, lung, liver, spleen, and kidney of lab. rats.  Of particular interest was the detn. of PEG-Hb's potential to form vacuoles in the tissues and whether these were transitory and article specific.  One hundred ten female Sprague-Dawley rats were used in this study.  The 1st expt. detd. whether vacuole formation was test article specific by infusing either stroma-free bovine Hb, PEG-Hb, bovine serum albumin, PEG-bovine serum albumin, or free PEG.  The 2nd expt. assessed the transitory nature of vacuolization.  In both expts., unconscious rats received an i.v. top-loading (bolus) injection of test article via the tail vein.  Rats were sacrificed at various time points following administration and had their tissues examd. for the presence of vacuoles by light microscope morphol. examn. and iron staining.  Formation of vacuoles appeared to be test article specific with only prolonged circulating, high-solute test articles producing vacuoles.  These vacuoles appeared dose responsive and transitory in nature.  The vacuolization found was nontoxic and believed to be due to the known effect of lysosomal overloading following the phagocytosis of vascularly persistent high-solute test articles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpokfGMvselj7Vg90H21EOLACvtfcHk0lhsztmYz_ALrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XnsFSju78%253D&md5=a2ac7ea8df398f07845d8ff59eb7a480</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.3109%2F10731199609118885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10731199609118885%26sid%3Dliteratum%253Aachs%26aulast%3DConover%26aufirst%3DC.%26aulast%3DLejeune%26aufirst%3DL.%26aulast%3DLinberg%26aufirst%3DR.%26aulast%3DShum%26aufirst%3DK.%26aulast%3DShorr%26aufirst%3DR.%2BG.%26atitle%3DTransitional%2520vacuole%2520formation%2520following%2520a%2520bolus%2520infusion%2520of%2520PEG-hemoglobin%2520in%2520the%2520rat%26jtitle%3DArtif.%2520Cells%252C%2520Blood%2520Substitutes%2520Immobil.%2520Biotechnol.%26date%3D1996%26volume%3D24%26spage%3D599%26epage%3D611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Rebekah L. Bower, Lauren Yule, Tayla A. Rees, Giuseppe Deganutti, Erica R. Hendrikse, Paul W. R. Harris, Renata Kowalczyk, Zachary Ridgway, Amy G. Wong, Katarzyna Swierkula, Daniel P. Raleigh, Augen A. Pioszak, Margaret A. Brimble, Christopher A. Reynolds, Christopher S. Walker, <span class="NLM_string-name hlFld-ContribAuthor">Debbie L. Hay</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2018,</strong> <em>1 </em>
                                    (1)
                                     , 32-49. <a href="https://doi.org/10.1021/acsptsci.8b00002" title="DOI URL">https://doi.org/10.1021/acsptsci.8b00002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.8b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.8b00002%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DMolecular%252BSignature%252Bfor%252BReceptor%252BEngagement%252Bin%252Bthe%252BMetabolic%252BPeptide%252BHormone%252BAmylin%26aulast%3DBower%26aufirst%3DRebekah%2BL.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19022018%26date%3D09052018%26date%3D23042018%26volume%3D1%26issue%3D1%26spage%3D32%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Cui</span>, <span class="hlFld-ContribAuthor ">Cai-Yun  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan  Lv</span>, <span class="hlFld-ContribAuthor ">Min-Ji  Wei</span>, <span class="hlFld-ContribAuthor ">Yan  Zhu</span>, <span class="hlFld-ContribAuthor ">Yun  Li</span>, <span class="hlFld-ContribAuthor ">Ya-Hong  Xia</span>, <span class="hlFld-ContribAuthor ">Yan  Liu</span>, <span class="hlFld-ContribAuthor ">Ji-Hong  Tian</span>, <span class="hlFld-ContribAuthor ">Pu  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Drug Metabolism and Pharmacokinetics</span><span> <strong>2020,</strong> <em>45 </em>
                                    (3)
                                     , 361-369. <a href="https://doi.org/10.1007/s13318-020-00605-9" title="DOI URL">https://doi.org/10.1007/s13318-020-00605-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13318-020-00605-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13318-020-00605-9%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Drug%2520Metabolism%2520and%2520Pharmacokinetics%26atitle%3DSafety%25252C%252BTolerability%252Band%252BPharmacokinetics%252Bof%252BSingle%252BDose%252BPolyethylene%252BGlycolated%252BExenatide%252BInjection%252B%252528PB-119%252529%252Bin%252BHealthy%252BVolunteers%26aulast%3DCui%26aufirst%3DHong%26date%3D2020%26date%3D2020%26volume%3D45%26issue%3D3%26spage%3D361%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christina  Picken</span>, <span class="hlFld-ContribAuthor ">Sahar  Awwad</span>, <span class="hlFld-ContribAuthor ">Mire  Zloh</span>, <span class="hlFld-ContribAuthor ">Hanieh  Khalili</span>, <span class="hlFld-ContribAuthor ">Steve  Brocchini</span>. </span><span class="cited-content_cbyCitation_article-title">Protein modification by bis-alkylation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 351-385. <a href="https://doi.org/10.1016/B978-0-444-64081-9.00016-4" title="DOI URL">https://doi.org/10.1016/B978-0-444-64081-9.00016-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-444-64081-9.00016-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-444-64081-9.00016-4%26sid%3Dliteratum%253Aachs%26atitle%3DProtein%252Bmodification%252Bby%252Bbis-alkylation%26aulast%3DPicken%26aufirst%3DChristina%26date%3D2020%26spage%3D351%26epage%3D385%26pub%3DElsevier%26atitle%3DPolymer-Protein%252BConjugates%26date%3D2020%26volume%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Annie  Hasib</span>. </span><span class="cited-content_cbyCitation_article-title">Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions. </span><span class="cited-content_cbyCitation_journal-name">Clinical Medicine Insights: Endocrinology and Diabetes</span><span> <strong>2020,</strong> <em>13 </em>, 117955142090584. <a href="https://doi.org/10.1177/1179551420905844" title="DOI URL">https://doi.org/10.1177/1179551420905844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1179551420905844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1179551420905844%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Medicine%2520Insights%253A%2520Endocrinology%2520and%2520Diabetes%26atitle%3DMultiagonist%252BUnimolecular%252BPeptides%252Bfor%252BObesity%252Band%252BType%252B2%252BDiabetes%25253A%252BCurrent%252BAdvances%252Band%252BFuture%252BDirections%26aulast%3DHasib%26aufirst%3DAnnie%26date%3D2020%26date%3D2020%26volume%3D13%26spage%3D117955142090584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aiping  Wang</span>, <span class="hlFld-ContribAuthor ">Xiuju  Yan</span>, <span class="hlFld-ContribAuthor ">Rongcai  Liang</span>, <span class="hlFld-ContribAuthor ">Linlin  Wang</span>, <span class="hlFld-ContribAuthor ">Liuxiang  Chu</span>, <span class="hlFld-ContribAuthor ">Kaoxiang  Sun</span>, <span class="hlFld-ContribAuthor ">Fenghua  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Development and Technology</span><span> <strong>2019,</strong> <em>24 </em>
                                    (10)
                                     , 1229-1235. <a href="https://doi.org/10.1080/10837450.2019.1651857" title="DOI URL">https://doi.org/10.1080/10837450.2019.1651857</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10837450.2019.1651857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10837450.2019.1651857%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Development%2520and%2520Technology%26atitle%3DPreparation%252Band%252Bevaluation%252Bof%252Blactic%252Bacid%252Bacylated%252Bexenatide%252Band%252Bits%252Blong-acting%252Bpreparation%26aulast%3DWang%26aufirst%3DAiping%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D10%26spage%3D1229%26epage%3D1235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ismael  González-García</span>, <span class="hlFld-ContribAuthor ">Edward  Milbank</span>, <span class="hlFld-ContribAuthor ">Carlos  Diéguez</span>, <span class="hlFld-ContribAuthor ">Miguel  López</span>, <span class="hlFld-ContribAuthor ">Cristina  Contreras</span>. </span><span class="cited-content_cbyCitation_article-title">Glucagon, GLP-1 and Thermogenesis. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (14)
                                     , 3445. <a href="https://doi.org/10.3390/ijms20143445" title="DOI URL">https://doi.org/10.3390/ijms20143445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20143445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20143445%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DGlucagon%25252C%252BGLP-1%252Band%252BThermogenesis%26aulast%3DGonz%25C3%25A1lez-Garc%25C3%25ADa%26aufirst%3DIsmael%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D14%26spage%3D3445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. J.  Brandt</span>, <span class="hlFld-ContribAuthor ">T. D.  Müller</span>, <span class="hlFld-ContribAuthor ">R. D.  DiMarchi</span>, <span class="hlFld-ContribAuthor ">M. H.  Tschöp</span>, <span class="hlFld-ContribAuthor ">K.  Stemmer</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide-based multi-agonists: a new paradigm in metabolic pharmacology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Internal Medicine</span><span> <strong>2018,</strong> <em>284 </em>
                                    (6)
                                     , 581-602. <a href="https://doi.org/10.1111/joim.12837" title="DOI URL">https://doi.org/10.1111/joim.12837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/joim.12837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjoim.12837%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Internal%2520Medicine%26atitle%3DPeptide-based%252Bmulti-agonists%25253A%252Ba%252Bnew%252Bparadigm%252Bin%252Bmetabolic%252Bpharmacology%26aulast%3DBrandt%26aufirst%3DS.%2BJ.%26date%3D2018%26date%3D2018%26volume%3D284%26issue%3D6%26spage%3D581%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Puxiu  Wang</span>, <span class="hlFld-ContribAuthor ">Yue  li</span>, <span class="hlFld-ContribAuthor ">Mingyan  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system. </span><span class="cited-content_cbyCitation_journal-name">Colloids and Surfaces B: Biointerfaces</span><span> <strong>2018,</strong> <em>171 </em>, 85-93. <a href="https://doi.org/10.1016/j.colsurfb.2018.04.063" title="DOI URL">https://doi.org/10.1016/j.colsurfb.2018.04.063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.colsurfb.2018.04.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.colsurfb.2018.04.063%26sid%3Dliteratum%253Aachs%26jtitle%3DColloids%2520and%2520Surfaces%2520B%253A%2520Biointerfaces%26atitle%3DEffects%252Bof%252Bthe%252Bmultilayer%252Bstructures%252Bon%252BExenatide%252Brelease%252Band%252Bbioactivity%252Bin%252Bmicrosphere%25252Fthermosensitive%252Bhydrogel%252Bsystem%26aulast%3DWang%26aufirst%3DPuxiu%26date%3D2018%26volume%3D171%26spage%3D85%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T. D.  Müller</span>, <span class="hlFld-ContribAuthor ">C.  Clemmensen</span>, <span class="hlFld-ContribAuthor ">B.  Finan</span>, <span class="hlFld-ContribAuthor ">R. D.  DiMarchi</span>, <span class="hlFld-ContribAuthor ">M. H.  Tschöp</span>, . </span><span class="cited-content_cbyCitation_article-title">Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2018,</strong> <em>70 </em>
                                    (4)
                                     , 712-746. <a href="https://doi.org/10.1124/pr.117.014803" title="DOI URL">https://doi.org/10.1124/pr.117.014803</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.117.014803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.117.014803%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DAnti-Obesity%252BTherapy%25253A%252Bfrom%252BRainbow%252BPills%252Bto%252BPolyagonists%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26date%3D2018%26date%3D2018%26volume%3D70%26issue%3D4%26spage%3D712%26epage%3D746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Megan E  Capozzi</span>, <span class="hlFld-ContribAuthor ">Richard D  DiMarchi</span>, <span class="hlFld-ContribAuthor ">Matthias H  Tschöp</span>, <span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">Jonathan E  Campbell</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. </span><span class="cited-content_cbyCitation_journal-name">Endocrine Reviews</span><span> <strong>2018,</strong> <em>39 </em>
                                    (5)
                                     , 719-738. <a href="https://doi.org/10.1210/er.2018-00117" title="DOI URL">https://doi.org/10.1210/er.2018-00117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1210/er.2018-00117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1210%2Fer.2018-00117%26sid%3Dliteratum%253Aachs%26jtitle%3DEndocrine%2520Reviews%26atitle%3DTargeting%252Bthe%252BIncretin%25252FGlucagon%252BSystem%252BWith%252BTriagonists%252Bto%252BTreat%252BDiabetes%26aulast%3DCapozzi%26aufirst%3DMegan%2BE%26date%3D2018%26date%3D2018%26volume%3D39%26issue%3D5%26spage%3D719%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christina Neuner  Boyle</span>, <span class="hlFld-ContribAuthor ">Thomas Alexander  Lutz</span>, <span class="hlFld-ContribAuthor ">Christelle  Le Foll</span>. </span><span class="cited-content_cbyCitation_article-title">Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. </span><span class="cited-content_cbyCitation_journal-name">Molecular Metabolism</span><span> <strong>2018,</strong> <em>8 </em>, 203-210. <a href="https://doi.org/10.1016/j.molmet.2017.11.009" title="DOI URL">https://doi.org/10.1016/j.molmet.2017.11.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molmet.2017.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molmet.2017.11.009%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Metabolism%26atitle%3DAmylin%252B%2525E2%252580%252593%252BIts%252Brole%252Bin%252Bthe%252Bhomeostatic%252Band%252Bhedonic%252Bcontrol%252Bof%252Beating%252Band%252Brecent%252Bdevelopments%252Bof%252Bamylin%252Banalogs%252Bto%252Btreat%252Bobesity%26aulast%3DBoyle%26aufirst%3DChristina%2BNeuner%26date%3D2018%26volume%3D8%26spage%3D203%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah  Will</span>, <span class="hlFld-ContribAuthor ">David C  Hornigold</span>, <span class="hlFld-ContribAuthor ">David J  Baker</span>, <span class="hlFld-ContribAuthor ">Matthew P  Coghlan</span>, <span class="hlFld-ContribAuthor ">Malcolm  Mesquita</span>, <span class="hlFld-ContribAuthor ">James L  Trevaskis</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Naylor</span>. </span><span class="cited-content_cbyCitation_article-title">Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2017,</strong> <em>37 </em>, 10-15. <a href="https://doi.org/10.1016/j.coph.2017.07.010" title="DOI URL">https://doi.org/10.1016/j.coph.2017.07.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2017.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2017.07.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DGut%252Bcheck%252Bon%252Bdiabesity%25253A%252Bleveraging%252Bgut%252Bmechanisms%252Bfor%252Bthe%252Btreatment%252Bof%252Btype%252B2%252Bdiabetes%252Band%252Bobesity%26aulast%3DWill%26aufirst%3DSarah%26date%3D2017%26volume%3D37%26spage%3D10%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sofie  Gydesen</span>, <span class="hlFld-ContribAuthor ">Kim Vietz  Andreassen</span>, <span class="hlFld-ContribAuthor ">Sara Toftegaard  Hjuler</span>, <span class="hlFld-ContribAuthor ">Lars I.  Hellgren</span>, <span class="hlFld-ContribAuthor ">Morten Asser  Karsdal</span>, <span class="hlFld-ContribAuthor ">Kim  Henriksen</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Physiology-Endocrinology and Metabolism</span><span> <strong>2017,</strong> <em>313 </em>
                                    (5)
                                     , E598-E607. <a href="https://doi.org/10.1152/ajpendo.00419.2016" title="DOI URL">https://doi.org/10.1152/ajpendo.00419.2016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/ajpendo.00419.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fajpendo.00419.2016%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Physiology-Endocrinology%2520and%2520Metabolism%26atitle%3DOptimization%252Bof%252Btolerability%252Band%252Befficacy%252Bof%252Bthe%252Bnovel%252Bdual%252Bamylin%252Band%252Bcalcitonin%252Breceptor%252Bagonist%252BKBP-089%252Bthrough%252Bdose%252Bescalation%252Band%252Bcombination%252Bwith%252Ba%252BGLP-1%252Banalog%26aulast%3DGydesen%26aufirst%3DSofie%26date%3D2017%26volume%3D313%26issue%3D5%26spage%3DE598%26epage%3DE607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rebekah L  Bower</span>, <span class="hlFld-ContribAuthor ">Debbie L  Hay</span>. </span><span class="cited-content_cbyCitation_article-title">Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2016,</strong> <em>173 </em>
                                    (12)
                                     , 1883-1898. <a href="https://doi.org/10.1111/bph.13496" title="DOI URL">https://doi.org/10.1111/bph.13496</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.13496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.13496%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DAmylin%252Bstructure-function%252Brelationships%252Band%252Breceptor%252Bpharmacology%25253A%252Bimplications%252Bfor%252Bamylin%252Bmimetic%252Bdrug%252Bdevelopment%26aulast%3DBower%26aufirst%3DRebekah%2BL%26date%3D2016%26date%3D2016%26volume%3D173%26issue%3D12%26spage%3D1883%26epage%3D1898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian  Finan</span>, <span class="hlFld-ContribAuthor ">Christoffer  Clemmensen</span>, <span class="hlFld-ContribAuthor ">Timo D.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. </span><span class="cited-content_cbyCitation_journal-name">Molecular and Cellular Endocrinology</span><span> <strong>2015,</strong> <em>418 </em>, 42-54. <a href="https://doi.org/10.1016/j.mce.2015.07.003" title="DOI URL">https://doi.org/10.1016/j.mce.2015.07.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mce.2015.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mce.2015.07.003%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520and%2520Cellular%2520Endocrinology%26atitle%3DEmerging%252Bopportunities%252Bfor%252Bthe%252Btreatment%252Bof%252Bmetabolic%252Bdiseases%25253A%252BGlucagon-like%252Bpeptide-1%252Bbased%252Bmulti-agonists%26aulast%3DFinan%26aufirst%3DBrian%26date%3D2015%26volume%3D418%26spage%3D42%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Costantino</span>, <span class="hlFld-ContribAuthor ">Daniela  Barlocco</span>. </span><span class="cited-content_cbyCitation_article-title">New perspectives on the development of antiobesity drugs. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2015,</strong> <em>7 </em>
                                    (3)
                                     , 315-336. <a href="https://doi.org/10.4155/fmc.14.167" title="DOI URL">https://doi.org/10.4155/fmc.14.167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.14.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.14.167%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bperspectives%252Bon%252Bthe%252Bdevelopment%252Bof%252Bantiobesity%252Bdrugs%26aulast%3DCostantino%26aufirst%3DLuca%26date%3D2015%26volume%3D7%26issue%3D3%26spage%3D315%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. (A) Side-Chain PEGylation Procedure for the Preparation of <b>6</b> and (B) Two Step Heterobifunctional PEGylation Strategy for the Preparation of <b>10</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Heterobifunctional PEGylation strategy and traditional options for the PEGylation of phybrid. N- or C-terminal PEGylation is not compatible with the AC3174-AC2307 phybrid.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PEG size/receptor potency relationship in the heterobifunctional PEG conjugates <b>8</b>, <b>9</b>, <b>10</b>, <b>12</b>, and <b>13</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0004.jpeg" id="rightTab-GRAPHIC-d2280e1132-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <i>In vivo</i> actions on glucose and body weight in Hsd/NIHS female mice over a 96 h period following subcutaneous injection of vehicle or test compounds. *<i>p</i> < 0.05 vs vehicle. (<b>A1,2</b>) AC2307, AC3174, AC2307 + AC3174 and phybrid <b>2</b> at 250 nmol/kg; (<b>B1,2</b>) AC2993 at 2.5 nmol/kg, <b>10</b> at doses of 3, 8, 25, 80, 250 nmol/kg. ED<sub>50</sub> of change in glucose were calculated at different time points; (<b>C1,2</b>) <b>10</b> and <b>6</b> at doses of 25 and 80 nmol/kg, <sup>#</sup><i>p</i> < 0.05 vs <b>6</b> (25 nmol/kg), <sup>$</sup><i>p</i> < 0.05 vs <b>6</b> (80 nmol/kg); (<b>D1,2</b>) AC2993 at 2.5 nmol/kg, <b>4</b> and <b>10</b> at 25 nmol/kg, <sup>̂</sup><i>p</i> < 0.05 vs <b>4</b>; and (<b>E1,2</b>) <b>3</b> at 250 nmol/kg. Error bars on data points represent the standard error of the mean.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0003.jpeg jm-2013-01418s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacodynamic actions in DIO rats on (A) food intake and (B) body weight reductions of <b>10</b>, the PEG-conjugates of the parent peptides <b>4</b> (PEG-AC3174), <b>3</b> (PEG-AC2307), and the combination of the two. Each conjugate was administered once-weekly over two weeks (on days 0 and 7 as indicated by the arrows) at a dose of 32 nmol/kg, and the effects were monitored for 29 days. *<i>p</i> < 0.05 <b>4</b> vs vehicle, <sup>̂</sup><i>p</i> < 0.05 both <b>3</b> and <b>4</b> monotherapies vs vehicle; <sup>+</sup><i>p</i> < 0.05 <b>10</b> vs vehicle and <b>4</b>; <sup>a</sup><i>p</i> < 0.05 for <b>10</b> and <b>4</b> + <b>3</b> vs vehicle, <b>4</b> and <b>3</b> monotherapy groups (days 3–29).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacodynamic/pharmacokinetic studies in DIO rats measuring change in body weight with a single subcutaneous injection of <b>10</b> at doses of 10.7, 32, and 64 nmol/kg and the plasma concentration of <b>10</b> at days 3, 7, 15, and 21. *<i>p</i> < 0.05 vs vehicle (days 1–21); <sup>+</sup><i>p</i> < 0.05 vs <b>10</b> (10.7 nmol/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Pharmacodynamic actions in DIO rats measuring change in body weight of conjugates with PEG sizes of 30 (<b>9</b>), 40 (<b>10</b>), 60 (<b>12</b>), and 80 kD (<b>13</b>) at a dose of 32 nmol/kg compared to vehicle-treated rats. *<i>p</i> < 0.05 vs vehicle, <sup>̂</sup><i>p</i> < 0.05 vs <b>12</b> and <b>13</b>; <sup>+</sup><i>p</i> < 0.05 vs <b>12</b> only.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/medium/jm-2013-01418s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Illustration depicting potential peptide/peptide and PEG/peptide interactions. Introduction of PEG as a spacer may reduce peptide1/peptide2 interferences; (B) introduction of PEG as a spacer may reduce peptide/receptor interferences.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-22/jm401418s/production/images/large/jm-2013-01418s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401418s&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27765" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27765" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 68 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Mack, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soares, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Athanacio, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turek, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedulin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jodka, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roland, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lwin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laugero, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterniti, J. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight</span> <span class="citation_source-journal">Int. J. Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Fijo.2009.238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2010&pages=385-395&author=C.+M.+Mackauthor=C.+J.+Soaresauthor=J.+K.+Wilsonauthor=J.+R.+Athanacioauthor=V.+F.+Turekauthor=J.+L.+Trevaskisauthor=J.+D.+Rothauthor=P.+A.+Smithauthor=B.+Gedulinauthor=C.+M.+Jodkaauthor=B.+L.+Rolandauthor=S.+H.+Adamsauthor=A.+Lwinauthor=J.+Herichauthor=K.+D.+Laugeroauthor=C.+Vuauthor=R.+Pittnerauthor=J.+R.+Paternitiauthor=M.+Hanleyauthor=S.+Ghoshauthor=D.+G.+Parkes&title=Davalintide+%28AC2307%29%2C+a+novel+amylin-mimetic+peptide%3A+enhanced+pharmacological+properties+over+native+amylin+to+reduce+food+intake+and+body+weight"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight</span></div><div class="casAuthors">Mack, C. M.; Soares, C. J.; Wilson, J. K.; Athanacio, J. R.; Turek, V. F.; Trevaskis, J. L.; Roth, J. D.; Smith, P. A.; Gedulin, B.; Jodka, C. M.; Roland, B. L.; Adams, S. H.; Lwin, A.; Herich, J.; Laugero, K. D.; Vu, C.; Pittner, R.; Paterniti, J. R., Jr.; Hanley, M.; Ghosh, S.; Parkes, D. G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Obesity</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">385-395</span>CODEN:
                <span class="NLM_cas:coden">IJOBDP</span>;
        ISSN:<span class="NLM_cas:issn">0307-0565</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Objective: The current set of studies describe the in vivo metabolic actions of the novel amylin-mimetic peptide davalintide (AC2307) in rodents and compares these effects with those of the native peptide.  Research design and methods: The anti-obesity effects of davalintide were examd. after i.p. injection or sustained peripheral infusion through s.c. implanted osmotic pumps.  The effect of davalintide on food intake after lesioning of the area postrema (AP) and neuronal activation as measured by c-Fos, were also investigated.  Results: Similar to amylin, davalintide bound with high affinity to amylin, calcitonin and calcitonin gene-related peptide receptors.  Acutely, davalintide displayed greater suppression of dark-cycle feeding and an extended duration of action compared with amylin (23 vs. 6 h).  Davalintide had no effect on locomotor activity or kaolin consumption at doses that decreased food intake.  Davalintide-induced wt. loss through infusion was dose dependent, durable up to 8 wk, fat-specific and lean-sparing, and was assocd. with a shift in food preference away from high-fat (palatable) chow.  Metabolic rate was maintained during active wt. loss.  Both davalintide and amylin failed to suppress food intake after lesioning of the AP and activated similar brain nuclei, with davalintide displaying an extended duration of c-Fos expression compared with amylin (8 vs. 2 h).  Conclusion: Davalintide displayed enhanced in vivo metabolic activity over amylin while retaining the beneficial properties possessed by the native mol.  In vitro receptor binding, c-Fos expression and AP lesion studies suggest that the metabolic actions of davalintide and amylin occur through activation of similar neuronal pathways.  International Journal of Obesity (2010) 34, 385-395; doi:10.1038/ijo.2009.238; published online 24 Nov. 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmq7OMUf0qq7Vg90H21EOLACvtfcHk0lg-0fVXNQpwNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFCrsrs%253D&md5=d9005c9cae2413347a146763bb6870af</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fijo.2009.238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fijo.2009.238%26sid%3Dliteratum%253Aachs%26aulast%3DMack%26aufirst%3DC.%2BM.%26aulast%3DSoares%26aufirst%3DC.%2BJ.%26aulast%3DWilson%26aufirst%3DJ.%2BK.%26aulast%3DAthanacio%26aufirst%3DJ.%2BR.%26aulast%3DTurek%26aufirst%3DV.%2BF.%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DSmith%26aufirst%3DP.%2BA.%26aulast%3DGedulin%26aufirst%3DB.%26aulast%3DJodka%26aufirst%3DC.%2BM.%26aulast%3DRoland%26aufirst%3DB.%2BL.%26aulast%3DAdams%26aufirst%3DS.%2BH.%26aulast%3DLwin%26aufirst%3DA.%26aulast%3DHerich%26aufirst%3DJ.%26aulast%3DLaugero%26aufirst%3DK.%2BD.%26aulast%3DVu%26aufirst%3DC.%26aulast%3DPittner%26aufirst%3DR.%26aulast%3DPaterniti%26aufirst%3DJ.%2BR.%26aulast%3DHanley%26aufirst%3DM.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3DDavalintide%2520%2528AC2307%2529%252C%2520a%2520novel%2520amylin-mimetic%2520peptide%253A%2520enhanced%2520pharmacological%2520properties%2520over%2520native%2520amylin%2520to%2520reduce%2520food%2520intake%2520and%2520body%2520weight%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2010%26volume%3D34%26spage%3D385%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Pan, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxton, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yung, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tom, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDougall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claus, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clairmont, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, J. P.</span><span> </span><span class="NLM_article-title">Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">12506</span><span class="NLM_x">–</span> <span class="NLM_lpage">12515</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=12506-12515&author=C.+Q.+Panauthor=J.+M.+Buxtonauthor=S.+L.+Yungauthor=I.+Tomauthor=L.+Yangauthor=H.+Chenauthor=M.+MacDougallauthor=A.+Bellauthor=T.+H.+Clausauthor=K.+B.+Clairmontauthor=J.+P.+Whelan&title=Design+of+a+long+acting+peptide+functioning+as+both+a+glucagon-like+peptide-1+receptor+agonist+and+a+glucagon+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DC.%2BQ.%26aulast%3DBuxton%26aufirst%3DJ.%2BM.%26aulast%3DYung%26aufirst%3DS.%2BL.%26aulast%3DTom%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMacDougall%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DA.%26aulast%3DClaus%26aufirst%3DT.%2BH.%26aulast%3DClairmont%26aufirst%3DK.%2BB.%26aulast%3DWhelan%26aufirst%3DJ.%2BP.%26atitle%3DDesign%2520of%2520a%2520long%2520acting%2520peptide%2520functioning%2520as%2520both%2520a%2520glucagon-like%2520peptide-1%2520receptor%2520agonist%2520and%2520a%2520glucagon%2520receptor%2520antagonist%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D12506%26epage%3D12515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Day, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaway, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gidda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findeisen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruemmer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hembree, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abplanalp, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruehl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirchner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockie, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogueiras, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfluger, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschop, M. H.</span><span> </span><span class="NLM_article-title">A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">757</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Fnchembio.209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=19597507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=749-757&author=J.+W.+Dayauthor=N.+Ottawayauthor=J.+T.+Pattersonauthor=V.+Gelfanovauthor=D.+Smileyauthor=J.+Giddaauthor=H.+Findeisenauthor=D.+Bruemmerauthor=D.+J.+Druckerauthor=N.+Chaudharyauthor=J.+Hollandauthor=J.+Hembreeauthor=W.+Abplanalpauthor=E.+Grantauthor=J.+Ruehlauthor=H.+Wilsonauthor=H.+Kirchnerauthor=S.+H.+Lockieauthor=S.+Hofmannauthor=S.+C.+Woodsauthor=R.+Nogueirasauthor=P.+T.+Pflugerauthor=D.+Perez-Tilveauthor=R.+DiMarchiauthor=M.+H.+Tschop&title=A+new+glucagon+and+GLP-1+co-agonist+eliminates+obesity+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</span></div><div class="casAuthors">Day, Jonathan W.; Ottaway, Nickki; Patterson, James T.; Gelfanov, Vasily; Smiley, David; Gidda, Jas; Findeisen, Hannes; Bruemmer, Dennis; Drucker, Daniel J.; Chaudhary, Nilika; Holland, Jenna; Hembree, Jazzminn; Abplanalp, William; Grant, Erin; Ruehl, Jennifer; Wilson, Hilary; Kirchner, Henriette; Lockie, Sarah Haas; Hofmann, Susanna; Woods, Stephen C.; Nogueiras, Ruben; Pfluger, Paul T.; Perez-Tilve, Diego; DiMarchi, Richard; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">749-757</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the efficacy of a new peptide with agonism at the glucagon and GLP-1 receptors that has potent, sustained satiation-inducing and lipolytic effects.  Selective chem. modification to glucagon resulted in a loss of specificity, with minimal change to inherent activity.  The structural basis for the co-agonism appears to be a combination of local positional interactions and a change in secondary structure.  Two co-agonist peptides differing from each other only in their level of glucagon receptor agonism were studied in rodent obesity models.  Administration of PEGylated peptides once per wk normalized adiposity and glucose tolerance in diet-induced obese mice.  Redn. of body wt. was achieved by a loss of body fat resulting from decreased food intake and increased energy expenditure.  These preclin. studies indicate that when full GLP-1 agonism is augmented with an appropriate degree of glucagon receptor activation, body fat redn. can be substantially enhanced without any overt adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4K1-_eVTTKbVg90H21EOLACvtfcHk0ljTVHX4LO25fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFWhsLk%253D&md5=74b57672bfd375dd4d073624a25eab9b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.209%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DJ.%2BW.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DPatterson%26aufirst%3DJ.%2BT.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DSmiley%26aufirst%3DD.%26aulast%3DGidda%26aufirst%3DJ.%26aulast%3DFindeisen%26aufirst%3DH.%26aulast%3DBruemmer%26aufirst%3DD.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DChaudhary%26aufirst%3DN.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DHembree%26aufirst%3DJ.%26aulast%3DAbplanalp%26aufirst%3DW.%26aulast%3DGrant%26aufirst%3DE.%26aulast%3DRuehl%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DH.%26aulast%3DKirchner%26aufirst%3DH.%26aulast%3DLockie%26aufirst%3DS.%2BH.%26aulast%3DHofmann%26aufirst%3DS.%26aulast%3DWoods%26aufirst%3DS.%2BC.%26aulast%3DNogueiras%26aufirst%3DR.%26aulast%3DPfluger%26aufirst%3DP.%2BT.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DDiMarchi%26aufirst%3DR.%26aulast%3DTschop%26aufirst%3DM.%2BH.%26atitle%3DA%2520new%2520glucagon%2520and%2520GLP-1%2520co-agonist%2520eliminates%2520obesity%2520in%2520rodents%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D749%26epage%3D757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Pocai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrington, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tota, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sountis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoprete, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capito, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chicchi, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SinhaRoy, R.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2258</span><span class="NLM_x">–</span> <span class="NLM_lpage">2266</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2009&pages=2258-2266&author=A.+Pocaiauthor=P.+E.+Carringtonauthor=J.+R.+Adamsauthor=M.+Wrightauthor=G.+Eiermannauthor=L.+Zhuauthor=X.+Duauthor=A.+Petrovauthor=M.+E.+Lassmanauthor=G.+Jiangauthor=F.+Liuauthor=C.+Millerauthor=L.+M.+Totaauthor=G.+Zhouauthor=X.+Zhangauthor=M.+M.+Sountisauthor=A.+Santopreteauthor=E.+Capitoauthor=G.+G.+Chicchiauthor=N.+Thornberryauthor=E.+Bianchiauthor=A.+Pessiauthor=D.+J.+Marshauthor=R.+SinhaRoy&title=Glucagon-like+peptide+1%2Fglucagon+receptor+dual+agonism+reverses+obesity+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DCarrington%26aufirst%3DP.%2BE.%26aulast%3DAdams%26aufirst%3DJ.%2BR.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DLassman%26aufirst%3DM.%2BE.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DTota%26aufirst%3DL.%2BM.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSountis%26aufirst%3DM.%2BM.%26aulast%3DSantoprete%26aufirst%3DA.%26aulast%3DCapito%26aufirst%3DE.%26aulast%3DChicchi%26aufirst%3DG.%2BG.%26aulast%3DThornberry%26aufirst%3DN.%26aulast%3DBianchi%26aufirst%3DE.%26aulast%3DPessi%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DSinhaRoy%26aufirst%3DR.%26atitle%3DGlucagon-like%2520peptide%25201%252Fglucagon%2520receptor%2520dual%2520agonism%2520reverses%2520obesity%2520in%2520mice%26jtitle%3DDiabetes%26date%3D2009%26volume%3D58%26spage%3D2258%26epage%3D2266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Bhat, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, V. A.</span><span> </span><span class="NLM_article-title">A novel GIP-Oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1662</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2013&pages=1655-1662&author=V.+K.+Bhatauthor=B.+D.+Kerrauthor=P.+R.+Flattauthor=V.+A.+Gault&title=A+novel+GIP-Oxyntomodulin+hybrid+peptide+acting+through+GIP%2C+glucagon+and+GLP-1+receptors+exhibits+weight+reducing+and+anti-diabetic+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DV.%2BK.%26aulast%3DKerr%26aufirst%3DB.%2BD.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DGault%26aufirst%3DV.%2BA.%26atitle%3DA%2520novel%2520GIP-Oxyntomodulin%2520hybrid%2520peptide%2520acting%2520through%2520GIP%252C%2520glucagon%2520and%2520GLP-1%2520receptors%2520exhibits%2520weight%2520reducing%2520and%2520anti-diabetic%2520properties%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D85%26spage%3D1655%26epage%3D1662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Bhat, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, V. A.</span><span> </span><span class="NLM_article-title">A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice</span> <span class="citation_source-journal">Diabetologia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1417</span><span class="NLM_x">–</span> <span class="NLM_lpage">1424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1417-1424&author=V.+K.+Bhatauthor=B.+D.+Kerrauthor=S.+Vasuauthor=P.+R.+Flattauthor=V.+A.+Gault&title=A+DPP-IV-resistant+triple-acting+agonist+of+GIP%2C+GLP-1+and+glucagon+receptors+with+potent+glucose-lowering+and+insulinotropic+actions+in+high-fat-fed+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DV.%2BK.%26aulast%3DKerr%26aufirst%3DB.%2BD.%26aulast%3DVasu%26aufirst%3DS.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DGault%26aufirst%3DV.%2BA.%26atitle%3DA%2520DPP-IV-resistant%2520triple-acting%2520agonist%2520of%2520GIP%252C%2520GLP-1%2520and%2520glucagon%2520receptors%2520with%2520potent%2520glucose-lowering%2520and%2520insulinotropic%2520actions%2520in%2520high-fat-fed%2520mice%26jtitle%3DDiabetologia%26date%3D2013%26volume%3D56%26spage%3D1417%26epage%3D1424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Mack, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Athanacio, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jodka, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide</span> <span class="citation_source-journal">Diabetes Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1105</span><span class="NLM_x">–</span> <span class="NLM_lpage">1113</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1111%2Fj.1463-1326.2011.01465.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Glt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1105-1113&author=C.+M.+Mackauthor=P.+A.+Smithauthor=J.+R.+Athanacioauthor=K.+Xuauthor=J.+K.+Wilsonauthor=J.+M.+Reynoldsauthor=C.+M.+Jodkaauthor=M.+G.+Luauthor=D.+G.+Parkes&title=Glucoregulatory+effects+and+prolonged+duration+of+action+of+davalintide%3A+a+novel+amylinomimetic+peptide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide</span></div><div class="casAuthors">Mack, C. M.; Smith, P. A.; Athanacio, J. R.; Xu, K.; Wilson, J. K.; Reynolds, J. M.; Jodka, C. M.; Lu, M. G. W.; Parkes, D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1105-1113</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims: Davalintide is a second-generation amylinomimetic peptide possessing enhanced pharmacol. properties over rat amylin to reduce food intake in preclin. models.  The current expts. in rats describe addnl. glucoregulatory actions of davalintide consistent with amylin agonism, and explore the duration of action of these effects.  Methods: S.c. (SC) injection of davalintide slowed gastric emptying with equal potency to amylin (ED50's = 2.3 and 4.1 μg/kg).  This effect was maintained for 8 h with davalintide, but not amylin.  I.p. injection of davalintide also reduced food intake with a potency similar to amylin (ED50's = 5.0 and 11.3 μg/kg).  Consistent with amylin agonism, davalintide (10 μg/kg, SC) suppressed the plasma glucagon response over 90 min following an i.v. arginine bolus in anesthetized rats.  The elimination t1/2 of davalintide (200 μg/kg, SC) was 26 min, similar to the t1/2 of amylin, suggesting that pharmacokinetic-independent mechanisms contribute to davalintide's enhanced duration of action.  Binding kinetic studies using 125I davalintide revealed no appreciable dissocn. from the amylin nucleus accumbens receptor after 7 h while 125I rat amylin did dissoc. from this receptor (Koff = 0.013/min).  Sustained SC infusion of davalintide (275 μg/kg/day) or amylin (300) decreased plasma glucose after an oral glucose challenge at 2 wk (by 27 and 31%) and suppressed gastric emptying at 3 wk (by 29 and 47%), demonstrating durable glucoregulatory actions of both peptides.  Conclusions: These data show glucoregulatory properties of davalintide consistent with amylin agonism and suggest that slowed receptor dissocn. plays a role in davalintide's prolonged pharmacodynamic actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQA3U1lLApkrVg90H21EOLACvtfcHk0lhN_MxTizGD6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Glt7rK&md5=abd7d900c627ecf99451a9264e935c2c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2011.01465.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2011.01465.x%26sid%3Dliteratum%253Aachs%26aulast%3DMack%26aufirst%3DC.%2BM.%26aulast%3DSmith%26aufirst%3DP.%2BA.%26aulast%3DAthanacio%26aufirst%3DJ.%2BR.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DJ.%2BK.%26aulast%3DReynolds%26aufirst%3DJ.%2BM.%26aulast%3DJodka%26aufirst%3DC.%2BM.%26aulast%3DLu%26aufirst%3DM.%2BG.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3DGlucoregulatory%2520effects%2520and%2520prolonged%2520duration%2520of%2520action%2520of%2520davalintide%253A%2520a%2520novel%2520amylinomimetic%2520peptide%26jtitle%3DDiabetes%2520Obes.%2520Metab.%26date%3D2011%26volume%3D13%26spage%3D1105%26epage%3D1113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Papo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahti, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochran, J. R.</span><span> </span><span class="NLM_article-title">Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">14067</span><span class="NLM_x">–</span> <span class="NLM_lpage">14072</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=14067-14072&author=N.+Papoauthor=A.+P.+Silvermanauthor=J.+L.+Lahtiauthor=J.+R.+Cochran&title=Antagonistic+VEGF+variants+engineered+to+simultaneously+bind+to+and+inhibit+VEGFR2+and+alphavbeta3+integrin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPapo%26aufirst%3DN.%26aulast%3DSilverman%26aufirst%3DA.%2BP.%26aulast%3DLahti%26aufirst%3DJ.%2BL.%26aulast%3DCochran%26aufirst%3DJ.%2BR.%26atitle%3DAntagonistic%2520VEGF%2520variants%2520engineered%2520to%2520simultaneously%2520bind%2520to%2520and%2520inhibit%2520VEGFR2%2520and%2520alphavbeta3%2520integrin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D14067%26epage%3D14072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Foote, J.</span><span> </span><span class="NLM_article-title">Immunology. Isomeric antibodies</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">1327</span><span class="NLM_x">–</span> <span class="NLM_lpage">1328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=1327-1328&author=J.+Foote&title=Immunology.+Isomeric+antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFoote%26aufirst%3DJ.%26atitle%3DImmunology.%2520Isomeric%2520antibodies%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D1327%26epage%3D1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">James, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roversi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawfik, D. S.</span><span> </span><span class="NLM_article-title">Antibody multispecificity mediated by conformational diversity</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">1362</span><span class="NLM_x">–</span> <span class="NLM_lpage">1367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1126%2Fscience.1079731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=12610298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsFWrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=1362-1367&author=L.+C.+Jamesauthor=P.+Roversiauthor=D.+S.+Tawfik&title=Antibody+multispecificity+mediated+by+conformational+diversity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody Multispecificity Mediated by Conformational Diversity</span></div><div class="casAuthors">James, Leo C.; Roversi, Pietro; Tawfik, Dan S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5611</span>),
    <span class="NLM_cas:pages">1362-1367</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A single antibody was shown to adopt different binding-site conformations and thereby bind unrelated antigens.  Anal. by both x-ray crystallog. and pre-steady-state kinetics revealed an equil. between different preexisting isomers, one of which possessed a promiscuous, low-affinity binding site for arom. ligands, including the immunizing hapten.  A subsequent induced-fit isomerization led to high-affinity complexes with a deep and narrow binding site.  A protein antigen identified by repertoire selection made use of an unrelated antibody isomer with a wide, shallow binding site.  Conformational diversity, whereby one sequence adopts multiple structures and multiple functions, can increase the effective size of the antibody repertoire but may also lead to autoimmunity and allergy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSE9e1ICjx9rVg90H21EOLACvtfcHk0liJlVhexKIhDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsFWrsrs%253D&md5=f696b3d1a9773f94563868a49e2e75a2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.1079731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1079731%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DL.%2BC.%26aulast%3DRoversi%26aufirst%3DP.%26aulast%3DTawfik%26aufirst%3DD.%2BS.%26atitle%3DAntibody%2520multispecificity%2520mediated%2520by%2520conformational%2520diversity%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D1362%26epage%3D1367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Baker, M.</span><span> </span><span class="NLM_article-title">Upping the ante on antibodies</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1065</span><span class="NLM_x">–</span> <span class="NLM_lpage">1072</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1065-1072&author=M.+Baker&title=Upping+the+ante+on+antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DM.%26atitle%3DUpping%2520the%2520ante%2520on%2520antibodies%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D1065%26epage%3D1072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ying, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grinnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clabbers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santora, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Taber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunes, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakorafas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarcsa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murtaza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghayur, T.</span><span> </span><span class="NLM_article-title">Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1290</span><span class="NLM_x">–</span> <span class="NLM_lpage">1297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=1290-1297&author=C.+Wuauthor=H.+Yingauthor=C.+Grinnellauthor=S.+Bryantauthor=R.+Millerauthor=A.+Clabbersauthor=S.+Boseauthor=D.+McCarthyauthor=R.+R.+Zhuauthor=L.+Santoraauthor=R.+Davis-Taberauthor=Y.+Kunesauthor=E.+Fungauthor=A.+Schwartzauthor=P.+Sakorafasauthor=J.+Guauthor=E.+Tarcsaauthor=A.+Murtazaauthor=T.+Ghayur&title=Simultaneous+targeting+of+multiple+disease+mediators+by+a+dual-variable-domain+immunoglobulin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DYing%26aufirst%3DH.%26aulast%3DGrinnell%26aufirst%3DC.%26aulast%3DBryant%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DClabbers%26aufirst%3DA.%26aulast%3DBose%26aufirst%3DS.%26aulast%3DMcCarthy%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DR.%2BR.%26aulast%3DSantora%26aufirst%3DL.%26aulast%3DDavis-Taber%26aufirst%3DR.%26aulast%3DKunes%26aufirst%3DY.%26aulast%3DFung%26aufirst%3DE.%26aulast%3DSchwartz%26aufirst%3DA.%26aulast%3DSakorafas%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DTarcsa%26aufirst%3DE.%26aulast%3DMurtaza%26aufirst%3DA.%26aulast%3DGhayur%26aufirst%3DT.%26atitle%3DSimultaneous%2520targeting%2520of%2520multiple%2520disease%2520mediators%2520by%2520a%2520dual-variable-domain%2520immunoglobulin%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D1290%26epage%3D1297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Chames, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baty, D.</span><span> </span><span class="NLM_article-title">Bispecific antibodies for cancer therapy: the light at the end of the tunnel?</span> <span class="citation_source-journal">MAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">539</span><span class="NLM_x">–</span> <span class="NLM_lpage">547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=539-547&author=P.+Chamesauthor=D.+Baty&title=Bispecific+antibodies+for+cancer+therapy%3A+the+light+at+the+end+of+the+tunnel%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChames%26aufirst%3DP.%26aulast%3DBaty%26aufirst%3DD.%26atitle%3DBispecific%2520antibodies%2520for%2520cancer%2520therapy%253A%2520the%2520light%2520at%2520the%2520end%2520of%2520the%2520tunnel%253F%26jtitle%3DMAbs%26date%3D2009%26volume%3D1%26spage%3D539%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Fitzgerald, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lugovskoy, A.</span><span> </span><span class="NLM_article-title">Rational engineering of antibody therapeutics targeting multiple oncogene pathways</span> <span class="citation_source-journal">MAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=299-309&author=J.+Fitzgeraldauthor=A.+Lugovskoy&title=Rational+engineering+of+antibody+therapeutics+targeting+multiple+oncogene+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DJ.%26aulast%3DLugovskoy%26aufirst%3DA.%26atitle%3DRational%2520engineering%2520of%2520antibody%2520therapeutics%2520targeting%2520multiple%2520oncogene%2520pathways%26jtitle%3DMAbs%26date%3D2011%26volume%3D3%26spage%3D299%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Lafleur, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramyan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakaraj, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kankanala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaritskaya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puffer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buasen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaithamana, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnette, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roschke, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiener, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilbert, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbas, C. F.</span><span> </span><span class="NLM_article-title">Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides</span> <span class="citation_source-journal">MAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">208</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=208-218&author=D.+W.+Lafleurauthor=D.+Abramyanauthor=P.+Kanakarajauthor=R.+G.+Smithauthor=R.+R.+Shahauthor=G.+Wangauthor=X.+T.+Yaoauthor=S.+Kankanalaauthor=E.+Boydauthor=L.+Zaritskayaauthor=V.+Namauthor=B.+A.+Pufferauthor=P.+Buasenauthor=S.+Kaithamanaauthor=A.+F.+Burnetteauthor=R.+Krishnamurthyauthor=D.+Patelauthor=V.+V.+Roschkeauthor=P.+A.+Kienerauthor=D.+M.+Hilbertauthor=C.+F.+Barbas&title=Monoclonal+antibody+therapeutics+with+up+to+five+specificities%3A+Functional+enhancement+through+fusion+of+target-specific+peptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLafleur%26aufirst%3DD.%2BW.%26aulast%3DAbramyan%26aufirst%3DD.%26aulast%3DKanakaraj%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DR.%2BG.%26aulast%3DShah%26aufirst%3DR.%2BR.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DYao%26aufirst%3DX.%2BT.%26aulast%3DKankanala%26aufirst%3DS.%26aulast%3DBoyd%26aufirst%3DE.%26aulast%3DZaritskaya%26aufirst%3DL.%26aulast%3DNam%26aufirst%3DV.%26aulast%3DPuffer%26aufirst%3DB.%2BA.%26aulast%3DBuasen%26aufirst%3DP.%26aulast%3DKaithamana%26aufirst%3DS.%26aulast%3DBurnette%26aufirst%3DA.%2BF.%26aulast%3DKrishnamurthy%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DRoschke%26aufirst%3DV.%2BV.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DHilbert%26aufirst%3DD.%2BM.%26aulast%3DBarbas%26aufirst%3DC.%2BF.%26atitle%3DMonoclonal%2520antibody%2520therapeutics%2520with%2520up%2520to%2520five%2520specificities%253A%2520Functional%2520enhancement%2520through%2520fusion%2520of%2520target-specific%2520peptides%26jtitle%3DMAbs%26date%3D2013%26volume%3D5%26spage%3D208%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Davidson, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bate, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Exenatide</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=713-714&author=M.+B.+Davidsonauthor=G.+Bateauthor=P.+Kirkpatrick&title=Exenatide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DM.%2BB.%26aulast%3DBate%26aufirst%3DG.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DExenatide%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D713%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dritselis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Liraglutide</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">268</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=267-268&author=D.+J.+Druckerauthor=A.+Dritselisauthor=P.+Kirkpatrick&title=Liraglutide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DDritselis%26aufirst%3DA.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DLiraglutide%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D267%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Pullman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darsow, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frias, J. P.</span><span> </span><span class="NLM_article-title">Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes</span> <span class="citation_source-journal">Vasc. Health Risk Manag.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.2147%2Fvhrm.2006.2.3.203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlars77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=203-212&author=J.+Pullmanauthor=T.+Darsowauthor=J.+P.+Frias&title=Pramlintide+in+the+management+of+insulin-using+patients+with+type+2+and+type+1+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes</span></div><div class="casAuthors">Pullman, John; Darsow, Tamara; Frias, Juan P.</div><div class="citationInfo"><span class="NLM_cas:title">Vascular Health and Risk Management</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-212</span>CODEN:
                <span class="NLM_cas:coden">VHRMAT</span>;
        ISSN:<span class="NLM_cas:issn">1176-6344</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  In patients with diabetes, dysregulation of multiple glucoregulatory hormones results in chronic hyperglycemia and an array of assocd. micro vascular and macrovascular complications.  Optimization of glycemic control, both overall (glycosylated Hb [A1C]) and in the postprandial period, may reduce the risk of long-term vascular complications.  However, despite significant recent therapeutic advances, most patients with diabetes are unable to attain and/or maintain normal or near-normal glycemia with insulin therapy alone.  Pramlintide, an analog of amylin, is the first in a new class of pharmaceutical agents and is indicated as an adjunct to mealtime insulin for the treatment of patients with type 1 and type 2 diabetes.  By mimicking the actions of the naturally occurring hormone amylin, pramlintide complements insulin by regulating the appearance of glucose into the circulation after meals via three primary mechanisms of action: slowing gastric emptying, suppressing inappropriate post-meal glucagon secretion, and increasing satiety.  In long-term clin. trials, adjunctive pramlintide treatment resulted in improved postprandial glucose control and significantly reduced A1C and body wt. compared with insulin alone.  The combination of insulin and pramlintide may provide a more physiol. balanced approach to managing diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYuz2pRbDx7LVg90H21EOLACvtfcHk0lgkqnRxqJtEgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlars77J&md5=ce380e30a64ce506c884783623a430fe</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2147%2Fvhrm.2006.2.3.203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fvhrm.2006.2.3.203%26sid%3Dliteratum%253Aachs%26aulast%3DPullman%26aufirst%3DJ.%26aulast%3DDarsow%26aufirst%3DT.%26aulast%3DFrias%26aufirst%3DJ.%2BP.%26atitle%3DPramlintide%2520in%2520the%2520management%2520of%2520insulin-using%2520patients%2520with%2520type%25202%2520and%2520type%25201%2520diabetes%26jtitle%3DVasc.%2520Health%2520Risk%2520Manag.%26date%3D2006%26volume%3D2%26spage%3D203%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Lebovitz, H. E.</span><span> </span><span class="NLM_article-title">Adjunct therapy for type 1 diabetes mellitus</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">326</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Fnrendo.2010.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=20404854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsVGmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=326-334&author=H.+E.+Lebovitz&title=Adjunct+therapy+for+type+1+diabetes+mellitus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Adjunct therapy for type 1 diabetes mellitus</span></div><div class="casAuthors">Lebovitz, Harold E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">326-334</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Insulin replacement therapy in type 1 diabetes mellitus (T1DM) leads to peripheral hyperinsulinemia, which is assocd. with potentially serious metabolic complications, such as increased hypoglycemia, wt. gain and postprandial hyperglucagonemia.  This Review discusses adjunctive therapies to minimize these complications in patients with T1DM, with a focus on the islet amyloid polypeptide analog pramlintide.  Insulin replacement therapy in type 1 diabetes mellitus (T1DM) is nonphysiol.  Hyperinsulinemia is generated in the periphery to achieve normal insulin concns. in the liver.  This mismatch results in increased hypoglycemia, increased food intake with wt. gain, and insufficient regulation of postprandial glucose excursions.  Islet amyloid polypeptide is a hormone synthesized in pancreatic β cells and cosecreted with insulin.  Circulating islet amyloid polypeptide binds to receptors located in the hindbrain and increases satiety, delays gastric emptying and suppresses glucagon secretion.  Thus, islet amyloid polypeptide complements the effects of insulin.  T1DM is a state of both islet amyloid polypeptide and insulin deficiency.  Pramlintide, a synthetic analog of islet amyloid polypeptide, can replace this hormone in patients with T1DM.  When administered as adjunctive therapy to such patients treated with insulin, pramlintide decreases food intake and causes wt. loss.  Pramlintide therapy is also assocd. with suppression of glucagon secretion and delayed gastric emptying, both of which decrease postprandial plasma glucose excursions.  Pramlintide therapy improves glycemic control and lessens wt. gain.  Agents that decrease intestinal carbohydrate digestion (alpha-glucosidase inhibitors) or decrease insulin resistance (metformin) might be alternative adjunctive therapies in T1DM, though its benefits are marginally supported by clin. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJXVrVnp5fSLVg90H21EOLACvtfcHk0liL5gt3APCUIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsVGmsbY%253D&md5=c58dc70e0ae7a4d94a102dc077b68b03</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2010.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2010.49%26sid%3Dliteratum%253Aachs%26aulast%3DLebovitz%26aufirst%3DH.%2BE.%26atitle%3DAdjunct%2520therapy%2520for%2520type%25201%2520diabetes%2520mellitus%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2010%26volume%3D6%26spage%3D326%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Tschop, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span> </span><span class="NLM_article-title">Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1309</span><span class="NLM_x">–</span> <span class="NLM_lpage">1314</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=1309-1314&author=M.+H.+Tschopauthor=R.+D.+DiMarchi&title=Outstanding+Scientific+Achievement+Award+Lecture+2011%3A+defeating+diabesity%3A+the+case+for+personalized+combinatorial+therapies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTschop%26aufirst%3DM.%2BH.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DOutstanding%2520Scientific%2520Achievement%2520Award%2520Lecture%25202011%253A%2520defeating%2520diabesity%253A%2520the%2520case%2520for%2520personalized%2520combinatorial%2520therapies%26jtitle%3DDiabetes%26date%3D2012%26volume%3D61%26spage%3D1309%26epage%3D1314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turek, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">“Weighing in” on synergy: preclinical research on neurohormonal anti-obesity combinations</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1350</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2Fj.brainres.2010.01.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKiurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1350&publication_year=2010&pages=86-94&author=J.+D.+Rothauthor=J.+L.+Trevaskisauthor=V.+F.+Turekauthor=D.+G.+Parkes&title=%E2%80%9CWeighing+in%E2%80%9D+on+synergy%3A+preclinical+research+on+neurohormonal+anti-obesity+combinations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">"Weighing in" on synergy: Preclinical research on neurohormonal anti-obesity combinations</span></div><div class="casAuthors">Roth, Jonathan D.; Trevaskis, James L.; Turek, Victoria F.; Parkes, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1350</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86-94</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Active wt. loss and the maintenance of a wt.-reduced state elicit potent counter-regulatory responses in multiple neurochem. pathways rendering monotherapy-based anti-obesity agents relatively ineffective.  Herein, we highlight potential strategies for overcoming counter-regulatory responses to states of neg. energy balance using combinatorial approaches.  We discuss methodol. and practical considerations for preclin. modeling of additive/synergistic wt. loss combinations that have emerged in our translational research program aimed at identifying naturally occurring neurohormonal synergies.  As an example of synergy, pharmacol. and mechanistic findings with the combined administration of the β-cell hormone amylin and the adipokine leptin are reviewed.  Finally, we briefly discuss what the future landscape of neurohormonal anti-obesity combinations may hold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmZ5KmVGM2L7Vg90H21EOLACvtfcHk0liL5gt3APCUIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKiurnM&md5=6f2fc186489db41ee5d10cea7fe91ea5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2010.01.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2010.01.027%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DTurek%26aufirst%3DV.%2BF.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3D%25E2%2580%259CWeighing%2520in%25E2%2580%259D%2520on%2520synergy%253A%2520preclinical%2520research%2520on%2520neurohormonal%2520anti-obesity%2520combinations%26jtitle%3DBrain%2520Res.%26date%3D2010%26volume%3D1350%26spage%3D86%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Cegla, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, S. R.</span><span> </span><span class="NLM_article-title">Gut-brain cross-talk in appetite regulation</span> <span class="citation_source-journal">Curr. Opin. Clin. Nutr. Metab. Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">588</span><span class="NLM_x">–</span> <span class="NLM_lpage">593</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1097%2FMCO.0b013e32833b64a3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A280%3ADC%252BC3cjktVejsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=588-593&author=J.+Ceglaauthor=T.+M.+Tanauthor=S.+R.+Bloom&title=Gut-brain+cross-talk+in+appetite+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Gut-brain cross-talk in appetite regulation</span></div><div class="casAuthors">Cegla Jaimini; Tan Tricia M; Bloom Stephen R</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in clinical nutrition and metabolic care</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">588-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  To review the role of gut hormones involved in appetite regulation and their potential in the treatment of obesity.  RECENT FINDINGS:  The medical treatment of obesity has been fraught with challenges.  With two centrally acting agents having been recently withdrawn from the market, new therapies are required.  The gut hormones are especially promising therapeutic targets.  This article looks at the interplay between gut and brain which mediates the regulation of appetite and energy expenditure.  Some recent developments that point the way towards the future development of gut hormone analogues as treatments for obesity are reviewed.  SUMMARY:  Our understanding of the interaction between gut hormones and the neuronal circuits controlling appetite regulation has made great advances over recent years.  This knowledge is essential if these peptides are to become potential obesity therapies, both from an efficacy and safety perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRx-vmpR40IMvLc4ARHEmzfW6udTcc2eaXLFcD41k_t7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjktVejsA%253D%253D&md5=ae6a4adbf32a6a7dd7cf130eb0cab0ce</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1097%2FMCO.0b013e32833b64a3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCO.0b013e32833b64a3%26sid%3Dliteratum%253Aachs%26aulast%3DCegla%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DT.%2BM.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26atitle%3DGut-brain%2520cross-talk%2520in%2520appetite%2520regulation%26jtitle%3DCurr.%2520Opin.%2520Clin.%2520Nutr.%2520Metab.%2520Care%26date%3D2010%26volume%3D13%26spage%3D588%26epage%3D593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Neary, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druce, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semjonous, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipsson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghatei, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, S. R.</span><span> </span><span class="NLM_article-title">Peptide YY3–36 and glucagon-like peptide-17–36 inhibit food intake additively</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">5120</span><span class="NLM_x">–</span> <span class="NLM_lpage">5127</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2005&pages=5120-5127&author=N.+M.+Nearyauthor=C.+J.+Smallauthor=M.+R.+Druceauthor=A.+J.+Parkauthor=S.+M.+Ellisauthor=N.+M.+Semjonousauthor=C.+L.+Dakinauthor=K.+Filipssonauthor=F.+Wangauthor=A.+S.+Kentauthor=G.+S.+Frostauthor=M.+A.+Ghateiauthor=S.+R.+Bloom&title=Peptide+YY3%E2%80%9336+and+glucagon-like+peptide-17%E2%80%9336+inhibit+food+intake+additively"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeary%26aufirst%3DN.%2BM.%26aulast%3DSmall%26aufirst%3DC.%2BJ.%26aulast%3DDruce%26aufirst%3DM.%2BR.%26aulast%3DPark%26aufirst%3DA.%2BJ.%26aulast%3DEllis%26aufirst%3DS.%2BM.%26aulast%3DSemjonous%26aufirst%3DN.%2BM.%26aulast%3DDakin%26aufirst%3DC.%2BL.%26aulast%3DFilipsson%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKent%26aufirst%3DA.%2BS.%26aulast%3DFrost%26aufirst%3DG.%2BS.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26atitle%3DPeptide%2520YY3%25E2%2580%259336%2520and%2520glucagon-like%2520peptide-17%25E2%2580%259336%2520inhibit%2520food%2520intake%2520additively%26jtitle%3DEndocrinology%26date%3D2005%26volume%3D146%26spage%3D5120%26epage%3D5127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Talsania, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anini, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, P. L.</span><span> </span><span class="NLM_article-title">Peripheral exendin-4 and peptide YY3–36 synergistically reduce food intake through different mechanisms in mice</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">3748</span><span class="NLM_x">–</span> <span class="NLM_lpage">3756</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2005&pages=3748-3756&author=T.+Talsaniaauthor=Y.+Aniniauthor=S.+Siuauthor=D.+J.+Druckerauthor=P.+L.+Brubaker&title=Peripheral+exendin-4+and+peptide+YY3%E2%80%9336+synergistically+reduce+food+intake+through+different+mechanisms+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTalsania%26aufirst%3DT.%26aulast%3DAnini%26aufirst%3DY.%26aulast%3DSiu%26aufirst%3DS.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DBrubaker%26aufirst%3DP.%2BL.%26atitle%3DPeripheral%2520exendin-4%2520and%2520peptide%2520YY3%25E2%2580%259336%2520synergistically%2520reduce%2520food%2520intake%2520through%2520different%2520mechanisms%2520in%2520mice%26jtitle%3DEndocrinology%26date%3D2005%26volume%3D146%26spage%3D3748%26epage%3D3756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Reidelberger, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haver, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apenteng, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anders, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steenson, S. M.</span><span> </span><span class="NLM_article-title">Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats</span> <span class="citation_source-journal">Obesity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Foby.2010.136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Wkt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=121-127&author=R.+D.+Reidelbergerauthor=A.+C.+Haverauthor=B.+A.+Apentengauthor=K.+L.+Andersauthor=S.+M.+Steenson&title=Effects+of+exendin-4+alone+and+with+peptide+YY%283-36%29+on+food+intake+and+body+weight+in+diet-induced+obese+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Exendin-4 Alone and With Peptide YY3-36 on Food Intake and Body Weight in Diet-Induced Obese Rats</span></div><div class="casAuthors">Reidelberger, Roger D.; Haver, Alvin C.; Apenteng, Bettye A.; Anders, Krista L.; Steenson, Sharalyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-127</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Significant wt. loss following Roux-en-Y gastric bypass surgery (RYGB) in obese humans correlates with enhanced secretion of anorexigenic gut hormones glucagon-like peptide-1 (GLP-1) and peptide YY3-36 (PYY3-36).  Our aim here was to identify a dosing strategy for i.p. (IP) infusion of GLP-1 homolog exendin-4 alone and with PYY3-36 that produces a sustained redn. in daily food intake and body wt. in diet-induced obese (DIO) rats.  We tested 12 exendin-4 strategies over 10 wk.  Exendin-4 infused during the first and last 3 h of the dark period at 15-20 pmol/h (0.15 nmol/kg/day) produced a sustained 24 ± 1% redn. in daily food intake for 17 days, and decreased body wt. by 7%.  In a sep. group of DIO rats, none of seven dosing strategies combining exendin-4 and PYY3-36 produced a similar redn. in daily food intake for >10 days.  The subsequent decline in efficacies of exendin-4 alone and with PYY3-36 on food intake and body wt. in each expt. suggested possible receptor downregulation and tolerance to treatments.  However, when treatments were discontinued for 1 day following losses in efficacies, daily food intake significantly increased.  Together, these results demonstrate that (i) intermittent IP infusion of a low dose of exendin-4 can produce a relatively prolonged redn. in daily food intake and body wt. in DIO rats, (ii) co-infusion of exendin-4 and PYY3-36 does not further prolong this response, and (iii) activation of an orexigenic mechanism gradually occurs to counteract the inhibitory effects of exendin-4 alone and with PYY3-36 on food intake and body wt.  Obesity (2011) 19 1, 121-127. doi:10.1038/oby.2010.136.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUYiytOvmcurVg90H21EOLACvtfcHk0lgDVC1LQ4JznQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Wkt73N&md5=cd9d65e9d53150cd6aa900c289e69021</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Foby.2010.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foby.2010.136%26sid%3Dliteratum%253Aachs%26aulast%3DReidelberger%26aufirst%3DR.%2BD.%26aulast%3DHaver%26aufirst%3DA.%2BC.%26aulast%3DApenteng%26aufirst%3DB.%2BA.%26aulast%3DAnders%26aufirst%3DK.%2BL.%26aulast%3DSteenson%26aufirst%3DS.%2BM.%26atitle%3DEffects%2520of%2520exendin-4%2520alone%2520and%2520with%2520peptide%2520YY%25283-36%2529%2520on%2520food%2520intake%2520and%2520body%2520weight%2520in%2520diet-induced%2520obese%2520rats%26jtitle%3DObesity%26date%3D2011%26volume%3D19%26spage%3D121%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Bello, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemm, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ofeldt, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, T. H.</span><span> </span><span class="NLM_article-title">Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates</span> <span class="citation_source-journal">Am. J. Physiol. Regul. Integr. Comp. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">R945</span><span class="NLM_x">–</span> <span class="NLM_lpage">R952</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2010&pages=R945-R952&author=N.+T.+Belloauthor=M.+H.+Kemmauthor=E.+M.+Ofeldtauthor=T.+H.+Moran&title=Dose+combinations+of+exendin-4+and+salmon+calcitonin+produce+additive+and+synergistic+reductions+in+food+intake+in+nonhuman+primates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBello%26aufirst%3DN.%2BT.%26aulast%3DKemm%26aufirst%3DM.%2BH.%26aulast%3DOfeldt%26aufirst%3DE.%2BM.%26aulast%3DMoran%26aufirst%3DT.%2BH.%26atitle%3DDose%2520combinations%2520of%2520exendin-4%2520and%2520salmon%2520calcitonin%2520produce%2520additive%2520and%2520synergistic%2520reductions%2520in%2520food%2520intake%2520in%2520nonhuman%2520primates%26jtitle%3DAm.%2520J.%2520Physiol.%2520Regul.%2520Integr.%2520Comp.%2520Physiol.%26date%3D2010%26volume%3D299%26spage%3DR945%26epage%3DR952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Lutz, T. A.</span><span> </span><span class="NLM_article-title">The interaction of amylin with other hormones in the control of eating</span> <span class="citation_source-journal">Diabetes Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1111%2Fj.1463-1326.2012.01670.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs1SrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=99-111&author=T.+A.+Lutz&title=The+interaction+of+amylin+with+other+hormones+in+the+control+of+eating"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The interaction of amylin with other hormones in the control of eating</span></div><div class="casAuthors">Lutz, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-111</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Twenty years of research established amylin as an important control of energy homeostasis.  Amylin controls nutrient and energy fluxes by reducing energy intake, by modulating nutrient utilization via an inhibition of postprandial glucagon secretion and by increasing energy disposal via a prevention of compensatory decreases of energy expenditure in wt. reduced individuals.  Like many other gastrointestinal hormones, amylin is secreted in response to meals and it reduces eating by promoting meal-ending satiation.  Not surprisingly, amylin interacts with many of these hormones to control eating.  These interactions seem to occur at different levels because amylin seems to mediate the eating inhibitory effect of some of these gastrointestinal hormones, and the combination of some of these hormones seems to lead to a stronger redn. in eating than single hormones alone.  Amylin's effect on eating is thought to be mediated by a stimulation of specific amylin receptors in the area postrema.  Secondary brain sites that were defined to mediate amylin action - and hence potential addnl. sites of interaction with other hormones - include the nucleus of the solitary tract, the lateral parabrachial nucleus, the lateral hypothalamic area and other hypothalamic nuclei.  The focus of this review is to summarize the current knowledge of amylin interactions in the control of eating.  In most cases, these interactions have only been studied at a descriptive rather than a mechanistic level and despite the clear knowledge on primary sites of amylin action, the interaction sites between amylin and other hormones are often unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMp801SIRndbVg90H21EOLACvtfcHk0lgL3AQz3lGMFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjs1SrtA%253D%253D&md5=ccfa089623388f1dca3de6031e9a53b4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2012.01670.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2012.01670.x%26sid%3Dliteratum%253Aachs%26aulast%3DLutz%26aufirst%3DT.%2BA.%26atitle%3DThe%2520interaction%2520of%2520amylin%2520with%2520other%2520hormones%2520in%2520the%2520control%2520of%2520eating%26jtitle%3DDiabetes%2520Obes.%2520Metab.%26date%3D2013%26volume%3D15%26spage%3D99%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Zuger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forster, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riediger, T.</span><span> </span><span class="NLM_article-title">Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli</span> <span class="citation_source-journal">Physiol. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">112–113C</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112%E2%80%93113C&publication_year=2013&pages=61-69&author=D.+Zugerauthor=K.+Forsterauthor=T.+A.+Lutzauthor=T.+Riediger&title=Amylin+and+GLP-1+target+different+populations+of+area+postrema+neurons+that+are+both+modulated+by+nutrient+stimuli"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZuger%26aufirst%3DD.%26aulast%3DForster%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DT.%2BA.%26aulast%3DRiediger%26aufirst%3DT.%26atitle%3DAmylin%2520and%2520GLP-1%2520target%2520different%2520populations%2520of%2520area%2520postrema%2520neurons%2520that%2520are%2520both%2520modulated%2520by%2520nutrient%2520stimuli%26jtitle%3DPhysiol.%2520Behav.%26date%3D2013%26volume%3D112%25E2%2580%2593113C%26spage%3D61%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turek, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span> </span><span class="NLM_article-title">Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin?</span> <span class="citation_source-journal">Physiol. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2010&pages=187-195&author=J.+L.+Trevaskisauthor=V.+F.+Turekauthor=P.+S.+Griffinauthor=C.+Wittmerauthor=D.+G.+Parkesauthor=J.+D.+Roth&title=Multi-hormonal+weight+loss+combinations+in+diet-induced+obese+rats%3A+therapeutic+potential+of+cholecystokinin%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DTurek%26aufirst%3DV.%2BF.%26aulast%3DGriffin%26aufirst%3DP.%2BS.%26aulast%3DWittmer%26aufirst%3DC.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26atitle%3DMulti-hormonal%2520weight%2520loss%2520combinations%2520in%2520diet-induced%2520obese%2520rats%253A%2520therapeutic%2520potential%2520of%2520cholecystokinin%253F%26jtitle%3DPhysiol.%2520Behav.%26date%3D2010%26volume%3D100%26spage%3D187%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Irwin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatt, P. R.</span><span> </span><span class="NLM_article-title">Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice</span> <span class="citation_source-journal">Diabetes Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">650</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1111%2Fdom.12079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=23388064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFelsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=650-659&author=N.+Irwinauthor=K.+Hunterauthor=I.+A.+Montgomeryauthor=P.+R.+Flatt&title=Comparison+of+independent+and+combined+metabolic+effects+of+chronic+treatment+with+%28pGlu-Gln%29-CCK-8+and+long-acting+GLP-1+and+GIP+mimetics+in+high+fat-fed+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice</span></div><div class="casAuthors">Irwin, N.; Hunter, K.; Montgomery, I. A.; Flatt, P. R.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">650-659</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim: The incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and cholecystokinin (CCK) are gastrointestinal peptides with important physiol. effects.  However, rapid enzymic degrdn. results in short-lived biol. actions.  Methods: This study has examd. metabolic actions of exendin-4, GIP[mPEG] and a novel CCK-8 analog, (pGlu-Gln)-CCK-8 as enzymically stable forms of GLP-1, GIP and CCK, resp.  Results: All peptides significantly (p < 0.01-p < 0.001) stimulated insulin secretion from BRIN BD11 cells, and acute in vivo expts. confirmed prominent antihyperglycemic and insulinotropic responses to GLP-1 or GIP receptor activation in normal mice.  Twice daily injection of (pGlu-Gln)-CCK-8 alone and in combination with exendin-4 or GIP[mPEG] in high fat-fed mice significantly decreased accumulated food intake (p < 0.05-p < 0.01), body wt. gain (p < 0.05-p < 0.01) and improved (p < 0.05) insulin sensitivity in high fat-fed mice.  However, there was no evidence for superior effects compared to (pGlu-Gln)-CCK-8 alone.  Combined treatment of (pGlu-Gln)-CCK-8 and exendin-4 resulted in significantly (p < 0.05) lowered circulating glucose levels and improved (p < 0.05) i.p. glucose tolerance.  These effects were superior to either treatment regime alone but not assocd. with altered insulin concns.  A single injection of (pGlu-Gln)-CCK-8, or combined with exendin-4, significantly (p < 0.05) lowered blood glucose levels 24 h post injection in untreated high fat-fed mice.  Conclusion: This study highlights the potential of (pGlu-Gln)-CCK-8 alone and in combination with incretin hormones for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpImTJPp-ycwrVg90H21EOLACvtfcHk0lgKfp5WR2q04Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFelsLo%253D&md5=08c9dec0813fe020feca849431ea4d65</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fdom.12079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12079%26sid%3Dliteratum%253Aachs%26aulast%3DIrwin%26aufirst%3DN.%26aulast%3DHunter%26aufirst%3DK.%26aulast%3DMontgomery%26aufirst%3DI.%2BA.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26atitle%3DComparison%2520of%2520independent%2520and%2520combined%2520metabolic%2520effects%2520of%2520chronic%2520treatment%2520with%2520%2528pGlu-Gln%2529-CCK-8%2520and%2520long-acting%2520GLP-1%2520and%2520GIP%2520mimetics%2520in%2520high%2520fat-fed%2520mice%26jtitle%3DDiabetes%2520Obes.%2520Metab.%26date%3D2013%26volume%3D15%26spage%3D650%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roland, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koda, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A. D.</span><span> </span><span class="NLM_article-title">Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">7257</span><span class="NLM_x">–</span> <span class="NLM_lpage">7262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1073%2Fpnas.0706473105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=18458326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=7257-7262&author=J.+D.+Rothauthor=B.+L.+Rolandauthor=R.+L.+Coleauthor=J.+L.+Trevaskisauthor=C.+Weyerauthor=J.+E.+Kodaauthor=C.+M.+Andersonauthor=D.+G.+Parkesauthor=A.+D.+Baron&title=Leptin+responsiveness+restored+by+amylin+agonism+in+diet-induced+obesity%3A+evidence+from+nonclinical+and+clinical+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from non-clinical and clinical studies</span></div><div class="casAuthors">Roth, Jonathan D.; Roland, Barbara L.; Cole, Rebecca L.; Trevaskis, James L.; Weyer, Christian; Koda, Joy E.; Anderson, Christen M.; Parkes, David G.; Baron, Alain D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7257-7262</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Body wt. is regulated by complex neurohormonal interactions between endocrine signals of long-term adiposity (e.g., leptin, a hypothalamic signal) and short-term satiety (e.g., amylin, a hindbrain signal).  We report that concurrent peripheral administration of amylin and leptin elicits synergistic, fat-sp. wt. loss in leptin-resistant, diet-induced obese rats.  Wt. loss synergy was specific to amylin treatment, compared with other anorexigenic peptides, and dissociable from amylin's effect on food intake.  The addn. of leptin after amylin pretreatment elicited further wt. loss, compared with either monotherapy condition.  In a 24-wk randomized, double-blind, clin. proof-of-concept study in overweight/obese subjects, coadministration of recombinant human leptin and the amylin analog Pramlintide elicited 12.7% mean wt. loss, significantly more than was obsd. with either treatment alone (P < 0.01).  In obese rats, amylin pretreatment partially restored hypothalamic leptin signaling (pSTAT3 immunoreactivity) within the ventromedial, but not the arcuate nucleus and up-regulated basal and leptin-stimulated signaling in the hindbrain area postrema.  These findings provide both nonclin. and clin. evidence that amylin agonism restored leptin responsiveness in diet-induced obesity, suggesting that integrated neurohormonal approaches to obesity pharmacotherapy may facilitate greater wt. loss by harnessing naturally occurring synergies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_oX_fM8x6RrVg90H21EOLACvtfcHk0lgKfp5WR2q04Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFCqsLw%253D&md5=16de45e90b9abf99bc23c79ef1805ff2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0706473105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0706473105%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DRoland%26aufirst%3DB.%2BL.%26aulast%3DCole%26aufirst%3DR.%2BL.%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DWeyer%26aufirst%3DC.%26aulast%3DKoda%26aufirst%3DJ.%2BE.%26aulast%3DAnderson%26aufirst%3DC.%2BM.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DBaron%26aufirst%3DA.%2BD.%26atitle%3DLeptin%2520responsiveness%2520restored%2520by%2520amylin%2520agonism%2520in%2520diet-induced%2520obesity%253A%2520evidence%2520from%2520nonclinical%2520and%2520clinical%2520studies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D7257%26epage%3D7262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span> </span><span class="NLM_article-title">Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">5679</span><span class="NLM_x">–</span> <span class="NLM_lpage">5687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2008&pages=5679-5687&author=J.+L.+Trevaskisauthor=T.+Coffeyauthor=R.+Coleauthor=C.+Leiauthor=C.+Wittmerauthor=B.+Walshauthor=C.+Weyerauthor=J.+Kodaauthor=A.+D.+Baronauthor=D.+G.+Parkesauthor=J.+D.+Roth&title=Amylin-mediated+restoration+of+leptin+responsiveness+in+diet-induced+obesity%3A+magnitude+and+mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DCoffey%26aufirst%3DT.%26aulast%3DCole%26aufirst%3DR.%26aulast%3DLei%26aufirst%3DC.%26aulast%3DWittmer%26aufirst%3DC.%26aulast%3DWalsh%26aufirst%3DB.%26aulast%3DWeyer%26aufirst%3DC.%26aulast%3DKoda%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%2BD.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26atitle%3DAmylin-mediated%2520restoration%2520of%2520leptin%2520responsiveness%2520in%2520diet-induced%2520obesity%253A%2520magnitude%2520and%2520mechanisms%26jtitle%3DEndocrinology%26date%3D2008%26volume%3D149%26spage%3D5679%26epage%3D5687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Chan, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weyer, C.</span><span> </span><span class="NLM_article-title">It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development</span> <span class="citation_source-journal">J. Invest. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">777</span><span class="NLM_x">–</span> <span class="NLM_lpage">783</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2009&pages=777-783&author=J.+L.+Chanauthor=J.+D.+Rothauthor=C.+Weyer&title=It+takes+two+to+tango%3A+combined+amylin%2Fleptin+agonism+as+a+potential+approach+to+obesity+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development</span></div><div class="casAuthors">Chan, Jean L.; Roth, Jonathan D.; Weyer, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">777-783</span>CODEN:
                <span class="NLM_cas:coden">JINVFI</span>;
        ISSN:<span class="NLM_cas:issn">1081-5589</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The discovery of leptin in 1994 was a seminal event in obesity research.  It helped to establish that body wt. is tightly regulated by a complex neurohormonal feedback system and that obesity should be viewed as a disorder with a strong biol. basis rather than simply the result of poor lifestyle choices and lack of willpower.  Leptin, secreted from adipocytes, acts as a prototypic long-term (tonic) adiposity signal.  Although nonclin. and clin. studies have provided unequivocal evidence that leptin plays a unique, pivotal role in body wt. regulation, efforts to develop recombinant leptin (metreleptin) as a monotherapy for obesity have proven unsuccessful.  Amylin, secreted from pancreatic β-cells, fulfills the criteria for a short-term (episodic) satiety signal.  The amylin analog pramlintide elicits sustained redns. in food intake and body wt. in obese rodents and humans.  A translational research program aimed at elucidating the interaction between different islet-, gut-, and adipocyte-derived hormones led to the discovery that combined amylin/leptin agonism induces marked, synergistic, fat-sp. wt. loss in leptin-resistant diet-induced obese rodents.  In obese humans, combination treatment with pramlintide/metreleptin led to an approx. 13% wt. loss after 24 wk, significantly more than after treatment with pramlintide or metreleptin alone.  Collectively, these findings suggest that combined amylin/leptin agonism may have therapeutic utility as part of an integrated, neurohormonal approach to obesity pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBni213syHjLVg90H21EOLACvtfcHk0lgrUCwJzww5rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsrjP&md5=852e145bd52c893c49c112b0509d9c48</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BL.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DWeyer%26aufirst%3DC.%26atitle%3DIt%2520takes%2520two%2520to%2520tango%253A%2520combined%2520amylin%252Fleptin%2520agonism%2520as%2520a%2520potential%2520approach%2520to%2520obesity%2520drug%2520development%26jtitle%3DJ.%2520Invest.%2520Med.%26date%3D2009%26volume%3D57%26spage%3D777%26epage%3D783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Trevaskis, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koda, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J. D.</span><span> </span><span class="NLM_article-title">Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats</span> <span class="citation_source-journal">Obesity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Foby.2009.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=19543217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sqt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=21-26&author=J.+L.+Trevaskisauthor=C.+Leiauthor=J.+E.+Kodaauthor=C.+Weyerauthor=D.+G.+Parkesauthor=J.+D.+Roth&title=Interaction+of+leptin+and+amylin+in+the+long-term+maintenance+of+weight+loss+in+diet-induced+obese+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of Leptin and Amylin in the Long-term Maintenance of Weight Loss in Diet-induced Obese Rats</span></div><div class="casAuthors">Trevaskis, James L.; Lei, Chunli; Koda, Joy E.; Weyer, Christian; Parkes, David G.; Roth, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-26</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have previously shown that combined amylin + leptin agonism elicits synergistic wt. loss in diet-induced obese (DIO) rats.  Here, we assessed the comparative efficacy of amylin, leptin, or amylin + leptin in the maintenance of amylin + leptin-mediated wt. loss.  DIO rats pretreated with the combination of rat amylin (50 μg/kg/day) and murine leptin (125 μg/kg/day) for 4 wk were subsequently infused with either vehicle, amylin, leptin, or amylin + leptin for an addnl. 4 wk.  Food intake, body wt., body compn., plasma parameters, and the expression of key metabolic genes in liver and white adipose tissue (WAT) were assessed.  Amylin + leptin treatment (weeks 0-4) reduced body wt. to 87.5% of baseline.  Rats subsequently maintained on vehicle or leptin regained all wt. (to 104.2 and 101.2% of baseline, resp.), those maintained on amylin had partial wt. regain (97.0%).  By contrast, wt. loss was largely maintained with continued amylin + leptin treatment (91.4%), assocd. with a 10% decrease in adiposity.  Cumulative food intake (weeks 5-8) was reduced by amylin and amylin + leptin, but not by leptin alone.  Amylin + leptin, but not amylin or leptin alone, reduced plasma triglycerides (by 55%), total cholesterol (by 19%), and insulin (by 57%) compared to vehicle.  Amylin + leptin also reduced hepatic stearoyl-CoA desaturase-1 (Scd1) mRNA, and increased WAT mRNA levels of adiponectin, fatty acid synthase (Fasn), and lipoprotein lipase (Lpl).  We conclude that, in DIO rats, maintenance of amylin + leptin-mediated wt. loss requires continued treatment with both agonists, and is accompanied by sustained improvements in body compn., and indexes of lipid metab. and insulin sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppo5IndLLHNLVg90H21EOLACvtfcHk0liO4v-0a3hprg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sqt7vP&md5=cdc490cd6cd0dc1540ffc66103571c35</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Foby.2009.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foby.2009.187%26sid%3Dliteratum%253Aachs%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DLei%26aufirst%3DC.%26aulast%3DKoda%26aufirst%3DJ.%2BE.%26aulast%3DWeyer%26aufirst%3DC.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26atitle%3DInteraction%2520of%2520leptin%2520and%2520amylin%2520in%2520the%2520long-term%2520maintenance%2520of%2520weight%2520loss%2520in%2520diet-induced%2520obese%2520rats%26jtitle%3DObesity%26date%3D2010%26volume%3D18%26spage%3D21%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Young, A. A.</span><span class="NLM_x"> (</span><span class="NLM_year">2005</span><span class="NLM_x">) </span> <span class="citation_source-book">Amylin: Physiology and Pharmacology</span>; <span class="NLM_publisher-name">Elsevier Academic Press</span>, <span class="NLM_publisher-loc">San Diego, CA</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=A.+A.+Young&title=Amylin%3A+Physiology+and+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DA.%2BA.%26date%3D2005%26btitle%3DAmylin%253A%2520Physiology%2520and%2520Pharmacology%26pub%3DElsevier%2520Academic%2520Press" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Riediger, T.; Lutz, T. A.; Schmid, H. A.; Scharrer, E.</span><span> </span><span class="NLM_article-title">The Area Postrema as a Major Target for Peptides Controlling Food Intake</span>;  <span class="citation_source-book">Abstracts</span>; <span class="NLM_publisher-name">New Orleans: Society for Neuroscience</span>: <span class="NLM_publisher-loc">Washington, DC</span>;<span class="NLM_x"> </span><span class="NLM_year">2000</span><span class="NLM_x">, </span>pp  <span class="NLM_fpage">369.310</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=369.310&author=T.+Riediger&author=T.+A.+Lutz&author=H.+A.+Schmid&author=E.+Scharrer&title=Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRiediger%26aufirst%3DT.%26atitle%3DThe%2520Area%2520Postrema%2520as%2520a%2520Major%2520Target%2520for%2520Peptides%2520Controlling%2520Food%2520Intake%26btitle%3DAbstracts%26pub%3DNew%2520Orleans%253A%2520Society%2520for%2520Neuroscience%26date%3D2000%26spage%3D369.310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Hargrove, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lwin, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herich, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedulin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jodka, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCowen, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. M.</span><span> </span><span class="NLM_article-title">Biological activity of AC3174, a peptide analog of exendin-4</span> <span class="citation_source-journal">Regul. Pept.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2Fj.regpep.2006.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1Kqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2007&pages=113-119&author=D.+M.+Hargroveauthor=E.+S.+Kendallauthor=J.+M.+Reynoldsauthor=A.+N.+Lwinauthor=J.+P.+Herichauthor=P.+A.+Smithauthor=B.+R.+Gedulinauthor=S.+D.+Flanaganauthor=C.+M.+Jodkaauthor=J.+A.+Hoytauthor=K.+M.+McCowenauthor=D.+G.+Parkesauthor=C.+M.+Anderson&title=Biological+activity+of+AC3174%2C+a+peptide+analog+of+exendin-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Biological activity of AC3174, a peptide analog of exendin-4</span></div><div class="casAuthors">Hargrove, Diane M.; Kendall, Eric S.; Reynolds, James M.; Lwin, Aung N.; Herich, John P.; Smith, Pamela A.; Gedulin, Bronislava R.; Flanagan, Shawn D.; Jodka, Carolyn M.; Hoyt, Julie A.; McCowen, Kevin M.; Parkes, David G.; Anderson, Christen M.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">113-119</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Exenatide, the active ingredient of BYETTA (exenatide injection), is an incretin mimetic that has been developed for the treatment of patients with type 2 diabetes.  Exenatide binds to and activates the known GLP-1 receptor with a potency comparable to that of the mammalian incretin GLP-1(7-36), thereby acting as a glucoregulatory agent.  AC 3174 is an analog of exenatide with leucine substituted for methionine at position 14, [Leu14]exendin-4.  The purpose of these studies was to evaluate the glucoregulatory activity and pharmacokinetics of AC 3174.  In RINm5f cell membranes, the potency of AC 3174 for the displacement of [125I]GLP-1 and activation of adenylate cyclase was similar to that of exenatide and GLP-1.  In vivo, AC 3174, administered as a single i.p. injection, significantly decreased plasma glucose concn. and glucose excursion following the administration of an oral glucose challenge in both non-diabetic (C57BL/6) and diabetic db/db mice.  The magnitude of glucose lowering of AC 3174 was comparable to exenatide.  The ED50 values of AC 3174 for glucose lowering (60 min post-dose) were 1.2 μg/kg in db/db mice and 1.3 μg/kg in C57BL/6 mice.  AC 3174 has insulinotropic activity in vivo.  Administration of AC 3174 resulted in a 4-fold increase in insulin concns. in normal mice following an i.p. glucose challenge.  AC 3174 was also shown to inhibit food intake and decrease gastric emptying in rodent models.  AC 3174 was stable in human plasma (>90% of parent peptide was present after 5 h of incubation).  In rats, the in vivo half-life of AC 3174 was 42-43 min following s.c. administration.  In summary, AC 3174 is an analog of exenatide that binds to the GLP-1 receptor in vitro and shares many of the biol. and glucoregulatory activities of exenatide and GLP-1 in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNG3k4BU7axLVg90H21EOLACvtfcHk0liO4v-0a3hprg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1Kqsro%253D&md5=5cc26bf4188689814949a4881f3770f3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.regpep.2006.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.regpep.2006.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DHargrove%26aufirst%3DD.%2BM.%26aulast%3DKendall%26aufirst%3DE.%2BS.%26aulast%3DReynolds%26aufirst%3DJ.%2BM.%26aulast%3DLwin%26aufirst%3DA.%2BN.%26aulast%3DHerich%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%2BA.%26aulast%3DGedulin%26aufirst%3DB.%2BR.%26aulast%3DFlanagan%26aufirst%3DS.%2BD.%26aulast%3DJodka%26aufirst%3DC.%2BM.%26aulast%3DHoyt%26aufirst%3DJ.%2BA.%26aulast%3DMcCowen%26aufirst%3DK.%2BM.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DAnderson%26aufirst%3DC.%2BM.%26atitle%3DBiological%2520activity%2520of%2520AC3174%252C%2520a%2520peptide%2520analog%2520of%2520exendin-4%26jtitle%3DRegul.%2520Pept.%26date%3D2007%26volume%3D141%26spage%3D113%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broyde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats</span> <span class="citation_source-journal">Cardiovasc. Diabetol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1186%2F1475-2840-9-32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A280%3ADC%252BC3cjltV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=32&author=Q.+Liuauthor=L.+Adamsauthor=A.+Broydeauthor=R.+Fernandezauthor=A.+D.+Baronauthor=D.+G.+Parkes&title=The+exenatide+analogue+AC3174+attenuates+hypertension%2C+insulin+resistance%2C+and+renal+dysfunction+in+Dahl+salt-sensitive+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats</span></div><div class="casAuthors">Liu Que; Adams Lisa; Broyde Anatoly; Fernandez Rayne; Baron Alain D; Parkes David G</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular diabetology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Activation of glucagon-like peptide-1 (GLP-1) receptors improves insulin sensitivity and induces vasodilatation and diuresis.  AC3174 is a peptide analogue with pharmacologic properties similar to the GLP-1 receptor agonist, exenatide.  Hypothetically, chronic AC3174 treatment could attenuate salt-induced hypertension, cardiac morbidity, insulin resistance, and renal dysfunction in Dahl salt-sensitive (DSS) rats.  METHODS:  DSS rats were fed low salt (LS, 0.3% NaCl) or high salt (HS, 8% NaCl) diets.  HS rats were treated with vehicle, AC3174 (1.7 pmol/kg/min), or GLP-1 (25 pmol/kg/min) for 4 weeks via subcutaneous infusion.  Other HS rats received captopril (150 mg/kg/day) or AC3174 plus captopril.  RESULTS:  HS rat survival was improved by all treatments except GLP-1.  Systolic blood pressure (SBP) was lower in LS rats and in GLP-1, AC3174, captopril, or AC3174 plus captopril HS rats than in vehicle HS rats (p < 0.05).  AC3174 plus captopril attenuated the deleterious effects of high salt on posterior wall thickness, LV mass, and the ratio of LV mass to body weight (P < or = 0.05).  In contrast, GLP-1 had no effect on these cardiovascular parameters.  All treatments reduced LV wall stress.  GLP-1, AC3174, captopril, or AC3174 plus captopril normalized fasting insulin and HOMA-IR (P < or = 0.05).  AC3174, captopril, or AC3174 plus captopril improved renal function (P < or = 0.05).  Renal morphology in HS rats was associated with extensive sclerosis.  Monotherapy with AC3174, captopril, or GLP-1 attenuated renal damage.  However, AC3174 plus captopril produced the most effective improvement.  CONCLUSIONS:  Thus, AC3174 had antihypertensive, cardioprotective, insulin-sensitizing, and renoprotective effects in the DSS hypertensive rat model.  Furthermore, AC3174 improved animal survival, an effect not observed with GLP-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSh3L1gBSfSRkGy1nwu7K2mfW6udTcc2ea-svH54C8K5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjltV2rsw%253D%253D&md5=eddd218bd506005f16b9ba5ac7ed9723</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F1475-2840-9-32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2840-9-32%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DAdams%26aufirst%3DL.%26aulast%3DBroyde%26aufirst%3DA.%26aulast%3DFernandez%26aufirst%3DR.%26aulast%3DBaron%26aufirst%3DA.%2BD.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3DThe%2520exenatide%2520analogue%2520AC3174%2520attenuates%2520hypertension%252C%2520insulin%2520resistance%252C%2520and%2520renal%2520dysfunction%2520in%2520Dahl%2520salt-sensitive%2520rats%26jtitle%3DCardiovasc.%2520Diabetol.%26date%3D2010%26volume%3D9%26spage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broyde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polizzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure</span> <span class="citation_source-journal">Cardiovasc. Diabetol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1186%2F1475-2840-9-76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252Fhtl2ksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=76&author=Q.+Liuauthor=C.+Andersonauthor=A.+Broydeauthor=C.+Polizziauthor=R.+Fernandezauthor=A.+Baronauthor=D.+G.+Parkes&title=Glucagon-like+peptide-1+and+the+exenatide+analogue+AC3174+improve+cardiac+function%2C+cardiac+remodeling%2C+and+survival+in+rats+with+chronic+heart+failure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure</span></div><div class="casAuthors">Liu Que; Anderson Christen; Broyde Anatoly; Polizzi Clara; Fernandez Rayne; Baron Alain; Parkes David G</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular diabetology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Accumulating evidence suggests glucagon-like peptide-1 (GLP-1) exerts cardioprotective effects in animal models of myocardial infarction (MI).  We hypothesized that chronic treatment with GLP-1 or the exenatide analog AC3174 would improve cardiac function, cardiac remodeling, insulin sensitivity, and exercise capacity (EC) in rats with MI-induced chronic heart failure (CHF) caused by coronary artery ligation.  METHODS:  Two weeks post-MI, male Sprague-Dawley rats were treated with GLP-1 (2.5 or 25 pmol/kg/min), AC3174 (1.7 or 5 pmol/kg/min) or vehicle via subcutaneous infusion for 11 weeks.  Cardiac function and morphology were assessed by echocardiography during treatment.  Metabolic, hemodynamic, exercise-capacity, and body composition measurements were made at study end.  RESULTS:  Compared with vehicle-treated rats with CHF, GLP-1 or AC3174 significantly improved cardiac function, including left ventricular (LV) ejection fraction, and end diastolic pressure.  Cardiac dimensions also improved as evidenced by reduced LV end diastolic and systolic volumes and reduced left atrial volume.  Vehicle-treated CHF rats exhibited fasting hyperglycemia and hyperinsulinemia.  In contrast, GLP-1 or AC3174 normalized fasting plasma insulin and glucose levels.  GLP-1 or AC3174 also significantly reduced body fat and fluid mass and improved exercise capacity and respiratory efficiency.  Four of 16 vehicle control CHF rats died during the study compared with 1 of 44 rats treated with GLP-1 or AC3174.  The cellular mechanism by which GLP-1 or AC3174 exert cardioprotective effects appears unrelated to changes in GLUT1 or GLUT4 translocation or expression.  CONCLUSIONS:  Chronic treatment with either GLP-1 or AC3174 showed promising cardioprotective effects in a rat model of CHF.  Hence, GLP-1 receptor agonists may represent a novel approach for the treatment of patients with CHF or cardiovascular disease associated with type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWFW2DXHgIRdXdcedVHT5tfW6udTcc2ea-svH54C8K5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252Fhtl2ksg%253D%253D&md5=6171b45c408d0c6cc41598551619d13b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2F1475-2840-9-76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1475-2840-9-76%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DAnderson%26aufirst%3DC.%26aulast%3DBroyde%26aufirst%3DA.%26aulast%3DPolizzi%26aufirst%3DC.%26aulast%3DFernandez%26aufirst%3DR.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3DGlucagon-like%2520peptide-1%2520and%2520the%2520exenatide%2520analogue%2520AC3174%2520improve%2520cardiac%2520function%252C%2520cardiac%2520remodeling%252C%2520and%2520survival%2520in%2520rats%2520with%2520chronic%2520heart%2520failure%26jtitle%3DCardiovasc.%2520Diabetol.%26date%3D2010%26volume%3D9%26spage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Lopez de Maturana, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willshaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntzsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, D.</span><span> </span><span class="NLM_article-title">The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">10195</span><span class="NLM_x">–</span> <span class="NLM_lpage">10200</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=10195-10200&author=R.+Lopez+de+Maturanaauthor=A.+Willshawauthor=A.+Kuntzschauthor=R.+Rudolphauthor=D.+Donnelly&title=The+isolated+N-terminal+domain+of+the+glucagon-like+peptide-1+%28GLP-1%29+receptor+binds+exendin+peptides+with+much+higher+affinity+than+GLP-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%2Bde%2BMaturana%26aufirst%3DR.%26aulast%3DWillshaw%26aufirst%3DA.%26aulast%3DKuntzsch%26aufirst%3DA.%26aulast%3DRudolph%26aufirst%3DR.%26aulast%3DDonnelly%26aufirst%3DD.%26atitle%3DThe%2520isolated%2520N-terminal%2520domain%2520of%2520the%2520glucagon-like%2520peptide-1%2520%2528GLP-1%2529%2520receptor%2520binds%2520exendin%2520peptides%2520with%2520much%2520higher%2520affinity%2520than%2520GLP-1%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D10195%26epage%3D10200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Westermark, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westermark, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betsholtz, C.</span><span> </span><span class="NLM_article-title">Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">5036</span><span class="NLM_x">–</span> <span class="NLM_lpage">5040</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1073%2Fpnas.87.13.5036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=2195544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK3cXkslWnsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=5036-5040&author=P.+Westermarkauthor=U.+Engstromauthor=K.+H.+Johnsonauthor=G.+T.+Westermarkauthor=C.+Betsholtz&title=Islet+amyloid+polypeptide%3A+pinpointing+amino+acid+residues+linked+to+amyloid+fibril+formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Islet amyloid polypeptide:  pinpointing amino acid residues linked to amyloid fibril formation</span></div><div class="casAuthors">Westermark, Per; Engstroem, Ulla; Johnson, Kenneth H.; Westermark, Gunilla T.; Betsholtz, Christer</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5036-40</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Islet amyloid polypeptide (IAPP), a putative polypeptide hormone, is a product of pancreatic β-cells and the major constituent of the amyloid deposits seen mainly in islets of type 2 diabetic humans and diabetic cats.  The connection between IAPP amyloid formation and diabetes is unknown, but a limited segment of the IAPP mol., positions 20-29, seems responsible for the aggregation to fibrils.  Differences in the amino acid sequence of this region probably det. whether or not islet amyloid can develop in a particular species.  Amyloid fibril formation can be mimicked in vitro with the aid of synthetic peptides.  Thus, peptides corresponding to IAPP positions 20-29 of human and cat, species that develop IAPP-derived islet amyloid, form amyloid-like fibrils in vitro.  The corresponding IAPP segment from three rodent species that do not develop IAPP-derived amyloid did not give rise to fibrils.  Substitution of the human IAPP-(20-29) decapeptide with one or two amino acid residues from species without islet amyloid generally reduced the capacity to form fibrils.  The sequence Ala-Ile-Leu-Ser-Ser, corresponding to positions 25-29 of human IAPP, is strongly amyloidogenic.  A proline-for-serine substitution is position 28, as in several rodents, almost completely inhibits formation of amyloid fibrils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolCo5Arch1sLVg90H21EOLACvtfcHk0liV5L_qADF74Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkslWnsL0%253D&md5=bdde90227d7efb3fe6cb5e9a94dc0f66</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.13.5036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.13.5036%26sid%3Dliteratum%253Aachs%26aulast%3DWestermark%26aufirst%3DP.%26aulast%3DEngstrom%26aufirst%3DU.%26aulast%3DJohnson%26aufirst%3DK.%2BH.%26aulast%3DWestermark%26aufirst%3DG.%2BT.%26aulast%3DBetsholtz%26aufirst%3DC.%26atitle%3DIslet%2520amyloid%2520polypeptide%253A%2520pinpointing%2520amino%2520acid%2520residues%2520linked%2520to%2520amyloid%2520fibril%2520formation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1990%26volume%3D87%26spage%3D5036%26epage%3D5040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Roberts, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockburn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schofield, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foot, E. A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">9662</span><span class="NLM_x">–</span> <span class="NLM_lpage">9666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1073%2Fpnas.86.24.9662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=2690069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK3cXls12ksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1989&pages=9662-9666&author=A.+N.+Robertsauthor=B.+Leightonauthor=J.+A.+Toddauthor=D.+Cockburnauthor=P.+N.+Schofieldauthor=R.+Suttonauthor=S.+Holtauthor=Y.+Boydauthor=A.+J.+Dayauthor=E.+A.+Foot&title=Molecular+and+functional+characterization+of+amylin%2C+a+peptide+associated+with+type+2+diabetes+mellitus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus</span></div><div class="casAuthors">Roberts, A. N.; Leighton, B.; Todd, J. A.; Cockburn, D.; Schofield, P. N.; Sutton, R.; Holt, S.; Boyd, Y.; Day, A. J.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9662-6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The 37-amino acid peptide called amylin is a major component of the islet amyloid deposited in the pancreases of persons with type 2 diabetes mellitus.  The isolation of a partial cDNA clone and a phage λ genomic clone of the coding region of the amylin gene is reported.  The DNA sequence encodes a protein sequence identical to that of amylin isolated from the amyloid found in the diabetic pancreas; amylin is likely to be synthesized as a precursor peptide, now named proamylin.  The amylin gene was demonstrated to be present on chromosome 12, and it is probably transcribed in the islets of Langerhans.  The sequences of the genes for amylin and the calcitonin gene-related peptides (CGRPs) show strong similarity, esp. over their 5' coding regions, where both peptides have a conserved intramol. SS bridge, and also over their 3' coding regions, where the presence of a glycine codon strongly suggests that the carboxyl-terminal residue of amylin, like that of CGRP, is amidated.  To examine the functional relevance of these posttranslational modifications, the biol. activity of amylin synthesized with or without the SS bridge and/or amidation was measured.  Both features were necessary for full biol. activity, thereby confirming the functional importance of those regions of the mol. whose sequences are conserved at both the protein and genetic levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofk2TFc0dVV7Vg90H21EOLACvtfcHk0liV5L_qADF74Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls12ksL4%253D&md5=42233943d47c9460f4f0cbcaccbd77b5</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1073%2Fpnas.86.24.9662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.86.24.9662%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DA.%2BN.%26aulast%3DLeighton%26aufirst%3DB.%26aulast%3DTodd%26aufirst%3DJ.%2BA.%26aulast%3DCockburn%26aufirst%3DD.%26aulast%3DSchofield%26aufirst%3DP.%2BN.%26aulast%3DSutton%26aufirst%3DR.%26aulast%3DHolt%26aufirst%3DS.%26aulast%3DBoyd%26aufirst%3DY.%26aulast%3DDay%26aufirst%3DA.%2BJ.%26aulast%3DFoot%26aufirst%3DE.%2BA.%26atitle%3DMolecular%2520and%2520functional%2520characterization%2520of%2520amylin%252C%2520a%2520peptide%2520associated%2520with%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1989%26volume%3D86%26spage%3D9662%26epage%3D9666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Roth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soares, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, D. G.</span><span> </span><span class="NLM_article-title">Amylin-based pharmacotherapy - past, present & future</span> <span class="citation_source-journal">Immunol., Endocr. Metab. Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.2174%2F187152208787169189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFCqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=317-324&author=J.+D.+Rothauthor=C.+M.+Mackauthor=C.+J.+Soaresauthor=S.+S.+Ghoshauthor=D.+G.+Parkes&title=Amylin-based+pharmacotherapy+-+past%2C+present+%26+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Amylin-based pharmacotherapy - past, present & future</span></div><div class="casAuthors">Roth, Jonathan D.; Mack, Christine M.; Soares, Christopher J.; Ghosh, Soumitra S.; Parkes, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-324</span>CODEN:
                <span class="NLM_cas:coden">IEMACA</span>;
        ISSN:<span class="NLM_cas:issn">1871-5222</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  We briefly summarize evidence from non-clin. and clin. studies that amylin agonism has a physiol. role in glucose and body wt. regulation.  Next, the amylin analog Pramlintide is highlighted as part of an integrated neurohormonal therapeutic approach in both diabetes and wt. management.  Finally, attributes of, and analoging strategies to, the amylin mol. are discussed with the goal of improving targeted properties leading to the development of an optimized therapeutic candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBaiPlpYK3e7Vg90H21EOLACvtfcHk0lgcigAWsyYwng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFCqsLg%253D&md5=185188f2385352571403133fcd6cf1dd</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F187152208787169189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152208787169189%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26aulast%3DMack%26aufirst%3DC.%2BM.%26aulast%3DSoares%26aufirst%3DC.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%2BS.%26aulast%3DParkes%26aufirst%3DD.%2BG.%26atitle%3DAmylin-based%2520pharmacotherapy%2520-%2520past%252C%2520present%2520%2526%2520future%26jtitle%3DImmunol.%252C%2520Endocr.%2520Metab.%2520Agents%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D317%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Caliceti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, F. M.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates</span> <span class="citation_source-journal">Adv. Drug. Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">–</span> <span class="NLM_lpage">1277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2FS0169-409X%2803%2900108-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=14499706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1yqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2003&pages=1261-1277&author=P.+Calicetiauthor=F.+M.+Veronese&title=Pharmacokinetic+and+biodistribution+properties+of+poly%28ethylene+glycol%29-protein+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates</span></div><div class="casAuthors">Caliceti, Paolo; Veronese, Francesco M.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1261-1277</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Peptide and protein PEGylation is usually undertaken to improve the biopharmaceutical properties of these drugs and, to date, several examples of conjugates with long permanence in the body as well as with localization ability in disease sites were reported.  Although a no. of studies on the in vivo behavior and fate of conjugates were performed, forecasting their pharmacokinetics is a difficult task since the pharmacokinetic profile is detd. by a no. of parameters which include physiol. and anatomical aspects of the recipient and physico-chem. properties of the deriv.  The most relevant perturbations of the protein mol. following PEG conjugation are: size enlargement, protein surface and glycosylation function masking, charge modification, and epitope shielding.  In particular, size enlargement slows down kidney ultrafiltration and promotes the accumulation into permeable tissues by the passive enhanced permeation and retention mechanism.  Charge and glycosylation function masking is revealed predominantly in reduced phagocytosis by the RES and liver cells.  Protein shielding reduces proteolysis and immune system recognition, which are important routes of elimination.  The specific effect of PEGylation on protein physico-chem. and biol. properties is strictly detd. by protein and polymer properties as well as by the adopted PEGylation strategy.  Relevant parameters to be considered in protein-polymer conjugates are: protein structure, mol. wt. and compn., polymer mol. wt. and shape, no. of linked polymer chains and conjugation chem.  The examples reported in this review show that general considerations could be useful in developing a target product, although significant deviations from the expected results can not be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUnGBuleSog7Vg90H21EOLACvtfcHk0lgcigAWsyYwng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1yqsb0%253D&md5=d26bf5b68a7aa9d1f4f0d10feb3e9593</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2803%2900108-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252803%252900108-X%26sid%3Dliteratum%253Aachs%26aulast%3DCaliceti%26aufirst%3DP.%26aulast%3DVeronese%26aufirst%3DF.%2BM.%26atitle%3DPharmacokinetic%2520and%2520biodistribution%2520properties%2520of%2520poly%2528ethylene%2520glycol%2529-protein%2520conjugates%26jtitle%3DAdv.%2520Drug.%2520Delivery%2520Rev.%26date%3D2003%26volume%3D55%26spage%3D1261%26epage%3D1277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Fee, C. J.</span><span> </span><span class="NLM_article-title">Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules</span> <span class="citation_source-journal">Biotechnol. Bioeng.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">731</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1002%2Fbit.21482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=17461424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1WntrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2007&pages=725-731&author=C.+J.+Fee&title=Size+comparison+between+proteins+PEGylated+with+branched+and+linear+poly%28ethylene+glycol%29+molecules"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules</span></div><div class="casAuthors">Fee, Conan J.</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology and Bioengineering</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">725-731</span>CODEN:
                <span class="NLM_cas:coden">BIBIAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3592</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Therapeutic proteins conjugated with branched poly(ethylene glycol) (PEG) have extended in vivo circulation half-lives compared to linear PEG-proteins, thought to be due partly to a greater hydrodynamic vol. of branched PEG-proteins, which reduces the glomerular sieving coeff.  In this paper, viscosity radii of PEGylated α-lactalbumin (Mr = 14.2 kDa) and bovine serum albumin (Mr = 67 kDa) prepd. with linear and branched PEGs (with nominal mol. wts. 5, 10, 20 and 40 kDa) were compared exptl. using size exclusion chromatog. (SEC).  PEG adduct:protein mol. wt. ratios of the PEGylated proteins covered the range 1:12 to 6:1.  Direct comparisons of exptl. measured viscosity radii were found to be misleading due to differences between actual and nominal mol. wts. of the PEG reagents used.  Comparison with predicted viscosity radii shows that there is no significant difference between the viscosity radii of branched and linear PEG-proteins having the same total mol. wt. of PEG adducts.  Therefore, longer in vivo circulation half-lives of branched PEG-proteins compared to linear PEG-proteins are not explained by size difference.  It is also calcd. that the mol. size cut-off for glomerular filtration, 60 Å for a 30 kDa PEG, matches the 30-50 Å size range for the pores of the glomerular basement membrane.  Finally, it is confirmed that prediction of PEG-protein viscosity radii should be based upon conservation of the total PEG adduct surface area to vol. ratio for both linear and branched PEG-proteins regardless of PEGylation extent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogxSksulLTmLVg90H21EOLACvtfcHk0lgcigAWsyYwng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1WntrnN&md5=7b2c65d12b11caeae6766175534aedb5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fbit.21482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbit.21482%26sid%3Dliteratum%253Aachs%26aulast%3DFee%26aufirst%3DC.%2BJ.%26atitle%3DSize%2520comparison%2520between%2520proteins%2520PEGylated%2520with%2520branched%2520and%2520linear%2520poly%2528ethylene%2520glycol%2529%2520molecules%26jtitle%3DBiotechnol.%2520Bioeng.%26date%3D2007%26volume%3D98%26spage%3D725%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Fee, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Alstine, J. M.</span><span> </span><span class="NLM_article-title">Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1304</span><span class="NLM_x">–</span> <span class="NLM_lpage">1313</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049843w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptVyrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=1304-1313&author=C.+J.+Feeauthor=J.+M.+Van+Alstine&title=Prediction+of+the+viscosity+radius+and+the+size+exclusion+chromatography+behavior+of+PEGylated+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of the Viscosity Radius and the Size Exclusion Chromatography Behavior of PEGylated Proteins</span></div><div class="casAuthors">Fee, Conan J.; Van Alstine, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1304-1313</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Size exclusion chromatog. (SEC) was used to det. the viscosity radii of equiv. spheres for proteins covalently grafted with poly(ethylene glycol) (PEG).  The viscosity radius of such PEGylated proteins was found to depend on the mol. wt. of the native protein and the total wt. of grafted PEG but not on PEG mol. wt., or PEG-to-protein molar grafting ratio.  Results suggest grafted PEG's form a dynamic layer over the surface of proteins.  The geometry of this layer results in a surface area-to-vol. ratio approx. equal to that of a randomly coiled PEG mol. of equiv. total mol. wt.  Two simple methods are given to predict the viscosity radius of PEGylated proteins.  Both methods accurately predicted (3% abs. error) the viscosity radii of various PEG-proteins produced using three native proteins, α-lactalbumin (14.2 kDa MW), β-lactoglobulin dimer (37.4 kDa MW), and bovine serum albumin (66.7 kDa MW), three PEG reagents (2400, 5600, and 22500 MW), and molar grafting ratios of 0 to 8.  Accurate viscosity radius prediction allows calcn. of the distribution coeff., Kav, for PEG-proteins in SEC.  The suitability of a given SEC step for the anal. or preparative fractionation of different PEGylated protein mixts. may therefore be assessed math.  The methods and results offer insight to several factors related to the prodn., purifn., and uses of PEGylated proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3SWkNNnDioLVg90H21EOLACvtfcHk0liKUlLQLkblnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptVyrtLo%253D&md5=a6c55e97ec1af032a6d885e0c3144627</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fbc049843w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049843w%26sid%3Dliteratum%253Aachs%26aulast%3DFee%26aufirst%3DC.%2BJ.%26aulast%3DVan%2BAlstine%26aufirst%3DJ.%2BM.%26atitle%3DPrediction%2520of%2520the%2520viscosity%2520radius%2520and%2520the%2520size%2520exclusion%2520chromatography%2520behavior%2520of%2520PEGylated%2520proteins%26jtitle%3DBioconjugate%2520Chem.%26date%3D2004%26volume%3D15%26spage%3D1304%26epage%3D1313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Nakaoka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaoka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikada, Y.</span><span> </span><span class="NLM_article-title">Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1997&pages=253-261&author=R.+Nakaokaauthor=Y.+Tabataauthor=T.+Yamaokaauthor=Y.+Ikada&title=Prolongation+of+the+serum+half-life+period+of+superoxide+dismutase+by+poly%28ethylene+glycol%29+modification"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakaoka%26aufirst%3DR.%26aulast%3DTabata%26aufirst%3DY.%26aulast%3DYamaoka%26aufirst%3DT.%26aulast%3DIkada%26aufirst%3DY.%26atitle%3DProlongation%2520of%2520the%2520serum%2520half-life%2520period%2520of%2520superoxide%2520dismutase%2520by%2520poly%2528ethylene%2520glycol%2529%2520modification%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D1997%26volume%3D46%26spage%3D253%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Kochendoerfer, G.</span><span> </span><span class="NLM_article-title">Chemical and biological properties of polymer-modified proteins</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1253</span><span class="NLM_x">–</span> <span class="NLM_lpage">1261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1517%2F14712598.3.8.1253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=14640951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlels7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=1253-1261&author=G.+Kochendoerfer&title=Chemical+and+biological+properties+of+polymer-modified+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical and biological properties of polymer-modified proteins</span></div><div class="casAuthors">Kochendoerfer, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1253-1261</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review and discussion.  Modification with polymers such as polyethylene glycol (PEG) can increase circulating lifetime, reduce immunogenicity and simplify the handling of pharmaceutical proteins.  These benefits are currently exploited in six marketed polymer-modified protein therapeutics and about a dozen product candidates in clin. trials.  However, traditional protein modification techniques are restricted by the limited control over polymer structure and the location and no. of polymer attachment sites.  New technol., in the form of chem. protein synthesis and the generation of precision polymers, has been applied to generate synthetic erythropoiesis protein.  This promising treatment for anemia has been synthesized with precision polymer modification methodol. to improve the target protein pharmaceutical.  The chem. and biol. properties of proteins prepd. by both traditional and novel approaches are contrasted in this discussion of chem. protein synthesis and polymer modification in protein drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM2eta3Q4x2rVg90H21EOLACvtfcHk0liXzX9ozUQvrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlels7Y%253D&md5=561a76e21906688a901909652e9db12c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1517%2F14712598.3.8.1253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.3.8.1253%26sid%3Dliteratum%253Aachs%26aulast%3DKochendoerfer%26aufirst%3DG.%26atitle%3DChemical%2520and%2520biological%2520properties%2520of%2520polymer-modified%2520proteins%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2003%26volume%3D3%26spage%3D1253%26epage%3D1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Ryan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantovani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddleton, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brayden, D. J.</span><span> </span><span class="NLM_article-title">Advances in PEGylation of important biotech molecules: delivery aspects</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1517%2F17425247.5.4.371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=18426380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFajsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=371-383&author=S.+M.+Ryanauthor=G.+Mantovaniauthor=X.+Wangauthor=D.+M.+Haddletonauthor=D.+J.+Brayden&title=Advances+in+PEGylation+of+important+biotech+molecules%3A+delivery+aspects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in PEGylation of important biotech molecules: delivery aspects</span></div><div class="casAuthors">Ryan, Sinead M.; Mantovani, Giuseppe; Wang, Xuexuan; Haddleton, David M.; Brayden, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Delivery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-383</span>CODEN:
                <span class="NLM_cas:coden">EODDAW</span>;
        ISSN:<span class="NLM_cas:issn">1742-5247</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Although various injected peptide and protein therapeutics have been developed successfully over the past 25 years, several pharmacokinetic and immunol. challenges are still encountered that can limit the efficacy of both novel and established biotech mols.  PEGylation is a popular technique to address such properties.  PEGylated drugs exhibit prolonged half-life, higher stability, water soly., lower immunogenicity and antigenicity, as well as potential for specific cell targeting.  Although PEGylated drug conjugates have been on the market for many years, the technol. has steadily developed in respect of site-specific chem., chain length, mol. wts. and purity of conjugate.  These developments have occurred in parallel to improvements in physicochem. methods of characterization.  This review will discuss recent achievements in PEGylation processes with an emphasis on novel PEG-drugs constructs, the unrealized potential of PEGylation for non-injected routes of delivery, and also on PEGylated versions of polymeric nanoparticles, including dendrimers and liposomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOmtIPVBXgwrVg90H21EOLACvtfcHk0liXzX9ozUQvrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFajsrs%253D&md5=76ab582c4c0b501df850542ead6bda3d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1517%2F17425247.5.4.371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425247.5.4.371%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DS.%2BM.%26aulast%3DMantovani%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHaddleton%26aufirst%3DD.%2BM.%26aulast%3DBrayden%26aufirst%3DD.%2BJ.%26atitle%3DAdvances%2520in%2520PEGylation%2520of%2520important%2520biotech%2520molecules%253A%2520delivery%2520aspects%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2008%26volume%3D5%26spage%3D371%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Fishburn, C. S.</span><span> </span><span class="NLM_article-title">The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">4167</span><span class="NLM_x">–</span> <span class="NLM_lpage">4183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1002%2Fjps.21278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=18200508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sgt7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2008&pages=4167-4183&author=C.+S.+Fishburn&title=The+pharmacology+of+PEGylation%3A+balancing+PD+with+PK+to+generate+novel+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics</span></div><div class="casAuthors">Fishburn, C. Simone</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4167-4183</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Conjugation of macromols. to polyethylene glycol (PEG) has emerged recently as an effective strategy to alter the pharmacokinetic (PK) profiles of a variety of drugs, and thereby to improve their therapeutic potential.  PEG conjugation increases retention of drugs in the circulation by protecting against enzymic digestion, slowing filtration by the kidneys and reducing the generation of neutralizing antibodies.  Often, PEGylation leads to a loss in binding affinity due to steric interference with the drug-target binding interaction.  This loss in potency is offset by the longer circulating half-life of the drugs, and the resulting change in PK-PD profile has led in some cases to enabling of drugs that otherwise could not be developed, and in others to improvements in existing drugs.  Thus, whereas most approaches to drug development seek to increase the activity of drugs directly, the creation of PEGylated drugs seeks to balance the pharmacodynamic (PD) and pharmacokinetic properties to produce novel therapies that will meet with both increased efficacy and greater compliance in the clin. setting.  This review examines some of the PEGylated drugs developed in recent years, and highlights some of the different strategies taken to employ PEG to maximize the overall PK-PD profiles of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC7WViWdoJF7Vg90H21EOLACvtfcHk0lhgYFxKGKCcIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sgt7rI&md5=d5e71d245c490eb575d9eda654badd45</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fjps.21278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21278%26sid%3Dliteratum%253Aachs%26aulast%3DFishburn%26aufirst%3DC.%2BS.%26atitle%3DThe%2520pharmacology%2520of%2520PEGylation%253A%2520balancing%2520PD%2520with%2520PK%2520to%2520generate%2520novel%2520therapeutics%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D97%26spage%3D4167%26epage%3D4183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Bailon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, C. Y.</span><span> </span><span class="NLM_article-title">PEG-modified biopharmaceuticals</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1517%2F17425240802650568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=19236204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktVahsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=1-16&author=P.+Bailonauthor=C.+Y.+Won&title=PEG-modified+biopharmaceuticals"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">PEG-modified biopharmaceuticals</span></div><div class="casAuthors">Bailon, Pascal; Won, Chee-Youb</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Delivery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-16</span>CODEN:
                <span class="NLM_cas:coden">EODDAW</span>;
        ISSN:<span class="NLM_cas:issn">1742-5247</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  PEGylation is a process in which one or more units of chem. activated polyethylene glycol reacts with a biomol., usually a protein, peptide, small mol. or oligonucleotide, creating a putative new mol. entity possessing physicochem. and physiol. characteristics that are distinct from its predecessor mols.  In recent years, PEGylation has been used not only as a drug delivery technol. but used also as a drug modification technol. to transform existing biopharmaceuticals clin. more efficacious than before their PEGylation.  PEGylation bestows several useful properties upon the native mol., resulting in improved pharmacokinetic and pharmacodynamic properties, which in turn enable the native mol. to achieve max. clin. potency.  In addn., PEGylation results in sustained clin. response with minimal dose and less frequency of dosing, leading to improved quality of life via increased patient compliance and reduced cost.  During the course of development of various pegylated protein therapeutics, several new insights have been gained.  This review article focuses on the approaches, strategies and the utilization of modern PEGylation concepts in the design and development of well-characterized pegylated protein therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf5II9oQ0hJLVg90H21EOLACvtfcHk0lhgYFxKGKCcIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktVahsw%253D%253D&md5=acb7ff4e9a7e77a6135f47be428a46bf</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1517%2F17425240802650568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425240802650568%26sid%3Dliteratum%253Aachs%26aulast%3DBailon%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DC.%2BY.%26atitle%3DPEG-modified%2520biopharmaceuticals%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2009%26volume%3D6%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Kang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deluca, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. C.</span><span> </span><span class="NLM_article-title">Emerging PEGylated drugs</span> <span class="citation_source-journal">Expert Opin. Emerg. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">–</span> <span class="NLM_lpage">380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1517%2F14728210902907847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=19453284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1Siu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=363-380&author=J.+S.+Kangauthor=P.+P.+Delucaauthor=K.+C.+Lee&title=Emerging+PEGylated+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging PEGylated drugs</span></div><div class="casAuthors">Kang, Jung Seok; De Luca, Patrick P.; Lee, Kang Choon</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">363-380</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  PEGylation is a pharmaceutical technol. that involves the covalent attachment of polyethylene glycol (PEG) to a drug to improve its pharmacokinetic, pharmacodynamic, and immunol. profiles, and thus, enhance its therapeutic effect.  Currently, PEGylation is used to modify proteins, peptides, oligonucleotides, antibody fragments, and small org. mols.  Research groups are striving to improve the consistencies of PEGylated drugs and to PEGylate commercialized proteins and small org. mols.  Furthermore, the PEGylations of novel medications, like oligonucleotides and antibody fragments, are being pursued to improve their bioavailabilities.  This active research in the PEGylation field and the continued growth of the biopharmaceutical market predicts that PEGylated drugs have a bright future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFgW3aHbmjMrVg90H21EOLACvtfcHk0lhgYFxKGKCcIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1Siu7c%253D&md5=2e7546517bbc9f2c5c48cefdfbc5c999</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1517%2F14728210902907847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728210902907847%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DDeluca%26aufirst%3DP.%2BP.%26aulast%3DLee%26aufirst%3DK.%2BC.%26atitle%3DEmerging%2520PEGylated%2520drugs%26jtitle%3DExpert%2520Opin.%2520Emerg.%2520Drugs%26date%3D2009%26volume%3D14%26spage%3D363%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Jevsevar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunstelj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porekar, V. G.</span><span> </span><span class="NLM_article-title">PEGylation of therapeutic proteins</span> <span class="citation_source-journal">Biotechnol J</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">128</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1002%2Fbiot.200900218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=20069580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVSlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=113-128&author=S.+Jevsevarauthor=M.+Kunsteljauthor=V.+G.+Porekar&title=PEGylation+of+therapeutic+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylation of therapeutic proteins</span></div><div class="casAuthors">Jevsevar, Simona; Kunstelj, Menci; Porekar, Vladka Gaberc</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-128</span>CODEN:
                <span class="NLM_cas:coden">BJIOAM</span>;
        ISSN:<span class="NLM_cas:issn">1860-6768</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Since the first PEGylated product was approved by the Food and Drug Administration in 1990, PEGylation has been widely used as a post-prodn. modification methodol. for improving biomedical efficacy and physicochem. properties of therapeutic proteins.  Applicability and safety of this technol. have been proven by use of various PEGylated pharmaceuticals for many years.  It is expected that PEGylation, as the most established technol. for extension of drug residence in the body, will play an important role in the next generation therapeutics, such as peptides, protein nanobodies and scaffolds, which due to their diminished mol. size need half-life extension.  This review focuses on several factors important in the prodn. of PEGylated biopharmaceuticals enabling efficient prepn. of highly purified PEG-protein conjugates that have to meet stringent regulatory criteria for their use in human therapy.  Areas addressed are PEG properties, the specificity of PEGylation reactions, sepn. and large-scale purifn., the availability and anal. of PEG reagents, anal. of PEG-protein conjugates, the consistency of products and processes and approaches used for rapid screening of pharmacokinetic properties of PEG-protein conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqjWpYHBYTybVg90H21EOLACvtfcHk0lgJjLmAevAMYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVSlsw%253D%253D&md5=ad29019bc10b1d52ef883f9f6f3f27ce</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fbiot.200900218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbiot.200900218%26sid%3Dliteratum%253Aachs%26aulast%3DJevsevar%26aufirst%3DS.%26aulast%3DKunstelj%26aufirst%3DM.%26aulast%3DPorekar%26aufirst%3DV.%2BG.%26atitle%3DPEGylation%2520of%2520therapeutic%2520proteins%26jtitle%3DBiotechnol%2520J%26date%3D2010%26volume%3D5%26spage%3D113%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Milla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dosio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattel, L.</span><span> </span><span class="NLM_article-title">PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.2174%2F138920012798356934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=21892917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVehs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=105-119&author=P.+Millaauthor=F.+Dosioauthor=L.+Cattel&title=PEGylation+of+proteins+and+liposomes%3A+a+powerful+and+flexible+strategy+to+improve+the+drug+delivery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery</span></div><div class="casAuthors">Milla, Paola; Dosio, Franco; Cattel, Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-119</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  PEGylation is one of the most successful strategies to improve the delivery of therapeutic mols. such as proteins, macromol. carriers, small drugs, oligonucleotides, and other biomols.  PEGylation increase the size and mol. wt. of conjugated biomols. and improves their pharmacokinetics and pharmacodynamics by increasing water soly., protecting from enzymic degrdn., reducing renal clearance and limiting immunogenic and antigenic reactions.  PEGylated mols. show increased half-life, decreased plasma clearance, and different biodistribution, in comparison with non-PEGylated counterparts.  These features appear to be very useful for therapeutic proteins, since the high stability and very low immunogenicity of PEGylated proteins result in sustained clin. response with minimal dose and less frequent administration.  PEGylation of liposomes improves not only the stability and circulation time, but also the "passive" targeting ability on tumoral tissues, through a process known as the enhanced permeation retention effect, able to improve the therapeutic effects and reduce the toxicity of encapsulated drug.  The mol. wt., shape, reactivity, specificity, and type of bond of PEG moiety are crucial in detg. the effect on PEGylated mols. and, at present, researchers have the chance to select among tens of PEG derivs. and PEG conjugation technologies, to design the best PEGylation strategy for each particular application.  The aim of the present review will be to elucidate the principles of PEGylation chem. and to describe the already marketed PEGylated proteins and liposomes by focusing the attention to some enlightening examples of how this technol. could dramatically influence the clin. application of therapeutic biomols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD88shv9IG2rVg90H21EOLACvtfcHk0lgJjLmAevAMYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVehs7o%253D&md5=92fc417438250224d434ec53bb2107b0</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.2174%2F138920012798356934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012798356934%26sid%3Dliteratum%253Aachs%26aulast%3DMilla%26aufirst%3DP.%26aulast%3DDosio%26aufirst%3DF.%26aulast%3DCattel%26aufirst%3DL.%26atitle%3DPEGylation%2520of%2520proteins%2520and%2520liposomes%253A%2520a%2520powerful%2520and%2520flexible%2520strategy%2520to%2520improve%2520the%2520drug%2520delivery%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D105%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Pasut, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, F. M.</span><span> </span><span class="NLM_article-title">State of the art in PEGylation: the great versatility achieved after forty years of research</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">461</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2Fj.jconrel.2011.10.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=22094104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1emu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2012&pages=461-472&author=G.+Pasutauthor=F.+M.+Veronese&title=State+of+the+art+in+PEGylation%3A+the+great+versatility+achieved+after+forty+years+of+research"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">State of the art in PEGylation: The great versatility achieved after forty years of research</span></div><div class="casAuthors">Pasut, Gianfranco; Veronese, Francesco M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">461-472</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the recent years, protein PEGylation has become an established and highly refined technol. by moving forward from initial simple random coupling approaches based on conjugation at the level of lysine ε-amino group.  Nevertheless, amino PEGylation is still yielding important conjugates, currently in clin. practice, where the degree of homogeneity was improved by optimizing the reaction conditions and implementing the purifn. processes.  However, the current research is mainly focused on methods of site-selective PEGylation that allow the obtainment of a single isomer, thus highly increasing the degree of homogeneity and the preservation of bioactivity.  Protein N-terminus and free cysteines were the first sites exploited for selective PEGylation but currently further positions can be addressed thanks to approaches like bridging PEGylation (disulfide bridges), enzymic PEGylation (glutamines and C-terminus) and glycoPEGylation (sites of O- and N-glycosylation or the glycans of a glycoprotein).  Furthermore, by combining the tools of genetic engineering with specific PEGylation approaches, the polymer can be basically coupled at any position on the protein surface, owing to the substitution of a properly chosen amino acid in the sequence with a natural or unnatural amino acid bearing an orthogonal reactive group.  On the other hand, PEGylation has not achieved the same success in the delivery of small drugs, despite the large interest and several studies in this field.  Targeted conjugates and PEGs for combination therapy might represent the promising answers for the so far unmet needs of PEG as carrier of small drugs.  This review presents a thorough panorama of recent advances in the field of PEGylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_K0FgZe0yr7Vg90H21EOLACvtfcHk0lhx3W0O9wobrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1emu7g%253D&md5=6c43f93f9acfb6b72833818ed751d089</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2011.10.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2011.10.037%26sid%3Dliteratum%253Aachs%26aulast%3DPasut%26aufirst%3DG.%26aulast%3DVeronese%26aufirst%3DF.%2BM.%26atitle%3DState%2520of%2520the%2520art%2520in%2520PEGylation%253A%2520the%2520great%2520versatility%2520achieved%2520after%2520forty%2520years%2520of%2520research%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2012%26volume%3D161%26spage%3D461%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Grace, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delorenzo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wylie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannon-Carlson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Indelicato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voloch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordens, R.</span><span> </span><span class="NLM_article-title">Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">6327</span><span class="NLM_x">–</span> <span class="NLM_lpage">6336</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=6327-6336&author=M.+J.+Graceauthor=S.+Leeauthor=S.+Bradshawauthor=J.+Chapmanauthor=J.+Spondauthor=S.+Coxauthor=M.+Delorenzoauthor=D.+Brassardauthor=D.+Wylieauthor=S.+Cannon-Carlsonauthor=C.+Cullenauthor=S.+Indelicatoauthor=M.+Volochauthor=R.+Bordens&title=Site+of+pegylation+and+polyethylene+glycol+molecule+size+attenuate+interferon-alpha+antiviral+and+antiproliferative+activities+through+the+JAK%2FSTAT+signaling+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrace%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DBradshaw%26aufirst%3DS.%26aulast%3DChapman%26aufirst%3DJ.%26aulast%3DSpond%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DS.%26aulast%3DDelorenzo%26aufirst%3DM.%26aulast%3DBrassard%26aufirst%3DD.%26aulast%3DWylie%26aufirst%3DD.%26aulast%3DCannon-Carlson%26aufirst%3DS.%26aulast%3DCullen%26aufirst%3DC.%26aulast%3DIndelicato%26aufirst%3DS.%26aulast%3DVoloch%26aufirst%3DM.%26aulast%3DBordens%26aufirst%3DR.%26atitle%3DSite%2520of%2520pegylation%2520and%2520polyethylene%2520glycol%2520molecule%2520size%2520attenuate%2520interferon-alpha%2520antiviral%2520and%2520antiproliferative%2520activities%2520through%2520the%2520JAK%252FSTAT%2520signaling%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D6327%26epage%3D6336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Dhalluin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leuthold, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gsell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senn, H.</span><span> </span><span class="NLM_article-title">Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">504</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049781%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslKlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=504-517&author=C.+Dhalluinauthor=A.+Rossauthor=L.+A.+Leutholdauthor=S.+Foserauthor=B.+Gsellauthor=F.+Mullerauthor=H.+Senn&title=Structural+and+biophysical+characterization+of+the+40+kDa+PEG-interferon-alpha2a+and+its+individual+positional+isomers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-α2a and Its Individual Positional Isomers</span></div><div class="casAuthors">Dhalluin, Christophe; Ross, Alfred; Leuthold, Luc-Alexis; Foser, Stefan; Gsell, Bernard; Mueller, Francis; Senn, Hans</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">504-517</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The human recombinant Interferon-α2a (IFNα2a) is a potent drug (Roferon-A) to treat various types of cancer and viral diseases including Hepatitis B/C infections.  To improve the pharmacol. properties of the drug, a new pegylated form of IFNα2a was developed (PEGASYS).  This 40 kDa PEG-conjugated IFNα2a (40PEG-IFNα2a) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side chain of IFNα2a.  40PEG-IFNα2a is a mixt. of mainly six monopegylated positional isomers modified at K31, K134, K131, K121, K164, and K70, resp.  Here we report the detailed structural and biophys. characterization of 40PEG-IFNα2a and its positional isomers, in comparison with IFNα2a, using NMR spectroscopy, anal. ultracentrifugation, CD, fluorescence spectroscopy, and differential scanning calorimetry.  Our results show that the three-dimensional structure of IFNα2a is not modified by the presence of the polymer in all positional isomers constituting 40PEG-IFNα2a.  Regardless of where the PEG-polymer is attached, it adopts a very mobile and flexible random coil conformation, producing a shield for the protein without a permanent coverage of the protein surface.  Hydrodynamic data indicate that the protein-attached PEG has a slightly more compact random-coil structure than the free PEG-polymer.  Our results also provide evidence of significant structural and physicochem. advantages conferred by the pegylation: increase of the effective hydrodynamic vol. and modification of the mol. shape, higher temp. stability, and reduced tendency for aggregation.  These results are of tremendous pharmacol. interest and benefit as was clin. shown with PEGASYS.  This study constitutes a new std. for the characterization of pegylated proteins and enables an important step toward the understanding on a mol. level of the binding of 40PEG-IFNα2a and its positional isomers to its cellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrak82Mw0wqNbVg90H21EOLACvtfcHk0liIPBjuzf9Ikg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslKlsr8%253D&md5=94dea271170d173257f370026078b60a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fbc049781%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049781%252B%26sid%3Dliteratum%253Aachs%26aulast%3DDhalluin%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DA.%26aulast%3DLeuthold%26aufirst%3DL.%2BA.%26aulast%3DFoser%26aufirst%3DS.%26aulast%3DGsell%26aufirst%3DB.%26aulast%3DMuller%26aufirst%3DF.%26aulast%3DSenn%26aufirst%3DH.%26atitle%3DStructural%2520and%2520biophysical%2520characterization%2520of%2520the%252040%2520kDa%2520PEG-interferon-alpha2a%2520and%2520its%2520individual%2520positional%2520isomers%26jtitle%3DBioconjugate%2520Chem.%26date%3D2005%26volume%3D16%26spage%3D504%26epage%3D517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Gaertner, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offord, R. E.</span><span> </span><span class="NLM_article-title">Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc950074d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK28XivVartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=38-44&author=H.+F.+Gaertnerauthor=R.+E.+Offord&title=Site-specific+attachment+of+functionalized+poly%28ethylene+glycol%29+to+the+amino+terminus+of+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins</span></div><div class="casAuthors">Gaertner, Hubert F.; Offord, Robin E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-44</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A convenient method for the construction of site-specifically modified poly(ethylene glycol)-protein conjugates is described.  This method relies on the ability to generate a reactive carbonyl group in place of the terminal amino group.  If the protein has N-terminal serine or threonine, this can be done by very mild periodate oxidn. and generates a glyoxylyl group.  A method less restricted by the nature of the N-terminal residue, but which requires somewhat harsher conditions, is metal-catalyzed transamination, which gives a keto group.  The N-terminal-introduced reactive carbonyl group specifically reacts, under mild acidic conditions, with an aminooxy-functionalized poly(ethylene glycol) to form a stable oxime bond.  Using polymers of different size and shape (linear or multibranched), various conjugates of IL-8, G-CSF, and IL-1ra were constructed and further characterized with respect to their biol. activity and pharmacokinetic behavior in rats.  Unlike most previous methods, this approach places a single PEG chain at a defined site on the protein.  It should therefore be more likely to conserve biol. activity when the latter depends on interaction with another macromol. (unlike enzymic activity which often survives multiple PEGylation).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgD3maoTsawLVg90H21EOLACvtfcHk0liIPBjuzf9Ikg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivVartw%253D%253D&md5=7d2ba2397b3c10544089ad7ebf5ad926</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fbc950074d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc950074d%26sid%3Dliteratum%253Aachs%26aulast%3DGaertner%26aufirst%3DH.%2BF.%26aulast%3DOfford%26aufirst%3DR.%2BE.%26atitle%3DSite-specific%2520attachment%2520of%2520functionalized%2520poly%2528ethylene%2520glycol%2529%2520to%2520the%2520amino%2520terminus%2520of%2520proteins%26jtitle%3DBioconjugate%2520Chem.%26date%3D1996%26volume%3D7%26spage%3D38%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Kinstler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molineux, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treuheit, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladd, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gegg, C.</span><span> </span><span class="NLM_article-title">Mono-N-terminal poly(ethylene glycol)-protein conjugates</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2FS0169-409X%2802%2900023-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=12052710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFKiu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=477-485&author=O.+Kinstlerauthor=G.+Molineuxauthor=M.+Treuheitauthor=D.+Laddauthor=C.+Gegg&title=Mono-N-terminal+poly%28ethylene+glycol%29-protein+conjugates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Mono-N-terminal poly(ethylene glycol)-protein conjugates</span></div><div class="casAuthors">Kinstler, Olaf; Molineux, Graham; Treuheit, Michael; Ladd, David; Gegg, Colin</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  A site-directed method of joining proteins to poly(ethylene glycol) is presented which allows for the prepn. of essentially homogeneous PEG-protein derivs. with a single PEG chain conjugated to the amine terminus of the protein.  This selectivity is achieved by conducting the reductive alkylation of proteins with PEG-aldehydes at lower pH.  Working examples demonstrating the application of this method to improve the delivery characteristics and therapeutic value of several proteins are provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbaIeOowSudLVg90H21EOLACvtfcHk0liIPBjuzf9Ikg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFKiu7k%253D&md5=bf32d0cad1c048a0da5aa83c5eb93b09</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2802%2900023-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252802%252900023-6%26sid%3Dliteratum%253Aachs%26aulast%3DKinstler%26aufirst%3DO.%26aulast%3DMolineux%26aufirst%3DG.%26aulast%3DTreuheit%26aufirst%3DM.%26aulast%3DLadd%26aufirst%3DD.%26aulast%3DGegg%26aufirst%3DC.%26atitle%3DMono-N-terminal%2520poly%2528ethylene%2520glycol%2529-protein%2520conjugates%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D477%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Shaunak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijayarangam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidelberger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zloh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brocchini, S.</span><span> </span><span class="NLM_article-title">Site-specific PEGylation of native disulfide bonds in therapeutic proteins</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">312</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1038%2Fnchembio786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=16633351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkslemuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=312-313&author=S.+Shaunakauthor=A.+Godwinauthor=J.+W.+Choiauthor=S.+Balanauthor=E.+Pedoneauthor=D.+Vijayarangamauthor=S.+Heidelbergerauthor=I.+Teoauthor=M.+Zlohauthor=S.+Brocchini&title=Site-specific+PEGylation+of+native+disulfide+bonds+in+therapeutic+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific PEGylation of native disulfide bonds in therapeutic proteins</span></div><div class="casAuthors">Shaunak, Sunil; Godwin, Antony; Choi, Ji-Won; Balan, Sibu; Pedone, Elisa; Vijayarangam, Damotharan; Heidelberger, Sibylle; Teo, Ian; Zloh, Mire; Brocchini, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">312-313</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Native disulfide bonds in therapeutic proteins are crucial for tertiary structure and biol. activity and are therefore considered unsuitable for chem. modification.  We show that native disulfides in human interferon α-2b and in a fragment of an antibody to CD4+ can be modified by site-specific bisalkylation of the two cysteine sulfur atoms to form a three-carbon PEGylated bridge.  The yield of PEGylated protein is high, and tertiary structure and biol. activity are retained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrGCvU5zTVVbVg90H21EOLACvtfcHk0liIPBjuzf9Ikg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkslemuro%253D&md5=7ce78a8100d6b9393c87724b573a015a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnchembio786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio786%26sid%3Dliteratum%253Aachs%26aulast%3DShaunak%26aufirst%3DS.%26aulast%3DGodwin%26aufirst%3DA.%26aulast%3DChoi%26aufirst%3DJ.%2BW.%26aulast%3DBalan%26aufirst%3DS.%26aulast%3DPedone%26aufirst%3DE.%26aulast%3DVijayarangam%26aufirst%3DD.%26aulast%3DHeidelberger%26aufirst%3DS.%26aulast%3DTeo%26aufirst%3DI.%26aulast%3DZloh%26aufirst%3DM.%26aulast%3DBrocchini%26aufirst%3DS.%26atitle%3DSite-specific%2520PEGylation%2520of%2520native%2520disulfide%2520bonds%2520in%2520therapeutic%2520proteins%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D312%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Brocchini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zloh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaunak, S.</span><span> </span><span class="NLM_article-title">Disulfide bridge based PEGylation of proteins</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2Fj.addr.2007.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=17920720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyit7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=3-12&author=S.+Brocchiniauthor=A.+Godwinauthor=S.+Balanauthor=J.+W.+Choiauthor=M.+Zlohauthor=S.+Shaunak&title=Disulfide+bridge+based+PEGylation+of+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Disulfide bridge based PEGylation of proteins</span></div><div class="casAuthors">Brocchini, Steve; Godwin, Antony; Balan, Sibu; Choi, Ji-won; Zloh, Mire; Shaunak, Sunil</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-12</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  PEGylation is a clin. proven strategy for increasing the therapeutic efficacy of protein-based medicines.  Our approach to site-specific PEGylation exploits the thiol selective chem. of the two cysteine sulfur atoms from an accessible disulfide.  It involves two key steps: (1) disulfide redn. to release the two cystine thiols, and (2) bis-alkylation to give a three-carbon bridge to which PEG is covalently attached.  During this process, irreversible denaturation of the protein does not occur.  Mechanistically, the conjugation is conducted by a sequential, interactive bis-alkylation using α,β-unsatd.-β'-mono-sulfone functionalized PEG reagents.  The combination of: - (a) maintaining the protein's tertiary structure after redn. of a disulfide, (b) bis-thiol selectivity of the PEG reagent, and (c) PEG assocd. steric shielding ensure that only one PEG mol. is conjugated at each disulfide.  Our studies have shown that peptides, proteins, enzymes and antibody fragments can be site-specifically PEGylated using a native and accessible disulfide without destroying the mols.' tertiary structure or abolishing its biol. activity.  As the stoichiometric efficiency of our approach also enables recycling of any unreacted protein, it offers the potential to make PEGylated biopharmaceuticals as cost-effective medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIQH8-GN_2O7Vg90H21EOLACvtfcHk0lhtEOSLpekHyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyit7vP&md5=7b88a509897ed35ab3a8cc1b1609f271</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DBrocchini%26aufirst%3DS.%26aulast%3DGodwin%26aufirst%3DA.%26aulast%3DBalan%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DJ.%2BW.%26aulast%3DZloh%26aufirst%3DM.%26aulast%3DShaunak%26aufirst%3DS.%26atitle%3DDisulfide%2520bridge%2520based%2520PEGylation%2520of%2520proteins%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2008%26volume%3D60%26spage%3D3%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Fontana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spolaore, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veronese, F. M.</span><span> </span><span class="NLM_article-title">Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1016%2Fj.addr.2007.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=17916398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyit7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=13-28&author=A.+Fontanaauthor=B.+Spolaoreauthor=A.+Meroauthor=F.+M.+Veronese&title=Site-specific+modification+and+PEGylation+of+pharmaceutical+proteins+mediated+by+transglutaminase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase</span></div><div class="casAuthors">Fontana, Angelo; Spolaore, Barbara; Mero, Anna; Veronese, Francesco M.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-28</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Transglutaminase (TGase, E.C. 2.3.2.13) catalyzes acyl transfer reactions between the γ-carboxamide groups of protein-bound glutamine (Gln) residues, which serve as acyl donors, and primary amines, resulting in the formation of new γ-amides of glutamic acid and ammonia.  By using an amino-deriv. of poly(ethylene glycol) (PEG-NH2) as substrate for the enzymic reaction with TGase it is possible to covalently bind the PEG polymer to proteins of pharmaceutical interest.  In our lab., we have conducted expts. aimed to modify proteins of known structure using TGase and, surprisingly, we were able to obtain site-specific modification or PEGylation of protein-bound Gln residue(s) in the protein substrates.  For example, in apomyoglobin (apoMb, myoglobin devoid of heme) only Gln91 was modified and in human growth hormone only Gln40 and Gln141, despite these proteins having many more Gln residues.  Moreover, we noticed that these proteins suffered highly selective limited proteolysis phenomena at the same chain regions being attacked by TGase.  We have analyzed also the results of other published expts. of TGase-mediated modification or PEGylation of several proteins in terms of protein structure and dynamics, among them α-lactalbumin and interleukin-2, as well as disordered proteins.  A noteworthy correlation was obsd. between chain regions of high temp. factor (B-factor) detd. crystallog. and sites of TGase attack and limited proteolysis, thus emphasizing the role of chain mobility or local unfolding in dictating site-specific enzymic modification.  We propose that enhanced chain flexibility favors limited enzymic reactions on polypeptide substrates by TGases and proteases, as well as by other enzymes involved in a no. of site-specific post-translational modifications of proteins, such as phosphorylation and glycosylation.  Therefore, it is possible to predict the site(s) of TGase-mediated modification and PEGylation of a therapeutic protein on the basis of its structure and dynamics and, consequently, the likely effects of modifications on the functional properties of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHfUAyNBhASrVg90H21EOLACvtfcHk0lhtEOSLpekHyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyit7vN&md5=fc7253a60058e436c29008041f768754</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DA.%26aulast%3DSpolaore%26aufirst%3DB.%26aulast%3DMero%26aufirst%3DA.%26aulast%3DVeronese%26aufirst%3DF.%2BM.%26atitle%3DSite-specific%2520modification%2520and%2520PEGylation%2520of%2520pharmaceutical%2520proteins%2520mediated%2520by%2520transglutaminase%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2008%26volume%3D60%26spage%3D13%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, F.</span><span> </span><span class="NLM_article-title">Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives</span> <span class="citation_source-journal">BioDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=209-215&author=C.+Zhangauthor=X.+L.+Yangauthor=Y.+H.+Yuanauthor=J.+Puauthor=F.+Liao&title=Site-specific+PEGylation+of+therapeutic+proteins+via+optimization+of+both+accessible+reactive+amino+acid+residues+and+PEG+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DX.%2BL.%26aulast%3DYuan%26aufirst%3DY.%2BH.%26aulast%3DPu%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DF.%26atitle%3DSite-specific%2520PEGylation%2520of%2520therapeutic%2520proteins%2520via%2520optimization%2520of%2520both%2520accessible%2520reactive%2520amino%2520acid%2520residues%2520and%2520PEG%2520derivatives%26jtitle%3DBioDrugs%26date%3D2012%26volume%3D26%26spage%3D209%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellows, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkey, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. W.</span><span> </span><span class="NLM_article-title">Simultaneous quantification of davalintide, a novel amylin-mimetic peptide, and its active metabolite in beagle and rat plasma by online SPE and LC-MS/MS</span> <span class="citation_source-journal">Bioanalysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span><span class="NLM_x">–</span> <span class="NLM_lpage">2152</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=2141-2152&author=Y.+Wangauthor=Y.+Quauthor=C.+L.+Bellowsauthor=J.+S.+Ahnauthor=J.+L.+Burkeyauthor=S.+W.+Taylor&title=Simultaneous+quantification+of+davalintide%2C+a+novel+amylin-mimetic+peptide%2C+and+its+active+metabolite+in+beagle+and+rat+plasma+by+online+SPE+and+LC-MS%2FMS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DBellows%26aufirst%3DC.%2BL.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DBurkey%26aufirst%3DJ.%2BL.%26aulast%3DTaylor%26aufirst%3DS.%2BW.%26atitle%3DSimultaneous%2520quantification%2520of%2520davalintide%252C%2520a%2520novel%2520amylin-mimetic%2520peptide%252C%2520and%2520its%2520active%2520metabolite%2520in%2520beagle%2520and%2520rat%2520plasma%2520by%2520online%2520SPE%2520and%2520LC-MS%252FMS%26jtitle%3DBioanalysis%26date%3D2012%26volume%3D4%26spage%3D2141%26epage%3D2152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Caldwell, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masucci, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hageman, W.</span><span> </span><span class="NLM_article-title">Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?</span> <span class="citation_source-journal">Eur. J. Drug Metab. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1007%2FBF03190588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=15230342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Kksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=133-143&author=G.+W.+Caldwellauthor=J.+A.+Masucciauthor=Z.+Yanauthor=W.+Hageman&title=Allometric+scaling+of+pharmacokinetic+parameters+in+drug+discovery%3A+can+human+CL%2C+Vss+and+t1%2F2+be+predicted+from+in-vivo+rat+data%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in-vivo rat data?</span></div><div class="casAuthors">Caldwell, Gary W.; Masucci, John A.; Yan, Zhengyin; Hageman, William</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-143</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Medecine et Hygiene</span>)
        </div><div class="casAbstract">In a drug discovery environment, reasonable go/no-go human in-vivo pharmacokinetic (PK) decisions must be made in a timely manner with a min. amt. of animal in-vivo or in-vitro data.  We have investigated the accuracy of the in-vivo correlation between rat and human for the prediction of the total systemic clearance (CL), the vol. of distribution at steady state (Vss), and the half-life (t1/2) using simple allometric scaling techniques.  We have shown, using a large diverse set of drugs, that a fixed exponent allometric scaling approach can be used to predict human in-vivo PK parameters CL, Vss and t1/2 solely from rat in-vivo PK data with acceptable accuracy for making go/no-go decisions in drug discovery.  Human in-vivo PK predictions can be obtained using the simple allometric scaling relationships CLHuman ≈ 40 CLRat (L/h), Vss Human ≈ 200 Vss Rat (L), and t1/2 Human ≈ 4 t1/2 Rat (hr).  The av. fold error for human CL predictions for N = 176 drugs was 2.25 with 79% of the drugs having a fold error less than 3.  The av. fold error for human Vss predictions for N = 144 drugs was 1.85 with 84% of the drugs having a fold error less than 3.  The av. fold error for human t1/2 predictions for N = 145 drugs was 2.05 with 76% of the drugs having a fold error less than 3.  Using these simple allometric relationships, the sorting of drug candidates into a low/medium/high/very high human classification scheme was also possible from rat data.  Since these simple allometric relationships between rat and human CL, Vss, and t1/2 are reasonably accurate, easy to remember and simple to calc., these equations should be useful for making early go/no-go in-vivo human PK decisions for drug discovery candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKsbTCr5uXfbVg90H21EOLACvtfcHk0lhFgBYA0g57hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Kksrw%253D&md5=d760f54997912a7c14c6022190477f10</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2FBF03190588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03190588%26sid%3Dliteratum%253Aachs%26aulast%3DCaldwell%26aufirst%3DG.%2BW.%26aulast%3DMasucci%26aufirst%3DJ.%2BA.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DHageman%26aufirst%3DW.%26atitle%3DAllometric%2520scaling%2520of%2520pharmacokinetic%2520parameters%2520in%2520drug%2520discovery%253A%2520can%2520human%2520CL%252C%2520Vss%2520and%2520t1%252F2%2520be%2520predicted%2520from%2520in-vivo%2520rat%2520data%253F%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2004%26volume%3D29%26spage%3D133%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silber, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rance, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wastall, P.</span><span> </span><span class="NLM_article-title">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+S.+Obachauthor=J.+G.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+human+pharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0lhPXZqKNRKp-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DBaxter%26aufirst%3DJ.%2BG.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Bendele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seely, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennello, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shopp, G.</span><span> </span><span class="NLM_article-title">Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.1093%2Ftoxsci%2F42.2.152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=9579027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK1cXislKlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=152-157&author=A.+Bendeleauthor=J.+Seelyauthor=C.+Richeyauthor=G.+Sennelloauthor=G.+Shopp&title=Short+communication%3A+renal+tubular+vacuolation+in+animals+treated+with+polyethylene-glycol-conjugated+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins</span></div><div class="casAuthors">Bendele, Alison; Seely, Jim; Richey, Carl; Sennello, Gina; Shopp, George</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-157</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">During toxicol. evaluation of a dimeric PEG-linked protein, tumor necrosis factor binding protein (TNF-bp), vacuolation of renal cortical tubular epithelium was seen in male and female Sprague-Dawley rats (200-300 g) given i.v. doses of 40, 20, or 10 mg/kg every other day for 3 mo.  Tubular lesions in rats treated with 20 or 40 mg/kg for 3 mo were only partially reversible after a 2-mo recovery period.  Despite the presence of marked vacuolation, there were no changes in BUN, creatinine, urinalysis parameters, urinary NAG, urinary B2-microglobulin, or fractional sodium excretion.  Single i.v. doses ≥20 mg/kg TNF-bp caused similar but milder-changes.  However, equiv. doses of PEG alone or the non-PEG-linked TNF-bp did not cause light microscopic evidence of vacuolation.  Treatment of rats with another PEG-linked protein of similar mol. wt. resulted in similar changes.  Immunostaining for TNF-bp revealed positivity in the apical cytoplasm of renal tubular epithelium within 1 h of i.v. dosing.  Immunostaining of kidneys from chronically dosed rats indicated that protein was present in some vacuoles as long as dosing continued; however, kidneys from animals on a reversibility study had vacuoles but no immunostaining for TNF-bp.  These results, along with a study that showed more severe lesions with PEG- linked proteins of lower mol. wt. and minimal if any lesions with PEG-linked proteins >70 kDa, suggest that TNF-bp is filtered through the glomerulus and that the protein with attached PEG is reabsorbed by the proximal tubules.  Vacuolation may be a result of fluid distension of lysosomes due to the hygroscopic nature of PEG.  These studies demonstrated that PEG-linked proteins have the capacity to induce renal tubular vacuolation at high doses.  However, the change was not assocd. with alteration of clin. pathol. or functional markers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobOPWYC0AWV7Vg90H21EOLACvtfcHk0lhPXZqKNRKp-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXislKlsbo%253D&md5=008e9d1e4ac6aa10b306e8d57bcffd60</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2F42.2.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252F42.2.152%26sid%3Dliteratum%253Aachs%26aulast%3DBendele%26aufirst%3DA.%26aulast%3DSeely%26aufirst%3DJ.%26aulast%3DRichey%26aufirst%3DC.%26aulast%3DSennello%26aufirst%3DG.%26aulast%3DShopp%26aufirst%3DG.%26atitle%3DShort%2520communication%253A%2520renal%2520tubular%2520vacuolation%2520in%2520animals%2520treated%2520with%2520polyethylene-glycol-conjugated%2520proteins%26jtitle%3DToxicol.%2520Sci.%26date%3D1998%26volume%3D42%26spage%3D152%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Conover, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lejeune, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shum, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shorr, R. G.</span><span> </span><span class="NLM_article-title">Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat</span> <span class="citation_source-journal">Artif. Cells, Blood Substitutes Immobil. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">611</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm401418s&amp;key=10.3109%2F10731199609118885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm401418s&amp;key=8922229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm401418s&amp;key=1%3ACAS%3A528%3ADyaK28XnsFSju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=599-611&author=C.+Conoverauthor=L.+Lejeuneauthor=R.+Linbergauthor=K.+Shumauthor=R.+G.+Shorr&title=Transitional+vacuole+formation+following+a+bolus+infusion+of+PEG-hemoglobin+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat</span></div><div class="casAuthors">Conover, Charles; Lejeune, Laura; Linberg, Rita; Shum, Kwok; Shorr, Robert G. L.</div><div class="citationInfo"><span class="NLM_cas:title">Artificial Cells, Blood Substitutes, and Immobilization Biotechnology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">599-611</span>CODEN:
                <span class="NLM_cas:coden">ABSBE4</span>;
        ISSN:<span class="NLM_cas:issn">1073-1199</span>.
    
            (<span class="NLM_cas:orgname">Dekker</span>)
        </div><div class="casAbstract">This study was designed to assess the morphol. effects of a bolus infusion of PEG-Hb on the heart, lung, liver, spleen, and kidney of lab. rats.  Of particular interest was the detn. of PEG-Hb's potential to form vacuoles in the tissues and whether these were transitory and article specific.  One hundred ten female Sprague-Dawley rats were used in this study.  The 1st expt. detd. whether vacuole formation was test article specific by infusing either stroma-free bovine Hb, PEG-Hb, bovine serum albumin, PEG-bovine serum albumin, or free PEG.  The 2nd expt. assessed the transitory nature of vacuolization.  In both expts., unconscious rats received an i.v. top-loading (bolus) injection of test article via the tail vein.  Rats were sacrificed at various time points following administration and had their tissues examd. for the presence of vacuoles by light microscope morphol. examn. and iron staining.  Formation of vacuoles appeared to be test article specific with only prolonged circulating, high-solute test articles producing vacuoles.  These vacuoles appeared dose responsive and transitory in nature.  The vacuolization found was nontoxic and believed to be due to the known effect of lysosomal overloading following the phagocytosis of vascularly persistent high-solute test articles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpokfGMvselj7Vg90H21EOLACvtfcHk0ljrOqSiG9OM0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XnsFSju78%253D&md5=a2ac7ea8df398f07845d8ff59eb7a480</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.3109%2F10731199609118885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10731199609118885%26sid%3Dliteratum%253Aachs%26aulast%3DConover%26aufirst%3DC.%26aulast%3DLejeune%26aufirst%3DL.%26aulast%3DLinberg%26aufirst%3DR.%26aulast%3DShum%26aufirst%3DK.%26aulast%3DShorr%26aufirst%3DR.%2BG.%26atitle%3DTransitional%2520vacuole%2520formation%2520following%2520a%2520bolus%2520infusion%2520of%2520PEG-hemoglobin%2520in%2520the%2520rat%26jtitle%3DArtif.%2520Cells%252C%2520Blood%2520Substitutes%2520Immobil.%2520Biotechnol.%26date%3D1996%26volume%3D24%26spage%3D599%26epage%3D611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i37"><a href="/doi/suppl/10.1021/jm401418s">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_35122"></div></div></div></div></div><hr /></hr><p class="last">HPLC-MS of all phybrids and peptide precursors, MALDI-MS, and SDS–PAGE gel of all conjugates associated with this article is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401418s/suppl_file/jm401418s_si_001.pdf">jm401418s_si_001.pdf (3.06 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401418s&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm401418s%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-22%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401418s" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679980470e303dbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
